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Abstract: PRAME-like genes (Preferentially expressed antigen in melanoma-like, Pramel) share struc-
tural similarities with the human cancer-testis antigen (CTA) PRAME. CTAs are usually expressed in
a variety of cancers and in germ cells. In the mouse, 18 members of the PRAME-like gene family have
been suggested until now, but their molecular function is largely elusive. Expression of one member,
Pramel7, was found in the pluripotent compartment of the mouse preimplantation embryo, the morula
and the inner cell mass (ICM) of a blastocyst. During these early stages of development, a replication-
coupled passive demethylation of the maternal genome is docu- mented. When Pramel7 is overexpressed
in mouse embryonic stem cells (mESCs), the pluripo- tent state of these cells can be maintained even
in the absence of the cytokine LIF (leukemia inhibitory factor). Moreover, when mESCs overexpressing
Pramel7 are exposed to differentia- tion cues, these cells show diminished differentiation capacity in vitro
and in vivo. In mESCs, the expression of Pramel7 can be induced by the activation of the LIF/STAT3
signalling and Pramel7 was shown to be a direct downstream target of STAT3. However, the molecular
func- tion of Pramel7 is unknown. Here, we identify UHRF1 as a potent interaction partner of Pramel7
in HEK293T cells and mESCs. The epigenetic regulator UHRF1 (Ubiquitin-like containing PHD and
RING finger domains, 1) mediates the faithful transmission of DNA methylation marks from mother to
daughter cells during DNA replication. To achieve this, UHRF1 is able to recognize hemimethylated
DNA and guide DNMT1 (DNA methyltransferase 1) to these sites. UHRF1 is also interacting with
other epigenetic regulators such as HDAC1, G9a and PARP1 or the N-terminal tail of H3. Thus, this
protein is considered to link DNA modification and the establishment of chromatin pat- terns. We show
that a region containing LRRs (Leucine-rich repeats) in the C-terminal area of Pramel7 is critical for
the interaction with UHRF1. Furthermore, the C-terminal part of UHRF1 contain- ing SRA and RING
domains significantly contributes to an efficient binding of the two proteins (Pramel7-UHRF1). In im-
munoprecipitation and mass spectrometry assays, we discover factors such as ElonginC, HP1￿, CHD4,
SPT16, PARP1, different types of histones, Polyubiquitin and other epigenetic regulators as interaction
partners of the Pramel7-UHRF1 complex, indicating a role for Pramel7 at chromatin sites. Of note, we
find that overexpression of mouse Pramel7 leads to a rapid, dose-dependent and reversible decrease of
endogenous UHRF1 protein levels in HEK293T (human UHRF1) and mESCs (mouse UHRF1). Further-
more, Pramel7 mutants with deletions in the LRR region are not able to provoke the degradation of wt
(wild type) UHRF1. Recombinant forms of UHRF1 lacking the C-terminal part of the protein cannot
be degraded by wt Pramel7. To summarize, UHRF1 protein degradation can be specifically mediated by
its direct interaction with Pramel7 and occurs via the 26S proteasome. We demonstrate that ectop- ic
expression of Pramel7 accompanied by a reduction of UHRF1 protein leads to drastically reduced levels
of 5mC (5-methylcytosine) in mESCs. This has a significant influence on the be- haviour of cells. In
self-renewing conditions, mESCs overexpressing Pramel7 exhibit a more active epigenetic profile on a
global scale shown by an enrichment of activating histone marks. This is corroborated by the aberrant
upregulation of the trophectodermal marker Elf5 in Pramel7-overexpressing mESCs, a phenomenon also
observed in mESCs with abrogated expres- sion of the three main DNMTs. Abstract II Differentiation
of mESCs requires activation of differentiation factors and silencing of pluripo- tency-associated genes.
DNA methylation is recognized as the ultimate epigenetic silencing mark. As a consequence of absent
DNA methylation, we observe that Pramel7-overexpressing mESCs exhibit major limitations in terminal
differentiation. After 14 days of differentiation and subsequent re-exposure to culture conditions main-
taining pluripotency, Pramel7- overexpressing mESCs are able to reconvert to a complete pluripotent
state and reactivate the expression of the classical pluripotency markers alkaline phosphatase, Oct4,
Nanog and Rex1. This indicates that upon differentiation, the presence of Pramel7 impairs the capacity
of mESCs to silence the pluripotency-associated genes. Under consideration of our mass spectrometry
data, we establish a functional model where Pramel7 acts as a substrate recognition component of an E3
Cullin-RING ligase (CRL) complex. Binding of Pramel7 and UHRF1 is thought to induce the attachment
of Ubiquitin to UHRF1 and finally to lead to proteasomal degradation of UHRF1. Taken together, for the
first time, we demonstrate a biologically significant role for a member of the PRAME-like protein fam-
ily. This model might support the understanding of the replication-coupled, passive DNA demethylation
mechanism occurring during the preimplantation development of the mouse embryo. Zusammenfas-
sung III Zusammenfassung Gene der PRAME-like (Preferentially expressed antigen in melanoma-like,
Pramel) Familie teilen strukturelle Ähnlichkeiten mit dem humanen Tumor-Hoden-Antigen PRAME.
Tumor-Hoden- Antigene sind üblicherweise in einer Vielzahl von Krebsarten und in Keimzellen exprim-
iert. Bis anhin sind in der Maus 18 PRAME-like-Gene identifiziert worden, ihre molekularen Funktio-
nen sind allerdings immer noch unbekannt. Pramel7, ein Mitglied der PRAME-like Familie, ist in den
pluripotenten Kompartimenten eines frühen Mausembryos exprimiert, genauer in Morula und der inneren
Zellmasse des Blastozysten. Während dieser frühen Phase der Embryonalent- wicklung findet eine rep-
likationsabhängige, passive Demethylierung des mütterlichen Genoms statt. Überexpression von Pramel7
in embryonalen Stammzellen der Maus (mESCs) erlaubt de- ren Propagierung auch ohne Zugabe des Cy-
tokins LIF (leukemia inhibitory factor) zum Kultur- medium. Wenn Pramel7-überexprimerende mESCs
zudem zur Differenzierung angeregt wer- den, zeigen sie eine verminderte Differenzierungskapazität in
vitro und in vivo. In mESCs kann die Expression von Pramel7 durch Aktivierung des LIF/STAT3-
Signalweges induziert werden, was Pramel7 zu einem nachgeordneten Zielgen des Transkriptionsfaktors
STAT3 macht. Trotz- dem ist die molekulare Funktion von Pramel7 immer noch unbekannt. In dieser
Arbeit identifizieren wir UHRF1 als einen Interaktionspartner von Pramel7 in HEK293T Zellen und
mESCs. Das epigenetische Regulatorprotein UHRF1 (Ubiquitin-like containing PHD and RING finger
domains, 1) dient dazu, DNA-Methylierungsmarkierungen während der DNA-Replikation zu- verlässig
vom Genom der Mutterzelle auf die Genome der beiden Tochterzellen zu übertragen. Dabei erkennt
UHRF1 Stellen hemimethylierter DNA und führt DNMT1 (DNA- methyltransferase 1) zu diesen Po-
sitionen. Neben DNMT1 interagiert UHRF1 auch mit anderen epigenetischen Regulatorproteinen wie
HDAC1, G9a oder PARP1 und mit dem N-terminalen Ende von H3. UHRF1 ist somit in der Lage, eine
Verbindung zwischen DNA-modifizierungen und dem Aufbau von Chromatinmustern herzustellen. Wir
zeigen, dass eine Region im C-terminalen Teil von Pramel7 LRRs (Leucine-rich repeats) enthält und dass
diese Region kritisch für eine erfolgreiche Interaktion mit URHF1 ist. Seitens UHRF1 trägt vor allem der
C-terminale Teil, genauer SRA und RING Domänen, zur effizienten Bindung zwischen den beiden Pro-
teinen bei. In Immunopräzipitationsexperimenten und mas- senspektrometrischen Untersuchengen iden-
tifizieren wir weitere potenzielle Bindungspartner des Pramel7-UHRF1 Komplexes, wie ElonginC, HP1￿,
CHD4, SPT16, PARP1, verschiedene Histone, Polyubiquitin und andere epigenetische Regulatoren. Im
Bezug auf Pramel7 könnte dies auf eine Rolle auf Chromatinebene hindeuten. Interessanterweise können
wir aufzeigen, dass forcierte Expression des Mausproteins Pramel7 in HEK293T Zellen (human) und in
mESCs (Maus) zu einer raschen, dosisabhängigen und reversiblen Degradation von endogenem UHRF1-
Protein führt. Dabei sind Versionen von Pramel7 mit Mutationen (Deletionen) in der LRR-Region nicht in
der Lage, die Degradation von wildtyp (wt) UHRF1 zu induzieren. Wiede- rum können mutierte Formen
von UHRF1 (fehlender C-terminaler Teil inklusive SRA- und RING-Domänen) nicht durch Expression
von wt Pramel7 degradiert werden. Zusammengefasst wird die Abnahme von UHRF1-Protein durch seine
spezifische Interaktion mit Pramel7 vermit- telt und erfolgt über den 26S-proteasomalen Degradation-
sweg. Als Konsequenz daraus finden wir in mESCs mit stabiler Überexpression von Pramel7 drastisch
reduzierte 5mC-Levels (5- Methylcytosin). Dies hat weitreichende Konsequenzen auf das Verhalten dieser
Zellen: Unter Kulturbedingungen, die Selbsterneuerung begünstigen, weisen Pramel7-überexprimierende
Zusammenfassung IV mESCs ein erhöhtes Vorkommen aktivierender Histonmarkierungen auf. Ferner ex-
primieren diese Zellen den trophectodermalen Marker Elf5, der in wt mESCs normalerweise nur schwach
aktiv ist, viel zu stark. Abnormale Überexpression von Elf5 kann auch in mESCs mit fehlender Expres-
sion aller DNMTs beobachtet werden. Ein erfolgreicher Differenzierungsprozess einer mESC erfordert
die Aktivierung von Differenzie- rungsgenen und die Abschaltung von Pluripotenzgenen. Dabei spielt
die DNA-Methylierung eine wichtige Rolle, so gilt sie doch als ultimative epigenetische Abschaltungs-
markierung. Als Konsequenz fehlender DNA-Methylierung können wir in Pramel7-überexprimierenden
mESCs beobachten, dass ihre Fähigkeit terminal zu differenzieren stark eingeschränkt ist: Nach 14-
tägiger Differenzierung und anschliessender Kultivierung unter Pluripotenz-fördernden Kultur- bedin-
gungen sind Pramel7-überexprimierende mESCs in der Lage, rasch wieder in ein pluripo- tentes Stadium
überzugehen. Dabei werden mit Pluripotenz assoziierte Marker wie Oct4, Na- nog und Rex1 wieder
2
reaktiviert. Diese Anzeichen erhärten die Annahme, dass die Präsenz von Pramel7 während des Dif-
ferenzierungsprozesses die Kapazität von mESCs, Pluripotenzgene auszuschalten, drastisch vermindert.
Unter Berücksichtigung unserer Massenspektrometriedaten stellen wir ein funktionelles Modell auf, in
dem Pramel7 die Rolle eines Substraterkennungsproteins in einem E3 Cullin-RING Liga- se-Komplex
einnimmt. Dabei wird angenommen, dass die Interaktion zwischen Pramel7 und UHRF1 zur Übertra-
gung von Ubiquitinresten auf das UHRF1-Protein und schlussendlich zur Degradation desselben führt.
Zusammengefasst präsentieren wir in dieser Arbeit zum ersten Mal überhaupt eine biologisch signifikante
Rolle für ein Protein der PRAME-like-Familie. In vivo könnten unsere Beobachtungen einen Beitrag zum
Verständnis der passiven, replikations- abhängigen Demethylierung des mütterlichen Genoms im frühen
Mausembryo leisten.
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Abstract  I 
Abstract 
PRAME-like genes (Preferentially expressed antigen in melanoma-like, Pramel) share structural 
similarities with the human cancer-testis antigen (CTA) PRAME. CTAs are usually expressed in a 
variety of cancers and in germ cells. In the mouse, 18 members of the PRAME-like gene family 
have been suggested until now, but their molecular function is largely elusive. Expression of 
one member, Pramel7, was found in the pluripotent compartment of the mouse preimplantation 
embryo, the morula and the inner cell mass (ICM) of a blastocyst. During these early stages of 
development, a replication-coupled passive demethylation of the maternal genome is docu-
mented. When Pramel7 is overexpressed in mouse embryonic stem cells (mESCs), the pluripo-
tent state of these cells can be maintained even in the absence of the cytokine LIF (leukemia 
inhibitory factor). Moreover, when mESCs overexpressing Pramel7 are exposed to differentia-
tion cues, these cells show diminished differentiation capacity in vitro and in vivo. In mESCs, 
the expression of Pramel7 can be induced by the activation of the LIF/STAT3 signalling and 
Pramel7 was shown to be a direct downstream target of STAT3. However, the molecular func-
tion of Pramel7 is unknown. 
Here, we identify UHRF1 as a potent interaction partner of Pramel7 in HEK293T cells and 
mESCs. 
The epigenetic regulator UHRF1 (Ubiquitin-like containing PHD and RING finger domains, 1) 
mediates the faithful transmission of DNA methylation marks from mother to daughter cells 
during DNA replication. To achieve this, UHRF1 is able to recognize hemimethylated DNA 
and guide DNMT1 (DNA methyltransferase 1) to these sites. UHRF1 is also interacting with 
other epigenetic regulators such as HDAC1, G9a and PARP1 or the N-terminal tail of H3. Thus, 
this protein is considered to link DNA modification and the establishment of chromatin pat-
terns.  
We show that a region containing LRRs (Leucine-rich repeats) in the C-terminal area of Pramel7 
is critical for the interaction with UHRF1. Furthermore, the C-terminal part of UHRF1 contain-
ing SRA and RING domains significantly contributes to an efficient binding of the two proteins 
(Pramel7-UHRF1). In immunoprecipitation and mass spectrometry assays, we discover factors 
such as ElonginC, HP1γ, CHD4, SPT16, PARP1, different types of histones, Polyubiquitin and 
other epigenetic regulators as interaction partners of the Pramel7-UHRF1 complex, indicating a 
role for Pramel7 at chromatin sites. Of note, we find that overexpression of mouse Pramel7 
leads to a rapid, dose-dependent and reversible decrease of endogenous UHRF1 protein levels 
in HEK293T (human UHRF1) and mESCs (mouse UHRF1). Furthermore, Pramel7 mutants with 
deletions in the LRR region are not able to provoke the degradation of wt (wild type) UHRF1. 
Recombinant forms of UHRF1 lacking the C-terminal part of the protein cannot be degraded by 
wt Pramel7. To summarize, UHRF1 protein degradation can be specifically mediated by its 
direct interaction with Pramel7 and occurs via the 26S proteasome. We demonstrate that ectop-
ic expression of Pramel7 accompanied by a reduction of UHRF1 protein leads to drastically 
reduced levels of 5mC (5-methylcytosine) in mESCs. This has a significant influence on the be-
haviour of cells. In self-renewing conditions, mESCs overexpressing Pramel7 exhibit a more 
active epigenetic profile on a global scale shown by an enrichment of activating histone marks. 
This is corroborated by the aberrant upregulation of the trophectodermal marker Elf5 in 
Pramel7-overexpressing mESCs, a phenomenon also observed in mESCs with abrogated expres-
sion of the three main DNMTs.  

Abstract  II 
Differentiation of mESCs requires activation of differentiation factors and silencing of pluripo-
tency-associated genes. DNA methylation is recognized as the ultimate epigenetic silencing 
mark. As a consequence of absent DNA methylation, we observe that Pramel7-overexpressing 
mESCs exhibit major limitations in terminal differentiation. After 14 days of differentiation and 
subsequent re-exposure to culture conditions maintaining pluripotency, Pramel7-
overexpressing mESCs are able to reconvert to a complete pluripotent state and reactivate the 
expression of the classical pluripotency markers alkaline phosphatase, Oct4, Nanog and Rex1. 
This indicates that upon differentiation, the presence of Pramel7 impairs the capacity of mESCs 
to silence the pluripotency-associated genes. 
Under consideration of our mass spectrometry data, we establish a functional model where 
Pramel7 acts as a substrate recognition component of an E3 Cullin-RING ligase (CRL) complex. 
Binding of Pramel7 and UHRF1 is thought to induce the attachment of Ubiquitin to UHRF1 and 
finally to lead to proteasomal degradation of UHRF1. Taken together, for the first time, we 
demonstrate a biologically significant role for a member of the PRAME-like protein family. This 
model might support the understanding of the replication-coupled, passive DNA demethylation 
mechanism occurring during the preimplantation development of the mouse embryo.  
 

Zusammenfassung  III 
Zusammenfassung  
Gene der PRAME-like (Preferentially expressed antigen in melanoma-like, Pramel) Familie teilen 
strukturelle Ähnlichkeiten mit dem humanen Tumor-Hoden-Antigen PRAME. Tumor-Hoden-
Antigene sind üblicherweise in einer Vielzahl von Krebsarten und in Keimzellen exprimiert. Bis 
anhin sind in der Maus 18 PRAME-like-Gene identifiziert worden, ihre molekularen Funktionen 
sind allerdings immer noch unbekannt. Pramel7, ein Mitglied der PRAME-like Familie, ist in 
den pluripotenten Kompartimenten eines frühen Mausembryos exprimiert, genauer in Morula 
und der inneren Zellmasse des Blastozysten. Während dieser frühen Phase der Embryonalent-
wicklung findet eine replikationsabhängige, passive Demethylierung des mütterlichen Genoms 
statt. Überexpression von Pramel7 in embryonalen Stammzellen der Maus (mESCs) erlaubt de-
ren Propagierung auch ohne Zugabe des Cytokins LIF (leukemia inhibitory factor) zum Kultur-
medium. Wenn Pramel7-überexprimerende mESCs zudem zur Differenzierung angeregt wer-
den, zeigen sie eine verminderte Differenzierungskapazität in vitro und in vivo. In mESCs kann 
die Expression von Pramel7 durch Aktivierung des LIF/STAT3-Signalweges induziert werden, 
was Pramel7 zu einem nachgeordneten Zielgen des Transkriptionsfaktors STAT3 macht. Trotz-
dem ist die molekulare Funktion von Pramel7 immer noch unbekannt. 
In dieser Arbeit identifizieren wir UHRF1 als einen Interaktionspartner von Pramel7 in 
HEK293T Zellen und mESCs. 
Das epigenetische Regulatorprotein UHRF1 (Ubiquitin-like containing PHD and RING finger 
domains, 1) dient dazu, DNA-Methylierungsmarkierungen während der DNA-Replikation zu-
verlässig vom Genom der Mutterzelle auf die Genome der beiden Tochterzellen zu übertragen. 
Dabei erkennt UHRF1 Stellen hemimethylierter DNA und führt DNMT1 (DNA-
methyltransferase 1) zu diesen Positionen. Neben DNMT1 interagiert UHRF1 auch mit anderen 
epigenetischen Regulatorproteinen wie HDAC1, G9a oder PARP1 und mit dem N-terminalen 
Ende von H3. UHRF1 ist somit in der Lage, eine Verbindung zwischen DNA-modifizierungen 
und dem Aufbau von Chromatinmustern herzustellen. 
Wir zeigen, dass eine Region im C-terminalen Teil von Pramel7 LRRs (Leucine-rich repeats) 
enthält und dass diese Region kritisch für eine erfolgreiche Interaktion mit URHF1 ist. Seitens 
UHRF1 trägt vor allem der C-terminale Teil, genauer SRA und RING Domänen, zur effizienten 
Bindung zwischen den beiden Proteinen bei. In Immunopräzipitationsexperimenten und mas-
senspektrometrischen Untersuchengen identifizieren wir weitere potenzielle Bindungspartner 
des Pramel7-UHRF1 Komplexes, wie ElonginC, HP1γ, CHD4, SPT16, PARP1, verschiedene 
Histone, Polyubiquitin und andere epigenetische Regulatoren. Im Bezug auf Pramel7 könnte 
dies auf eine Rolle auf Chromatinebene hindeuten. Interessanterweise können wir aufzeigen, 
dass forcierte Expression des Mausproteins Pramel7 in HEK293T Zellen (human) und in mESCs 
(Maus) zu einer raschen, dosisabhängigen und reversiblen Degradation von endogenem 
UHRF1-Protein führt. Dabei sind Versionen von Pramel7 mit Mutationen (Deletionen) in der 
LRR-Region nicht in der Lage, die Degradation von wildtyp (wt) UHRF1 zu induzieren. Wiede-
rum können mutierte Formen von UHRF1 (fehlender C-terminaler Teil inklusive SRA- und 
RING-Domänen) nicht durch Expression von wt Pramel7 degradiert werden. Zusammengefasst 
wird die Abnahme von UHRF1-Protein durch seine spezifische Interaktion mit Pramel7 vermit-
telt und erfolgt über den 26S-proteasomalen Degradationsweg. Als Konsequenz daraus finden 
wir in mESCs mit stabiler Überexpression von Pramel7 drastisch reduzierte 5mC-Levels (5-
Methylcytosin). Dies hat weitreichende Konsequenzen auf das Verhalten dieser Zellen: Unter 
Kulturbedingungen, die Selbsterneuerung begünstigen, weisen Pramel7-überexprimierende 

Zusammenfassung  IV 
mESCs ein erhöhtes Vorkommen aktivierender Histonmarkierungen auf. Ferner exprimieren 
diese Zellen den trophectodermalen Marker Elf5, der in wt mESCs normalerweise nur schwach 
aktiv ist, viel zu stark. Abnormale Überexpression von Elf5 kann auch in mESCs mit fehlender 
Expression aller DNMTs beobachtet werden. 
Ein erfolgreicher Differenzierungsprozess einer mESC erfordert die Aktivierung von Differenzie-
rungsgenen und die Abschaltung von Pluripotenzgenen. Dabei spielt die DNA-Methylierung 
eine wichtige Rolle, so gilt sie doch als ultimative epigenetische Abschaltungsmarkierung. Als 
Konsequenz fehlender DNA-Methylierung können wir in Pramel7-überexprimierenden mESCs 
beobachten, dass ihre Fähigkeit terminal zu differenzieren stark eingeschränkt ist: Nach 14-
tägiger Differenzierung und anschliessender Kultivierung unter Pluripotenz-fördernden Kultur-
bedingungen sind Pramel7-überexprimierende mESCs in der Lage, rasch wieder in ein pluripo-
tentes Stadium überzugehen. Dabei werden mit Pluripotenz assoziierte Marker wie Oct4, Na-
nog und Rex1 wieder reaktiviert. Diese Anzeichen erhärten die Annahme, dass die Präsenz von 
Pramel7 während des Differenzierungsprozesses die Kapazität von mESCs, Pluripotenzgene 
auszuschalten, drastisch vermindert.  
Unter Berücksichtigung unserer Massenspektrometriedaten stellen wir ein funktionelles Modell 
auf, in dem Pramel7 die Rolle eines Substraterkennungsproteins in einem E3 Cullin-RING Liga-
se-Komplex einnimmt. Dabei wird angenommen, dass die Interaktion zwischen Pramel7 und 
UHRF1 zur Übertragung von Ubiquitinresten auf das UHRF1-Protein und schlussendlich zur 
Degradation desselben führt. Zusammengefasst präsentieren wir in dieser Arbeit zum ersten 
Mal überhaupt eine biologisch signifikante Rolle für ein Protein der PRAME-like-Familie. In 
vivo könnten unsere Beobachtungen einen Beitrag zum Verständnis der passiven, replikations-
abhängigen Demethylierung des mütterlichen Genoms im frühen Mausembryo leisten. 
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A. Introduction 
PRAME-like genes (Preferentially expressed antigen in melanoma-like, Pramel) are structurally 
similar to the human cancer-testis antigen (CTA) PRAME. Expression of CTAs is mainly restrict-
ed to the testis and is also found in various types of cancer. Pramel7, a member of this gene 
family, was found expressed in the morula and the inner cell mass (ICM) of the blastocyst in the 
preimplantation mouse embryo. Moreover, expression of Pramel7 was implicated to support 
pluripotency in mouse embryonic stem cells (mESCs), shown by increased stability of Pramel7 
overexpressing mESCs in the absence of the cytokine LIF (Leukemia inhibitory factor), an extrin-
sic factor required for the maintenance of pluripotency in vitro. However, the exact molecular 
role of Pramel7 in the preimplantation embryo and mESCs and of PRAME-like proteins in gen-
eral is still elusive. In this work, we identify UHRF1 (Ubiquitin-like, containing PHD and RING 
finger domains, 1) as a specific interaction partner of Pramel7. We provide data confirming that 
Pramel7 mediates the degradation of UHRF1 at the protein level. Thereby, Pramel7 participates 
in chromatin remodelling in mESCs. Finally, we draw a possible mechanistic model explaining 
its role in pluripotency maintenance in vitro and preimplantation development in vivo. 
1. Pluripotent stem cells and epigenetic regulation of pluripotency 
1.1. Characteristics of pluripotent stem cells 
Stem cells are a specialized population of cells existing in multicellular organisms. The main 
function of these cells is to maintain tissue homeostasis by replacing damaged, injured or old 
terminally differentiated cells. Differentiation is defined by a transition of a cell from a higher to 
a lower degree of potency, finally reaching the status of a terminally differentiated and special-
ized cell without the ability to self-renew further. A typical feature of stem cells can be ob-
served in cell division. Firstly stem cells can self-renew and give rise to two identical daughter 
stem cells. In addition, they can divide asymmetrically. One daughter cell retains stem cell 
properties whereas the fate of the second daughter cell will be shifted towards differentiation 
(Smith, 2001).  
Embryonic stem cells (ESCs) are pluripotent, meaning they can give rise to tissues of all three 
germ layers of an adult organism, ectoderm, mesoderm and endoderm (Evans and Kaufman, 
1981), (Martin, 1981). These striking features make this cell type a promising tool in clinical 
research and regenerative medicine. The ability to molecularly control and steer stem cells by 
enforcing their differentiation into a cell type of interest would enable the indefinite generation 
of cell pools for the treatment of diseases as diabetes, myocardial infarction or neurodegenera-
tive disorders. However, it is challenging to achieve this, and many hurdles have to be over-
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come. One drawback is characterized by the incomplete or inefficient differentiation of stem 
cells previously propagated in an in vitro environment resulting in enhanced tendency for tu-
mour formation. Furthermore, the in vivo environment, the so-called stem cell niche, markedly 
differs from the artificial in vitro one. Thus, it has to be addressed how stem cells can efficiently 
be transferred from a culture dish into a living organism without any negative side effects such 
as tumorigenesis. Finally, a main goal of regenerative medicine is to overcome the problem of 
immunological rejection upon transplantation of foreign tissue, e.g. donor organs or stem cells. 
Murine embryonic stem cells (mESCs) are derived from the inner cell mass (ICM) of a mouse 
blastocyst stage embryo. mESCs can be maintained in vitro by cultivating them in medium sup-
plemented with leukemia inhibitory factor (LIF) and fetal bovine serum (FBS) containing bone 
morphogenetic protein 4 (BMP). LIF activates the transition of the transcription factor, Signal 
transducer and activator of transcription 3 (STAT3) from cytoplasm into the nucleus driving the 
expression of its target genes and maintaining self-renewal (Niwa et al., 1998). The serum com-
ponent BMP4 is thought to have an anti-differentiation effect by activating SMAD- (Similar to 
mothers against decapentaplegic) and Id- (Inhibitor of differentiation) genes that in turn lead to 
the activation of the core pluripotency factors Oct4 and SOX2 (Ying et al., 2003). mESCs are 
the most intensively studied and thus the most well characterized type of ESCs. They can be 
indefinitely propagated and genetically modified in vitro, and when injected into a donor blas-
tocyst, they have the potential to contribute to the development of a new embryo. These fea-
tures make mESCs a very powerful tool for genetic engineering and the well-established genera-
tion of transgenic animals. These transgenic models allow the study of various diseases and 
support the characterization of new genes and proteins. 
In 2006, Takahashi and Yamanaka presented an approach revolutionizing stem cell research. 
The two Japanese scientists were asking if it was possible to change the norm and reverse the 
order of cellular development at which cells of high developmental potency steadily differenti-
ate into cells of lower potency. To achieve this they first screened databases for interesting can-
didates and isolated 24 genes that were subsequently narrowed down to four factors. Indeed, 
when next the four candidate genes coding for transcription factors named Oct4, SOX2, Klf4 
and c-myc, nowadays also called the “Yamanaka-factors”, were retrovirally introduced they 
were able to reprogram differentiated mouse embryonic fibroblasts (MEFs) from 14 days old 
embryos back to so called induced pluripotent stem cells (iPSCs), resembling embryonic stem 
cells to a remarkably great extent (Takahashi and Yamanaka, 2006). iPSCs express the same sets 
of genes as ESCs and when injected into a blastocyst, they are able to participate in the devel-
opment of a new organism. Furthermore, upon injection into immuno-deficient mice, iPSCs 
give rise to teratomas containing tissues of all three germ layers (Wernig et al., 2007). This re-
markable finding potentially allows the generation of patient-specific stem cells 
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However, it soon became clear that iPSCs are not absolutely similar to ESCs. They exhibit a 
high tendency for tumour formation most likely due to genetic and epigenetic aberrations ob-
tained during the reprogramming process. Furthermore, c-myc displays strong oncogenic char-
acter. Finally, there exists a feature of iPSCs termed the “epigenetic memory”. During the re-
programming process, a differentiated cell of a certain tissue carrying a unique chromatin struc-
ture has to be converted into an ESC-like cell with an open and dynamic chromatin structure. 
Thus epigenetic marks of differentiated cells have to be erased and chromatin patterns of a plu-
ripotent cell have to be set up. During this conversion some loci of iPSCs retain the epigenetic 
marks of the original somatic cell, which is termed epigenetic memory. In addition, cells ac-
quire other genetic and epigenetic anomalies for example alterations in gene copies, compro-
mised function of imprinted genes, changed patterns in DNA methylation or point mutations 
(Kim et al., 2010), (Vaskova et al., 2013). Therefore, a lot of research still has to be undertaken 
in this field until these cells can be used for clinical applications in regenerative medicine. 
1.2. The core pluripotency network and intrinsic markers of pluripotency 
The in vitro maintenance of pluripotent mESCs requires defined and stringent culture condi-
tions. Generally the pluripotent state of mESCs is metastable and even minor changes in the 
environment of cells can lead to the loss of pluripotency and induction of differentiation. The 
pluripotent state is maintained through a network of numerous transcription factors activating 
targets that maintain pluripotency or repress factors driving differentiation. The proteins Oct4, 
SOX2 and Nanog represent the three core factors of this transcriptional network. Additional key 
players are Rex1, Sall4, Dax1 or Tcl1. All these transcription factors act in concert and in dif-
ferent combinations to maintain pluripotency. Moreover, chromatin-modifying enzymes regu-
lating the accession of promoters and thus the expression of associated genes are integrated in 
the complexes. Studies aiming on assessing the chromatin occupancy of Oct4, SOX2 and 
Nanog, in combination with analyses of various other transcription factors, have led to this ex-
tremely complex regulatory networks controlling transcription of target genes and maintaining 
pluripotency (Orkin and Hochedlinger, 2011).  
The in vitro characterization of pluripotent cells can be evaluated by testing the expression of 
the so-called pluripotency markers, representing the pluripotent state. Three examples are Oct4 
and Nanog, members of the core pluripotency network, and Rex1.  
The octamer-binding transcription factor 4 (Oct4) is encoded by the gene POU5F1 (Takeda et 
al., 1992). As a special case, Oct4 requires a precise degree of expression to maintain devel-
opmental potency. An expression above the critical level was shown to lead to differentiation 
of mESCs into primitive endoderm or mesoderm and expression below a certain threshold re-
sulted in differentiation into trophectodermal tissue. Thus, Oct4 expression needs to be kept in 
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a tight balance for an adequate maintenance of the pluripotent state (Niwa et al., 2000). A re-
cent study states that a defined level of Oct4 is required for pluripotency entry. Once the plu-
ripotent state is reached this expression level can be decreased up to seven-fold without loss of 
self-renewal. Furthermore, it was observed that mESCs expressing Oct4 at levels representing 
the ESC-state efficiently differentiated to all germ layers and germ line. In contrast, cells exhibit-
ing decreased levels of Oct4 were not able to differentiate and maintained the expression of 
pluripotency-associated genes. Thus, the expression level of Oct4 is the decision maker be-
tween the establishment of pluripotency and commitment to embryonic lineages 
(Radzisheuskaya et al., 2013). Early mouse embryos deficient in Oct4 fail to form an ICM and 
instead differentiate into trophectodermal tissue. Thus, a certain level of Oct4 is also crucial for 
the regulation of pluripotency in the in vivo condition preventing premature differentiation of 
embryos and guaranteeing a faithful development of the ICM (Nichols et al., 1998). 
When the homeobox protein Nanog is overexpressed mESCs deprived of LIF are very robust but 
not completely refractory to spontaneous differentiation (Hatano et al., 2005). On the other 
hand, Nanog-/- mESCs differentiate into extraembryonic endodermal tissues. Nanog expression 
is also shown to fluctuate in mESCs and its transient downregulation predisposes cells towards 
differentiation but does not mark commitment. When Nanog is genetically deleted resulting 
mESCs are prone to differentiation but still able to self-renew indefinitely. Moreover, Nanog-/- 
cells participate in the development of embryonic germ layers and are able to differentiate in 
multiple lineages. Nanog-/- mESCs, although recruited to the germ line, fail to reach the genital 
ridge. When repairing the mutant allele the defect is rescued. Thus Nanog is more likely to be 
important for the construction of ICM- and germ cells rather than directly involved in the 
housekeeping machinery maintaining the pluripotent state (Chambers et al., 2007). Nanog-
deficient embryos analysed at E5.5 are lacking primitive endoderm and fail to further develop 
(Mitsui et al., 2003).  
Reduced expression 1 (Rex1, also Zfp42) was first described after its specific expression had 
been observed in pluripotent F9 embryonic carcinoma cells (Hosler et al., 1989). Rex1 is ex-
pressed in pluripotent cells such as ESCs (Rogers et al., 1991), multipotent adult progenitor cells 
(Jiang et al., 2002), amniotic fluid cells (Karlmark et al., 2005), in germ cells of testis and in the 
ICM and early trophectoderm of the early mouse embryo (Rogers et al., 1991). Expression of 
Rex1 is positively correlated to increased pluripotency in mESCs (Toyooka et al., 2008), human 
embryonic stem cells (hESCs) (Brivanlou et al., 2003) and iPSCs (Chan et al., 2009) and is thus 
thought to be a reliable and a stringent marker for pluripotency.  
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1.3. History and features of epigenetics 
The field of epigenetics describes mitotically and/or meiotically heritable changes in gene function 
that cannot be explained by changes in DNA sequence (Russo, 1996). In 1882 Walther Flemming 
first mentioned the term chromatin after having developed new histological staining methods ena-
bling the observation of a specific fibrous structure in the cell nucleus. Approximately 50 years 
later, by identifying two different degrees of compaction in the interphase nucleus Emil Heitz made 
the distinction between heterochromatin and euchromatin. 
Nowadays, heterochromatin is associated with tightly compacted DNA regions and silent, non-
transcribed areas of the DNA. Heterochromatin can further be divided in constitutive and faculta-
tive heterochromatin. DNA regions of a given organism that are packed identically in all cells are 
termed constitutive heterochromatin. This type of heterochromatin is predominantly found around 
centromeres (centric and pericentric heterochromatin) and at telomeres. Facultative heterochroma-
tin, on the other hand, is not comparable between different cell types. For example, depending on 
the requirement of a specific cell type, lineage specific genes may be present as silenced hetero-
chromatin or active euchromatin. In contrast to heterochromatin, euchromatic regions are less 
compact and are actively transcribed (Gaspar-Maia et al., 2011). 
The unwrapped DNA of a eukaryotic cell has a length of two to three meters. To fit this tremen-
dous amount of information into a nucleus of around 6-10µm diameter, the DNA is tightly packed 
into chromosomes composed of chromatin fibre loops. These loops consist of nucleosomes, the 
repeating particles responsible for the primary level of DNA compaction. Each nucleosome is 
formed by the association of an octamer of the four core histones H2A, H2B, H3 and H4. The 
stretch of double stranded DNA is wrapped almost two times around each nucleosome (Luger et 
al., 1997) and the DNA between nucleosomes is connected by the linker histone H1 
(Ramakrishnan et al., 1993).  
Particles of the nucleosome complex can undergo reversible remodelling concomitant with un-
wrapping and rewrapping of the DNA. Furthermore, tails of histones are covalently modified by the 
addition of post-translational modifications (PTMs). In general, modifications are found in both 
histones and DNA. Methylation is the typical epigenetic mark for DNA. It is associated with tran-
scriptional repression and mediated by DNA methyltransferases. The maintenance DNA methyl-
transferase 1 (DNMT1) is responsible for transferring the correct DNA methylation pattern from 
mother to daughter cells after DNA replication (Jair et al., 2006). In contrast, de novo DNA methyl-
transferases 3a and 3b (DNMT3a/3b) are able to create new methylation marks, thus, to change the 
epigenetic signature (Okano et al., 1999). Compared to histone modifications, methylation of DNA 
is typically more stable and can be inherited for several cell generations. However, DNA methyla-
tion can be lost when specific enzymes crucial for DNMT1 function are missing during replication 
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(Gaspar-Maia et al., 2011). Recent findings indicate that methylations at cytosine residues can be 
oxidized into hydroxymethyl groups by enzymes of the Tet-dioxygenase family (Tet1-3) (Tahiliani 
et al., 2009). Hydroxymethylation is involved in the regulation of gene expression, embryonic de-
velopment, stem cell function and cancer. It is also seen to facilitate the demethylation of DNA, 
but the molecular circuitries underlying these features remain poorly defined (Pastor et al., 2013). 
PTMs of histones are very diverse and contain features such as methylation (me), acetylation (ac), 
ubiquitination (ub) and sumoylation of lysine (K) residues, methylation and citrullination of argi-
nine (R) residues, phosphorylation of serine (S) and threonine (T) residues, and ADP-ribosylation of 
glutamate (K) and arginine (R) residues (Bannister and Kouzarides, 2011). The most common his-
tone marks representing active transcription are H3K4me1/3, H3K9me1, H3K9ac, H3K14ac, 
H3K27me1, H3K27ac and H3K79me1/2, whereas H3K9me2/3, H3K27me2/3 and H3K79me3 rep-
resent repressive modifications (Tab. 1) (Benevolenskaya, 2007), (Barski et al., 2007), (Koch et al., 
2007), (Steger et al., 2008), (Rosenfeld et al., 2009), (Creyghton et al., 2010). A schematic illustra-
tion of DNA modifications and PTMs of histones is depicted in Fig. 1. This broad range is mediated 
and regulated by various enzymes such as histone acetyltransferases (HATs), histone deacetylases 
(HDACs), histone methyltransferases (HMTs), histone demethylases (HDMs), kinases or phospha-
tases which are able to add or remove the histone marks and are usually involved in big protein 
complexes (Musselman and Kutateladze, 2011). Two prominent examples are the Trithorax (trxG) 
and the Polycomb group (PcG) complexes. TrxG proteins were identified as activators of Drosophi-
la Hox-genes important for body patterning (Schuettengruber et al., 2007). They catalyse trimethyl-
ation of histone H3K4 (H3K4me3), a mark associated with active transcription. In mammalian 
cells, proteins catalysing H3K4me3 are the H3K4-methylases SET1A, SET1B, and mixed lineage 
leukemia (MLL) proteins 1-4. As mentioned above, these factors cannot function alone and require 
additional subunits for activity (Shilatifard, 2012).  
 
Tab. 1: Selected variants of histone modifications with their effector functions. 
A = activation, R = repression. 
 
Modification 
Histone 
H3K4 H3K9 H3K14 H3K27 H3K36 H3K79 H4 H4K20 
Monomethylation A A   A   A A A 
Dimethylation   R   R   A     
Trimethylation A R   R A A/R     
Acetylation   A A A       
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Fig. 1: Schematic illustration of epigenetic modifications. 
Histones are coloured in orange, DNA in purple. DNA is wrapped approximately 1.6x around histone 
octamers. 5mC=5-methyl cytosine, 5hmC=5-hydroxymehtyl cytosine, K=lysine, R=arginine, S=serine, 
Ub=ubiquitination, Me=methylation, ADP-r=ADP-ribosylation, Ac=acetylation, P=phosphorylation, 
Ci=citrullination, Su=sumoylation. 
 
PcG protein complexes were first observed in Drosophila as responsible factors for the silencing of 
Hox-genes (Schuettengruber et al., 2007). Proteins of the PcG form the multi-subunit repressive 
complexes PRC1 and PRC2 (Polycomb repressive complex 1 and 2) (Margueron and Reinberg, 
2011), (Simon and Kingston, 2009). The PRC2 histone methyltransferase EZH2 (Enhancer of zeste 
homolog 2) mediates trimethylation of H3K27 (H3K27me3), a prominent mark in the establishment 
of repressive chromatin in both the adult organism and early development (Czermin et al., 2002). 
PRC1 unites different complexes containing the RING1A/B ubiquitin ligase and is therefore as-
sumed to mediate silencing of its targets at least in part by ubiquitination of H2AK119 (Gao et al., 
2012). However, the exact mechanism of PRC1-mediated gene repression and chromatin compac-
tion still remains elusive (Simon and Kingston, 2013). 
Finally, the incorporation of histone variants such as H3.3, H2A.Z or macroH2A can change the 
state of chromatin, leading to a more open or closed conformation (Gaspar-Maia et al., 2011). 
1.4. ESCs display a unique epigenetic landscape 
Even though a big effort still has to be undertaken to molecularly decrypt the functional entity 
of histone modifications, recent studies have provided genome-wide insights into how these 
marks might function in vivo. Since human and murine ESCs harbour a huge potential for bio-
logical research and medical applications, there is a big interest in mapping and understanding 
the epigenetic landscape of this special cell type (Voigt et al., 2013). When localizing chroma-
tin modifications in ESCs, histone marks as H3K4me1 and H3K27ac can be found at active 
enhancers and H3K4me3 and H3K27me3 within active and silent promoters. These signatures 
are basically present in all mammalian cell types (Zhou et al., 2011) but certain features appear 
to be specifically more abundant in ESCs. There is a substantial fraction of genes, many of them 
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regulating developmental processes, carrying both the activating mark H3K4me3 and the re-
pressive modification H3K27me3 at the same time. These on the first sight contrarious marks 
are termed “bivalent” domains and were mentioned for the first time in 2006 by Bernstein et al. 
after having performed sequential ChIP analysis against different histone modifications 
(Bernstein et al., 2006). Although these special domains are most abundant in ESCs they are 
also occurring in cell types with more restricted potency (Voigt et al., 2013).  
Above observations have led to the hypothesis that bivalent domains may maintain genes in a 
state poised or primed for differentiation, allowing either rapid activation or silencing upon 
sensing appropriate stimuli. This is supported by several follow-up studies showing that on a 
genome wide scale, genes with bivalent profiles exhibit associated expression changes upon 
induction of differentiation (Pan et al., 2007), (Mikkelsen et al., 2007), (Zhao et al., 2007).  
Most of the bivalent genes in ESCs are targets of PcG proteins. Thus, valuable information about 
their importance can be gained from knockout studies of PRC complex members. For example, 
in ESCs with depleted Eed protein (Eed-/-), which together with Suz12 and EZH2 constitutes the 
essential components of PRC2, a premature expression of bivalent genes can be observed 
(Azuara et al., 2006), (Boyer et al., 2006). The same is true for Suz12-/--ESCs (Pasini et al., 
2007). However, despite premature expression of genes related to differentiation, self-renewal 
capacity and cell viability are not impaired. Nevertheless, PRC2-deficient ESCs exhibit a com-
promised differentiation potential (Pasini et al., 2007), (Shen et al., 2008), (Chamberlain et al., 
2008). In conclusion, these findings indicate that PRCs are crucial for adequate differentiation 
of ESCs, most likely by controlling bivalent promoters of target genes coding for proteins in-
volved in development. 
When an ESC differentiates, its bivalent promoters either undergo activation or silencing. When 
the expression of such a gene is activated repressive marks in the promoter region have to be 
removed and vice versa. Thus, activation of a bivalent gene requires erasure of H3K27me3 
while repression is mediated by the removal of H3K4me3 (Voigt et al., 2013). These processes 
are initiated when the cell experiences developmental cues and transfers them into the nucleus 
via cell signalling cascades. This is often accompanied by the recruitment of specific transcrip-
tion factors, leading to the activation of the target gene. At many bivalent promoters, the related 
transcription factors are absent or inactive in the pluripotent state (Ku et al., 2008). They are 
recruited upon induction of differentiation, which might be a key process in activating the tran-
scription of these genes. In favour of this assumption, overexpression of transcription factors 
regulating developmental genes results in alterations of transcriptional programs and heavily 
affects bivalent genes (Nishiyama et al., 2009), (Sharov et al., 2011). Unlike bivalent genes, 
housekeeping genes do not show altered expression upon differentiation, most likely due to the 
presence of a persistent and sufficient amount of protein complexes activating transcription. 
Introduction  9 
Finally, extrinsic signals are also able to modulate the nuclear levels of chromatin modifiers and 
influence the structure of the chromatin by facilitating or impeding transcription (Badeaux and 
Shi, 2013).  
1.5. DNA methylation and mESCs 
Because of their highly dynamic chromatin, mESCs are one of the most well studied systems for 
epigenetic changes. When mESCs differentiate, genes associated with pluripotency have to be 
silenced rapidly while other factors driving differentiation are activated. Surprisingly, mESCs are 
tolerant to global demethylation. Despite depletion of all three DNA methyltransferases 
(DNMT1-/-/3a-/-/3b-/-), the molecular signature of pluripotency is unaffected and self-renewal is 
not lost (Tsumura et al., 2006). Nevertheless, differentiation capacity of DNMT triple knockout 
mESCs is drastically reduced. On one hand, triple knockout cells loose the ability of upregulat-
ing markers associated with germ layers and on the other hand, they fail to efficiently shut 
down promoters of pluripotency genes (Jackson et al., 2004). Upon differentiation, gene pro-
moters such as Oct4 and Nanog are silenced by hypermethylation. Silencing of Oct4, as an 
example for a gene promoter of a gene associated with pluripotency, is initiated first by re-
pressor binding and subsequent H3K9 methylation, mediated by the histone methyltransferase 
G9a and recruitment of heterochromatin protein 1 (HP1) and is accomplished by de novo DNA 
methylation. However, when G9a expression is absent silencing of Oct4 is inefficient and re-
versible (Feldman et al., 2006). During the differentiation process, DNA methylation of distinct 
promoters occurs concomitantly with nucleosome assembly preventing further binding of tran-
scription factors to target promoters (You et al., 2011). It is moreover shown that silencing of 
Oct4 can be forced in vitro by artificial targeting of HP1α to the Oct4 promoter, resulting in 
methylation of H3K9 and subsequent DNA methylation. When carried out in MEFs, this de 
novo silencing is stable and heritable after removal of the HP1α-targeting stimulus but in mESCs 
withdrawal leads to demethylation and reactivation of Oct4-expression (Hathaway et al., 
2012).  
A unique feature of mESCs that is not found in other cell types is the presence of DNA methyla-
tion in non-CpG background, most commonly in CpA dinucleotides probably reflecting a state 
of hyperactive de novo DNMT3a/b activity (Ramsahoye et al., 2000). Even though globally 
occurring, this non-CpG type of methylation is enriched at certain genomic loci. It co-localizes 
with high degrees of CpG methylation and is silenced on differentiation (Ziller et al., 2011). 
Furthermore, DNA methylation is exhibiting a buffer function in extraembryonic commitment 
(Jackson et al., 2004), (Ng et al., 2008). DNMT1-/- mESCs exhibit a uniquely high potential for 
the trophectodermal lineage verified by the upregulation of the transcription factor Elf5. To-
gether with other factors such as Cdx2 and Eomes, Elf5 takes a crucial role in trophectodermal 
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specification during the development of an early mouse embryo. More importantly, expression 
of these genes induces a competition with genes associated with the pluripotency network 
(Smith and Meissner, 2013). In contrast, in a wild type (wt) population of mESCs, promoters of 
these genes are methylated and only a very small fraction of cells is able to differentiate into 
trophectodermal tissue (Ng et al., 2008). 
Taken together, how exactly DNA methylation is orchestrated with other mechanisms of gene 
silencing still is a complex question. It remains a challenging task to evaluate the role of CpG 
methylations in different developmental contexts (Smith and Meissner, 2013). 
1.6. Epigenetic events during preimplantation development of the mouse embryo 
The preimplantation process in the mouse starts with the fertilization of the oocyte by the sperm 
and ends with the implantation of the embryo in the uterus. This process can be divided into 
the well-organized stages ovulation (E0), fertilization (E0.5), zygotic stage (E0.5-1.5), cell cleav-
age (E1.5-E2.5), morula formation (E2.5-E3.5), blastocyst formation (E3.5-E4.5) and implanta-
tion (E4.5). The induction of the above stages is regulated on both the genetic and epigenetic 
level, and these two levels of regulation are strictly interrelated. In mammalian embryos, the 
oocyte stores a bunch of maternal RNAs and proteins subsequently expressed in the earliest 
phase of preimplantation development (Wang and Dey, 2006). Fertilization acts as a trigger for 
the degradation of these maternal factors, which at the 2-cell stage are almost undetectable 
anymore (Nothias et al., 1995). Then, the newly assembled zygotic genome initiates its expres-
sion between the 2- and the 4-cell stage and genetic patterns required for subsequent develop-
ment of the embryo are established. This process is also known as zygotic genome activation 
(ZGA) (Wang and Dey, 2006). Preceding morula and blastocyst stage, a second wave of gene 
activation peaks at the 8-cell stage, the so-called mid-preimplantation gene activation (MGA), 
involving the activation of adhesion molecules required for blastomere polarity and compac-
tion (Hamatani et al., 2004). 
Genetic expression patterns during early embryonic development are very well characterized. 
Based on this knowledge research soon focused on the generation of corresponding epigenetic 
profiles (Shi and Wu, 2009). Every epigenetic event requires certain enzymes that need to be 
obligatorily expressed in advance, for example DNMTs, HDACs or HMTs or even whole chro-
matin remodelling complexes. Some epigenetic regulators are expressed concomitantly with 
ZGA. One example is HDAC1, whose expression is initiated at the single cell stage and gradu-
ally increases until blastocyst stage (Ma and Schultz, 2008). On the other hand, the expression 
of other regulators such as the histone methyltransferase SETB1 is not seen until the blastocyst 
stage when maternal SETB1 gets exhausted (Dodge et al., 2004).  
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Epigenetic regulation always functions in cooperation with genetic control. The early preim-
plantation embryo has to first differentiate into two compartments, the inner cell mass (ICM) 
and the trophectoderm. The ICM will give rise to the whole organism while the trophectoderm 
develops into extraembryonic tissues. Consequently, cells of the ICM retain their pluripotent 
expression profiles whereas trophectodermal tissues lose them. Thus, as described previously in 
chapter 1.2, the expression of Oct4 defining the pluripotent population of cells needs to be 
precisely regulated. In cells of the ICM, the transcription factor Sall4 binds at the promoter re-
gion of Oct4 and activates Oct4-expression (Zhang et al., 2006). Then, Oct4 is able to interact 
with the proximal region of Nanog promoter activating Nanog expression (Kuroda et al., 2005). 
In the outer cells of the morula the transcription factor TEAD4 controls the expression of Cdx2, 
which in turn blocks the activity of Oct4 and Nanog, leading to the establishment of the 
trophectodermal line (Nishioka et al., 2008). At the same time, levels of DNA- and histone 
methylation and histone acetylation at the promoter of Oct4 might be altered to fix the perma-
nent shutdown of the Oct4 gene (Hattori et al., 2004). 
 
Fig. 2: Regulatory events defining the first steps of differentiation in the early mouse embryo. 
In the early morula stage inner cells maintain the expression of Sall4 and Oct4 leading to the activation 
of Nanog. In the outer, future trophectodermal cells expression of TEAD4 is activating Cdx2, antagoniz-
ing Oct4 expression in the inner cells. Subsequent activation of Eomes and Elf5 is stabilizing the 
trophectodermal fate. In the late blastocyst the ICM is separated in primitive endoderm, specified by the 
expression of GATA6 antagonizing the expression of Nanog expressed in the cells of the epiblast. From 
Ralston and Rossant, 2005, modified. 
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TEAD4 and Cdx2 in concert activate the expression of Eomes leading to the upregulation of 
Elf5, further specifying trophectodermal fate (Sasaki, 2010). However, how exactly cells are 
poised for one or the other fate still remains a debate. The key regulatory processes in the de-
velopment of the early embryo are illustrated in Fig. 2. 
During preimplantation development, DNA methylation undergoes dynamic changes. After 
fertilization, maternal and paternal pronuclei are formed. Just after fertilization the murine pa-
ternal genome exchanges protamines, substitutes of histones in spermatogenesis, with maternal-
ly inherited histones (Adenot et al., 1997) and the paternal genome is actively demethylated 
rapidly (Mayer et al., 2000). How this active demethylation is mediated in detail is still not un-
derstood. Recent studies reveal that 5-mehtylcytosine (5mC) can sequentially be oxidized to 5-
hydroxymethylcytosine (5hmC) (Tahiliani et al., 2009), 5-formylcytosine (5fC) and 5-
carboxymethylcytosine (5caC) (He et al., 2011), (Ito et al., 2011) by the enzymes Tet1-3. Tet3 is 
highly expressed in oocytes and zygotes but downregulated at the 2-cell stage. Furthermore, 
5hmC accumulates in the paternal genome while 5mC levels decrease, leading to the assump-
tion that the active loss of 5mC in the paternal genome is at least in part due to the oxidation of 
5mC by Tet3 (Iqbal et al., 2011).  
 
Fig. 3: Alterations in DNA-modification profiles in the early mouse embryo. 
A: Fertilization of the oocyte by the sperm. B: Soon after fertilization protamines in the paternal pronu-
cleus are replaced by maternally provided histones. DNA in the paternal nucleus is actively demethylat-
ed very fast. C: From 2 cell to the blastocyst stage the maternal genome is demethylated by a passive 
mechanism. In the late blastocyst the ICM is separated into epiblast and primitive endoderm (see Fig. 2). 
D: From the late blastocyst stage onwards a wave of DNA remethylation is induced. In the postimplanta-
tion epiblast primordial germ cell precursor cells are specified. PP= paternal pronucleus, MP= maternal 
pronucleus, TE= trophectoderm, PE= primitive endoderm, PGC= primordial germ cells. From Cantone 
and Fisher, 2013, modified. 
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In the maternal genome, the protein Dppa3 (Stella) interacts with H3K9me2 and prevents Tet3 
access (Nakamura et al., 2012). Thus, the conversion from 5mC to 5hmC is less evident. The 
loss of 5mC in the maternal genome is thought to occur via a rather passive mechanism by re-
peated cell divisions resulting in an overall reduction of 5mC levels (Fig. 3) (Rougier et al., 
1998), (Santos et al., 2002), (Inoue and Zhang, 2011). However, since DNMT1 is present 
throughout preimplantation development and is sufficient to maintain DNA methylation at im-
printed regions (Hirasawa et al., 2008), the mechanism by which 5mC is passively lost still 
needs to be clarified. From the blastocyst stage onwards, the first differentiation processes are 
accompanied by de novo methylation mediated by DNMT3a/3b leading to silencing of genes 
responsible for the maintenance of pluripotency (Santos et al., 2002).  
Compared to DNA methylation the situation for histone modifications and histone variants is 
more complex. Histone tails can be extensively modified and from the experimental data ac-
cessible no general model can be drawn so far. As for DNA methylation, there is a dramatic 
change in histone modifications during preimplantation development in specific stages and cell 
types (Shi and Wu, 2009). In addition, it is observed that within one embryo different cells can 
exhibit divergent mRNA expression patterns for DNMTs and HMTs, 5mC-binding proteins and 
other chromatin modifiers. Therefore, different cells carry different epigenetic profiles further 
complicating the analysis (May et al., 2009). Taken together, these findings suggest a tight tem-
poral and spatial program orchestrating DNA- and chromatin-modifications, resulting in the 
establishment of the zygotic developmental program (Cantone and Fisher, 2013).  
2. Preferentially expressed antigen in melanoma-like 7 (Pramel7) 
2.1. PRAME, the founding member of a big gene family 
The leucine-rich repeat (LRR) containing human protein PRAME (Preferentially expressed anti-
gen in melanoma) is considered the founding member of the Pramel (PRAME-like) gene family 
(Preferentially expressed antigen in melanoma-like). PRAME was originally found as a gene 
coding for an antigenic peptide presented to autologous tumour-specific cytolytic T lympho-
cytes that were derived from a patient suffering from melanoma (Ikeda et al., 1997). Expression 
profiles of PRAME define it as a cancer-testis antigen (CTA). These genes are usually highly ex-
pressed in tumours while in to healthy tissues they are predominantly found in germinal cells 
(Haqq et al., 2005). However, specific expression of PRAME was also detected in adrenal tis-
sues, placenta and endometrium (Ikeda et al., 1997). In addition, levels of PRAME in malignant 
tissues of breast cancer and neuroblastoma correlated with poor clinical outcome and thus acts 
as a useful marker for the progression of the disease (van 't Veer et al., 2002), (Oberthuer et al., 
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2004). Since the exact regulatory mechanisms of PRAME are not completely understood its 
molecular functions in healthy tissues and malignancies still remain elusive.  
In 2005 Epping et al. described PRAME as a dominant repressor of retinoic acid (RA) signalling. 
F9 embryonic carcinoma cells expressing PRAME were observed to be resistant to RA treat-
ment. In general, RA signalling was shown to induce differentiation, arrest of proliferation and 
apoptosis, and failure in RA signalling could be linked to cancer. The authors proposed a mod-
el for healthy cells, where RA is binding to its ligand RAR (Retinoic acid receptor) inducing the 
expression of RA target genes. This cascade is ultimately leading to differentiation of cells and 
growth arrest. In contrast, in PRAME-positive tumour cells, PRAME is interacting with RAR. This 
leads to the recruitment of PcG proteins such as the histone methyltransferase EZH2. As a con-
sequence, RA targets are silenced, RA-dependent features cannot be triggered and uncontrolled 
proliferation is provoked (Epping et al., 2005). A comparable effect could be observed in mye-
logenous immortalized leukemia cells (K562) where inhibition of PRAME caused growth arrest 
and apoptosis (Tanaka et al., 2011). Finally, PRAME-knockdown in Hodgkin lymphoma cells 
induced an increase in retinoic acid signalling and cytotoxic drug sensitivity (Kewitz and 
Staege, 2013). 
On the molecular level, a recent study states that PRAME is able to act as a substrate recogni-
tion subunit of a Cullin2-based Cullin-RING ligase (CRL) targeting substrates for proteasomal 
degradation. The authors found that many members of the large PRAME gene family harbour 
conserved BC- and Cullin2-boxes and stated that they might function as recognition compo-
nents, with different levels of specificity in substrate selection. Furthermore, chromatin im-
munoprecipitation-based experiments revealed enriched levels of PRAME at active promoters 
that were also bound by the nuclear transcription factor Y (NFY). Recruitment of PRAME was 
linked to high transcriptional activation of these NFY-loci. Nevertheless, how these novel mo-
lecular features of PRAME are implicated in the progression of malignant tumours still remains 
elusive (Costessi et al., 2011). 
2.2. Pramel7 and other PRAME-like proteins 
Arisen from gene duplications, 18 PRAME-like (Pramel) genes and 15 pseudogenes were pre-
dicted in a gene cluster-region on mouse chromosome 4 in the mouse (Birtle et al., 2005). Two 
members of the Pramel-family (Pramel1 on chromosome 4 and Pramel3 on the X-chromosome) 
are described as a group of proteins exclusively expressed in male germ cells of an adult mouse 
(Wang et al., 2001). A recent work focusing on the expression of Pramel1 in spermatogenesis 
shows that its expression in testis starts from week 3 onwards. Developing spermatids exhibit a 
positive staining in the acrosome and parts of the flagellum, suggesting a hypothetical role for 
Pramel1 in the acrosomal development and sperm maturation (Mistry et al., 2013).  
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In 2003, Bortvin et al. asked why cloned embryos were not surviving as efficiently as normal 
embryos and hypothesized that cloned embryos may not correctly reactivate certain pluripo-
tency-related genes as Oct4. To assess this, the authors aimed at identifying genes in cloned 
embryos in comparison to normal embryos displaying similar expression changes as Oct4 and 
found that a majority of ten identified candidates were not correctly expressed in cloned em-
bryos. Indeed, correct reactivation of Oct4-related genes correlated with the efficiency of the 
embryonic development of blastocysts cloned from either somatic cells or mESCs. Intriguingly, 
four out of ten candidates encoded proteins of the Pramel-family, Pramel4, Pramel5, Pramel6 
and Pramel7 whose expression in early embryonic cleavage stages could be shown (Bortvin et 
al., 2003).  
A study from Cinelli et al. demonstrated the generation of germ line competent ESCs from the 
non-permissive mouse strain FVB. These cells ectopically expressed STAT3, the key transcrip-
tion factor crucial for the maintenance of mESCs in vitro activated by the cytokine LIF. When 
comparing the transcriptome of STAT3-overexpressing and wt FVB ESCs in a microarray exper-
iment a set of 26 differentially regulated genes were isolated including Pramel7, exhibiting an 
upregulation of 8.5-fold in STAT3-overexpressing cells. When examining the expression of 
Pramel7 in the early mouse embryo positive in situ hybridization signals were detected in the 
central part of the morula and the ICM of the blastocyst, the pluripotent compartments of the 
early embryo. In addition, upon overexpression of Pramel7, mESCs could be maintained in a 
pluripotent state even in the absence of LIF (Cinelli et al., 2008).  
Similar to STAT3-overexpressing mESCs, Pramel7-expression was also observed to be upregu-
lated also in Smad4-/- mESCs. In the early embryo, Smad4 is required for axis patterning. Smad4-
null embryos arrest shortly after implantation and have a shortened proximodistal axis, a re-
duced epiblast and a thickened visceral endoderm layer. Concomitantly, Smad4 mutant mESCs 
and embryoid bodies display reduced nascent mesoderm markers and enhanced expression of 
other non-canonical pluripotency markers as Zscan4 and Tbx3 whose functions are not precise-
ly defined (Costello et al., 2009).  
To confirm that the expression of Pramel7 is regulated by LIF/STAT3 and to examine the role in 
self-renewal of mESCs in general, Casanova et al. provided evidence that Pramel7 is mediating 
LIF/STAT3-dependent self-renewal in mESCs. Upon ablation of Pramel7 mESCs began to differ-
entiate, whereas its overexpression blocked the capacity of mESCs to differentiate in vitro and in 
vivo. Consequently, Pramel7-overexpressing mESCs were not able to participate in the genera-
tion of chimeric mice. Interestingly, after transgenic excision of Pramel7, mESCs regained this 
feature. When assessing the differentiation ability of mESCs overexpressing Pramel7 in vivo a 
similar outcome was observed. Upon injection of cells into immuno-deficient mice no teratoma 
could be generated. On the molecular level, the expression of Pramel7 was found to be con-
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trolled by LIF-signalling via both STAT3-dependent regulation on the transcriptional level and 
via phosphorylation of glycogen synthase kinase 3ß (GSK3ß), dependent on phosphatidylinosi-
tide 3-kinase (PI3K) signalling. Furthermore, upon induced knockdown of Pramel7 mESCs start-
ed to differentiate even in the presence of LIF and enforced activation of STAT3. These findings 
suggest that Pramel7 is an important and essential gene in the molecular circuitry of the plurip-
otency maintenance network (Casanova et al., 2011). However, the exact mechanism and the 
role of the protein Pramel7 in vitro and in vivo still need to be understood.  
 
3. Ubiquitin-like, containing PHD and RING finger domains, 1 (UHRF1): An 
important regulator of epigenetic patterning 
Before initiating this project we were interested in the molecular function of Pramel7 within the 
cell. Analysis of the amino acid composition of the protein sequence indicated the absence of 
DNA-binding domains suggesting that Pramel7 is unlikely to act as a transcription factor. Nev-
ertheless, it was possible to identify the presence of leucine rich repeats (LRRs) implying a role 
of Pramel7 in protein-protein interaction. As a next step, using the yeast two-hybrid approach, 
we identified the protein ubiquitin-like, containing PHD and RING finger domains, 1 (UHRF1) 
as a potential binding partner. The following chapter tries to summarize the most important 
benchmark data from the last years on UHRF1 describing this multi-functional epigenetic regu-
lator protein. 
3.1. Nomenclature and protein architecture 
It was in 1998 when Fujimori et al. described NP95 (95kDa Nuclear Protein) as the first member of 
the UHRF protein family in mouse. After detection of differential expression patterns throughout 
different stages of the cell cycle it was defined as a “novel nuclear protein in cell cycle progression 
and/or in DNA replication” (Fujimori et al., 1998). Two years later, Hopfner et al. discovered the 
human UHRF1 counterpart ICBP90 (Inverted CCAAT-binding protein 90), a 90kDa protein with 
similar domains as NP95. By yeast one-hybrid screening, ICBP90 was shown to bind the promoter 
region of topoisomerase IIα and thereby regulate topoisomerase IIα expression. Since the modula-
tion of this gene was thought to enhance the sensitivity to anti-topoisomerase II drugs ICBP90 was 
selected with the intention to find new anti-cancer drugs and new markers for proliferation. Thus, 
UHRF1 was assumed to have potential roles in cell proliferation processes and cancer mechanisms 
(Hopfner et al., 2000). According to the comparable composition of domains, the Human Genome 
Organization (HUGO) nomenclature committee then assigned the term UHRF1 (Ubiquitin-like, 
containing PHD and RING finger domains) to both the human and the mouse protein variants. In 
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the following years additional family members were described (UHRF2 and UHRF3) but up to now 
the main scientific focus has been on UHRF1.  
UHRF1 is a multi-domain protein thought to be involved in cellular processes such as epigenetic 
control, cell cycle progression or ubiquitination. A schematic overview showing the structure of 
UHRF1 is illustrated in Fig. 4. The UBL (ubiquitin-like) domain is located the most N-terminally of 
all UHRF1 domains and can be found in almost all members of the UHRF protein family. The do-
main per se shares 35% homology with ubiquitin. UBL comprises a typical alpha/beta ubiquitin 
fold. The two surface lysine residues K33 and K52 are structurally conserved with lysine residues of 
ubiquitin (K29 and K48), which is the key signal for degradation in the proteasome when attached 
to a target protein in several copies. However, the role of UBL is unclear. Since a transfer of 
UHRF1’s UBL to another protein is unlikely, the domain may rather have a structural role or be 
involved in protein-protein interactions than actively polyubiquitinating other proteins (Bronner et 
al., 2007).  
 
Fig. 4: UHRF1 domain architecture. 
UHRF1 is composed of an N-terminal UBL-domain, followed by a Tandem-Tudor and a PHD domain. 
SRA and RING domains are located most C-terminally. UBL=Ubiquitin-like, PHD=Plant homeodomain, 
SRA=SET and Ring finger-associated, RING=Really interesting new gene. 
 
Tandem-Tudor and PHD (Plant homeodomain) domains are involved in the recognition of the H3-
tail (see Introduction chapter 3.4.1). The SRA (SET and Ring finger associated) domain is able to act 
as a reader unit for hemimethylated DNA during DNA replication leading to the recruitment of 
DNMT1 to particular sites and enabling a faithful propagation of DNA methylation (see Introduc-
tion chapter 3.4.2). Finally the RING (Really Interesting New Gene) domain possesses E3 ubiquitin 
ligase activity and might be involved in processes concerning protein degradation (see Introduction 
chapter 3.3). 
3.2. UHRF1 is involved in the maintenance of DNA methylation 
3.2.1. UHRF1 is essential for the maintenance of global DNA methylation 
Two independent research groups uncovered the biological key function of UHRF1 around the 
same time in 2007. They proposed a model describing UHRF1 mediating the faithful propagation 
of DNA methylation patterns from mother to daughter cells during DNA replication. The studies in 
detail showed that in Uhrf1-/- mESCs a substantial global loss of DNA methylation is observed. This 
loss could not be explained by concomitant reduction of DNA methyltransferases since the 
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amounts of DNMT1, DNMT3a and 3b were not lowered. In addition, UHRF1 was shown to be 
physically associated with DNMT1 and a reduction of UHRF1 deleted the association of DNMT1 
with chromatin. However, depletion of DNMT1 did not reduce the interaction of UHRF1 with 
chromatin. Finally, DNMT1 enrichment in heterochromatin could not be observed anymore during 
the S-phase of the cell cycle in Uhrf1-/- mESCs. These findings suggest that UHRF1 has a role in 
guiding DNMT1 to chromatin (Bostick et al., 2007), (Sharif et al., 2007). 
Besides binding to DNMT1, UHRF1 was also shown to interact with the de novo DNA methyl-
transferases DNMT3 and 3b. Meilinger et al. made use of the fact that the CMV promoter is rapidly 
silenced in mESCs und used the feature as a model for studying the importance of the three mole-
cules in silencing of CMV. First, DNMT3a-/-/3b-/- double and DNMT1-/-/3a-/-/3b-/- triple knockout 
mESCs were unable to silence CMV. Knockout of DNMT1 resulted in only weak CMV silencing 
indicating a major importance of the de novo methyltransferases DNMT3a and 3b in this process. 
Surprisingly, complete loss of CMV silencing was observed in UHRF1-/- mESCs despite the presence 
of a full set of functional DNA methyltransferases. These observations emphasize the importance of 
UHRF1 and DNMT3a/b in the silencing process. In wt cells CMV silencing preceded the emer-
gence of DNA methylation. Based on this finding the authors hypothesized that other factors such 
as the histone methyltransferase G9a may mediate immediate silencing. Indeed, G9a-/- cells were 
unable to induce silencing of the CMV promoter. In consideration of the fact that UHRF1 is able to 
interact with DNMT3a, DNMT3b and as well G9a these factors might be involved in a common 
immediate silencing pathway independent of DNA methylation (see Introduction chapter 3.2.3) 
(Meilinger et al., 2009). 
3.2.2. The SRA domain mediates the recognition of hemimethylated DNA 
Shortly after Avvakumov et al., Hashimoto et al. and Arita et al. independently deciphered the mo-
lecular reading mechanism by which the SRA domain of UHRF1 recognizes hemimethylated CpG 
(hemCpG) sites emerging during the synthesis of new DNA strands. By doing so, UHRF1 hands 
over the DNA to DNMT1 by direct interaction ensuring the accurate copy of methylation marks 
during S-phase of the cell cycle (Arita et al., 2008). In addition, besides hemCpG recognition the 
SRA domain was shown to be responsible for the mediation of the interaction of UHRF1 with 
DNMT1 (Achour et al., 2008). The mechanism works by flipping out the methylated CpG from the 
double helix, placing it into a binding pocket specific for hemCpG and finally filling the resulting 
gaps in major and minor grooves of the DNA with two specialized SRA loops. The so-called “NKR 
finger” (Asn-Lys-Arg are present at this specific site) fills the gap in the major groove and is capable 
of reading the residual opposite nucleotides of the CpG duplex. The resulting gap in the minor 
groove is filled by the “thumb” which shows no direct interaction with the nucleotides but is linked 
to the NKR finger via Van der Waals interactions, resulting in a kind of “finger-thumb” grasping 
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(Avvakumov et al., 2008). As a conclusion, a model for a faithful transfer of the methylation pat-
terns from mother to daughter strands was described in which the SRA domain recognizes a hem-
CpG-duplex and interacts with the methylated cytosine residue by base-flipping.  
3.2.3. Subsequent studies characterizing the epigenetic function of UHRF1 
When looking more closely at intracellular UHRF1 dynamics it was found that after photobleach-
ing UHRF1 recovery between DNMT1-/- single- and DNMT1-/-/3a-/-/3b-/- triple-knockout mESC was 
comparable. This observation indicates that the prevalence of methylated DNA and DNA methyl-
transferases does not influence the overall binding kinetics of UHRF1 to chromatin. Moreover, re-
covery after photobleaching was more efficient for DNMT1 than for UHRF1 what was explained 
with the tight association of UHRF1 with hemCpGs (Rottach et al., 2010). 
The histone methyltransferase G9a (EHMT2) is a potent epigenetic regulator involved in transcrip-
tional silencing (Tachibana et al., 2002). G9a was seen to interact with RING and SRA domains of 
UHRF1, with a higher affinity for RING. As seen in UHRF1-/- mESCs lack of UHRF1 lead to de-
creased amounts of G9a on chromatin, suggesting a role for UHRF1 in the recruitment of G9a to 
chromatin (Kim et al., 2009). This observation might also affect transcriptional silencing and the 
generation of heterochromatin. 
In a very recent study, Nishiyama et al. found that recruitment of DNMT1 during S-phase is not 
conveyed solely by direct interaction between DNMT1 and UHRF1, but requires ubiquitination of 
H3K23 (H3K23ub) mediated by the RING domain of UHRF1. In Xenopus egg extracts, depletion of 
UHRF1 firstly caused a decrease in the recruitment of DNMT1 to chromatin and secondly, reduced 
DNA methylation. Intriguingly, efficiency and timing of DNA replication were not affected. Re-
duced amounts of DNMT1 enhanced the presence of UHRF1 on chromatin, most likely due to 
increased amounts of hemimethylated DNA. Furthermore, it was shown that the RING domain of 
UHRF1 mediates the ubiquitination of H3 at lysine 23 and DNMT1 specifically interacts with 
H3K23ub, whereas neither unmodified H3 nor UHRF1 displayed a binding with H3K23ub. In ad-
dition, despite a RING-deficient mutant of UHRF1 was seen to co-localize with the replication 
complex and to form nuclear foci in UHRF1-/- HeLa cells, the RING mutant was not able to restore 
the correct distribution of DNMT1 at nuclear foci. Taken together, ubiquitination of H3 by UHRF1 
provides the platform for recruiting DNMT1 to sites of DNA replication (Nishiyama et al., 2013).  
 
3.3. The C-terminal RING domain and its function as an E3 ubiquitin ligase 
RING domains are small Zn-binding domains frequently linked with ubiquitin ligase activity 
(Freemont, 2000), (Pickart, 2001). Ubiquitin (Ub) is a 76AA protein and has pivotal roles in protein 
degradation, transcriptional regulation or gene transcription when attached to other proteins in one 
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or several copies (Sun, 2003), (Kerscher et al., 2006). Its activation occurs through the formation of 
a thiol ester bond with the Ub-activating enzyme (E1) followed by the transfer to an E2-Ub-
conjugating enzyme and finally its attachment to the substrate by an E3 ubiquitin ligase complex 
(Haas et al., 1982). E3 ligase complexes assign specificity to the reaction since they are able to rec-
ognize and select for different substrates (Citterio et al., 2004). The biological consequences of 
ubiquitination processes are diverse and depend on the number of Ub molecules added to the tar-
get protein. Monoubiquitination of histones for example can lead to chromatin remodelling caus-
ing alterations in transcription. However, the most common ubiquitin modification is polyubiquiti-
nation where several Ub molecules are added to a substrate, leading to its degradation in the 26S 
proteasome (Jenkins et al., 2005), (Kerscher et al., 2006).  
UHRF1 was observed to ubiquitinate all core histones, with a preference towards H3 (Citterio et 
al., 2004). Previous to this, ubiquitination of histones had only been described for elongating sper-
matids where it was thought to relax the nucleosome structure facilitating the access for the tran-
scription machinery or restructuring chromatin (Chen et al., 1998). Jenkins et al. later on described 
autoubiquitination activity of UHRF1 mediated by the RING domain (Jenkins et al., 2005).  
As mentioned above, UHRF1 recruits DNMT1 to hemimethylated DNA at replication forks. Inter-
estingly, UHRF1 is also able to ubiquitinate DNMT1 priming it for proteasomal degradation. In this 
interplay, a protein called USP7 (HAUSP, Ubiquitin carboxyl-terminal hydrolase 7) holds an im-
portant role. USP7 was demonstrated to first interact with and then deubiquitinate DNMT1 and 
thus preventing DNMT1 from proteasomal degradation. In addition, acetylation of DNMT1 by the 
acetyltransferase Tip60 was illustrated to stimulate proteasomal degradation of DNMT1. Based on 
these findings, it was hypothesized that during DNA replication DNMT1 is guided to hemimethyl-
ated DNA by UHRF1. In this time frame, the activity of UHRF1-RING is inhibited either by direct 
interaction with USP7 or indirectly by continuous deubiquitination of DNMT1 by USP7. The 
whole mechanism is thought to proceed as follows. During DNA replication DNMT1 is found as-
sociated with UHRF1, Tip60 and USP7, in which the latter two stabilize DNMT1 by deacetylation 
and deubiquitination. After completion of DNA replication, USP7 dissociates from the complex 
and Tip60 acetylates DNMT1 serving as a stimulus for UHRF1 to polyubiquitinate DNMT1, induc-
ing proteasomal degradation of DNMT1 in G2 (Fig. 5) (Du et al., 2010). Felle et al. later confirmed 
the interactions between UHRF1, USP7 and DNMT1. However, when performing DNA digestion 
preceding immunoprecipitation, the binding of USP7 to UHRF1 was significantly reduced, in con-
trast to USP7-DNMT1 that remained very stable, even in a soluble environment. Thus, when de-
tached from chromatin USP7 was suggested to be found in a stable dimeric complex with only 
DNMT1 whereas when present on chromatin a trimeric complex including USP7, DNMT1 and 
UHRF1 is formed. Furthermore, USP7 can deubiquitinate UHRF1 leading to reduced proteasomal 
degradation and stabilization of UHRF1 levels. Therefore, USP7 might act as an amplifying and 
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supporting module in the stabilization and faithful maintenance of DNA methylation patterns with-
in the trimeric complex USP7-DNMT1-UHRF1 (Felle et al., 2011).  
 
Fig. 5: Mechanistic model describing a complex mediating the faithful propagation of DNA methylation 
patterns during the S-phase of the cell cycle. 
During DNA replication DNMT1 is associated with UHRF1, Tip60 and USP7. USP7 and Tip60 stabilize 
DNMT1 by deacetylation and deubiquitination. After completion of DNA replication USP7 dissociates 
from the complex and Tip60 acetylates DNMT1, stimulating UHRF1 to polyubiquitinate DNMT1, induc-
ing proteasomal degradation of DNMT1 in G2. From Du et al., 2010, modified. 
 
How UHRF1 is molecularly targeted for degradation was clarified in a more recent work. The re-
spective study identified the SCFß-TrCP E3-ligase complex to be responsible mediating the ubiquitina-
tion and subsequent proteasomal degradation of UHRF1. In addition, in the N-terminal region of 
UHRF1, a phosphodegron was identified and phosphorylation of S108 was found to be crucial for 
UHRF1 ubiquitination by SCFß-TrCP. A phosphodegron is defined as a protein site that gets unstruc-
tured upon phosphorylation, what is the sign for the degradation process to initiate (Schrader et al., 
2009). When UHRF1 S108 was not phosphorylated, no interaction of UHRF1 and SCFß-TrCP could 
be observed. The kinase responsible for the phosphorylation was deciphered as CK1∂ (Casein ki-
nase isoform ∂) triggering UHRF1 ubiquitination by SCFß-TrCP (Chen et al., 2013). CK1∂ is an essen-
tial serine/threonine-protein kinase regulating various cellular growth and survival processes in-
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cluding Wnt-signalling, DNA repair and circadian rhythms (Peters et al., 1999), (Hoekstra et al., 
1991), (Etchegaray et al., 2009). To summarize, the interplay between protein-protein interactions 
and ubiquitination reactions maintain a correct homeostasis of the molecular participants involved 
in the faithful maintenance of DNA methylation and possibly histone modifications. Nevertheless, 
the exact mechanisms modulating the levels of UHRF1 are still unclear.  
3.4. PHD- and Tandem-Tudor domains are recognizing the N-terminal tail of H3 
3.4.1. PHD fingers can read the histone code 
PHD fingers consist of a conserved zinc finger motif and exist in numerous chromatin regulators. 
Moreover, they were shown to play a role in many biological processes like reading of the histone 
code (Shi et al., 2006) or E3 ubiquitin binding (Dul and Walworth, 2007). For a long time this par-
ticular structure was thought to be involved in protein-protein interactions until it was demonstrat-
ed that the PHD finger of the histone acetyltransferase p300 interacts with its neighbouring bromo-
domain in binding histones. Both domains were observed to interact with nucleosomes while also 
interconnect with each other (Ragvin et al., 2004). Nowadays a reasonable number of works have 
been published linking PHD fingers to interactions with differentially modified H3 tails and thus to 
gene repression, transcriptional activation and chromatin dynamics (Eberharter et al., 2004), 
(Martin et al., 2006), (Vermeulen et al., 2007), (Palacios et al., 2008). Many H3 binding proteins 
carrying a PHD finger are macromolecules with own catalytic activity (e.g. histone methyltransfer-
ases or demethylases). Other PHD proteins function as scaffolding molecules linking enzymatic 
complexes with other subunits to particular regions in the genome. Therefore, many of these pro-
teins are able to induce changes in the chromatin state. Even though most publications describe 
interactions of PHD domains with H3, there are studies demonstrating the ability of PHD fingers to 
bind to non-histone proteins. This increases the complexity of biological effects mediated by PHD 
domains. Moreover, most of the PHD domains are found in molecules containing more than one 
PHD finger or other features capable of reading the epigenetic code, for example chromodomains, 
bromodomains or the Tandem-Tudor domain of UHRF1. Taken together, PHD domains are mani-
fold elements changing chromatin state and thus rule crucial intracellular DNA-based processes 
such as transcription or epigenetic silencing (Musselman and Kutateladze, 2011).  
3.4.2. The Tandem-Tudor domain recognizes modifications of the H3-tail 
When screening databases it became evident that the sequence between UHRF1 UBL- and PHD 
domains contains a conserved region with high structural similarity to the family of Tudor domains 
(Rottach et al., 2010). Hallmarks of this class of domains are two subdomains (Tandem-Tudor) cre-
ating an aromatic cage formed by three highly conserved amino acids (Phe152, Tyr188 and Tyr191 
in UHRF1) resulting in a hydrophobic pocket able to place an H3K9me3 N-terminal tail. A similar 
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feature is shown for the chromodomain of heterochromatin protein 1ß (HP1ß), which also interacts 
with H3K9me and is important in the establishment of pericentric heterochromatin. One of the 
structurally resolved Tandem-Tudor domains is incorporated in the Lysine-specific demethylase 4A 
(KDM4A, JMJD2A), a member of a histone demethylase superfamily (Tsukada et al., 2006). This 
specific hybrid Tandem-Tudor domain possesses the capacity of interacting with two distinct pep-
tides, H3K4me3 and H4K20me3, with the same affinity while two adjacent arginine residues, R2 
and R19, are stabilizing the binding (Lee et al., 2008). These findings imply that the Tandem-Tudor 
domain can potentially recognize different combinations of H3 modifications at one time what 
highlights the complexity of methyl-lysine recognition (Adams-Cioaba and Min, 2009).  
3.4.3. UHRF1 in targeting the N-terminal H3-tail 
In 2004 Citterio et al. showed that UHRF1 is able to interact with histones showing a strong prefer-
ence for histone H3, followed by histone H1 and histone H2B. Interactions were mediated by the 
N-terminal tails of histones (Citterio et al., 2004).  
There are numerous proteins with known methyltransferase activity against H3K9, including G9a, 
SUV39H1, SUV39H2, ESET/SETDB1 or EuHTMase1 (O'Carroll et al., 2000), (Ogawa et al., 2002), 
(Rea et al., 2000), (Schultz et al., 2002), (Yang et al., 2002). Although they recognize the same 
PTM, there are relevant differences concerning their distribution, chemistry and molecular roles. 
PTMs catalysed by the above enzymes can in turn be removed by specific histone demethylases 
like Kdm4c, Jmid2b or Jhdm3a (Cloos et al., 2006) (Fodor et al., 2006), (Klose et al., 2006).  
Karagianni et al. could localize UHRF1 to heterochromatic regions enriched in H3K9me3. Indeed, 
this PTM was shown to be required for proper heterochromatic localization of UHRF1. MEFs defi-
cient for the histone methyltransferase Suv39h-/- or NIH3T3 cells overexpressing the histone deme-
thylase JMJD2A, both exhibiting defects in the methylation of H3K9, lost the typical heterochro-
matic pattering of the chromatin and the signal intensity for UHRF1 was lowered. In addition, Bart-
ke et al. showed that in the context of mCpG, UHRF1 interaction with nucleosomes carrying 
H3K9me3 methylation was much stronger than with H3K9me3 in unmethylated DNA regions 
(Bartke et al., 2010) indicating a supportive effect of H3K9me3 on the localization of UHRF1.  
When UHRF1 Tandem-Tudor is isolated from the full-length protein, in comparison to other H3 
PTMs a highly significant preference for H3K9me3 was observed (Rottach et al., 2010). However, 
this effect was less prominent for the full-length version of the protein. Interestingly, the presence of 
acetylated H3K9 (H3K9ac, activation mark) inhibited the interaction with Tandem-Tudor. It also 
became evident that the binding of Tandem-Tudor and H3K9me3 additionally required H3K4 in an 
unmodified or monomethylated state whereas di- or trimethylated H3K4 (activation mark) fully 
abolished the interaction. These findings suggest that UHRF1 is enriched at genomic sites harbour-
ing the H3K4/H3K9me3 signature. The enrichment is potentiated by the presence of methylated 
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DNA (Nady et al., 2011). Nonetheless, it is difficult to draw conclusions from assays using only 
single UHRF1 domains since in context of the full-length protein observed effects might be altered 
by the presence of other functional domains. Follow-up studies revealed that the PHD domain spe-
cifically recognizes unmodified H3R2 while Tandem-Tudor targets H3K9me3. Different experi-
ments showed that Tandem-Tudor is necessary but not sufficient for the recognition of the whole 
H3 tail. Summarizing, it is assumed that the PHD domain by interacting with unmodified H3R2 
mediates the overall binding activity of the whole protein and that Tandem-Tudor confers binding 
specificity by targeting H3K9me3 (Cheng et al., 2013), (Liu et al., 2013). 
A recent study systematically tried to assess to what extent the H3-binding Tandem-Tudor and the 
hemCpG-binding SRA domains are providing binding strength to the interaction of UHRF1 to 
chromatin. Moreover, it was of interest how strong the two domains influence the targeting of 
DNMT1 to the replication fork and the maintenance of DNA methylation in general. To achieve 
this, different mutants were generated either defective in H3K9 recognition (Tandem-Tudor mutant) 
or hemCpG binding (SRA-mutant). Surprisingly, when transfected in UHRF1-/- mESCs, both mutants 
were able to partially rescue heterochromatin association, DNMT1 recruitment and even DNA 
methylation. However, when expressing a Tandem-Tudor/SRA double mutant in UHRF1-/- mESCs, 
rescue of neither of the above features was observed. This leads to the conclusion that in UHRF1-/- 
mESCs UHRF1 can at least partially target DNMT1 to DNA replication sites through unconnected 
recognition of the H3-tail on the newly assembled nucleosomes and/or hemCpG on the nascent 
DNA (Liu et al., 2013). 
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Aim of the work 
 
To shed light into the molecular role of Pramel7 in the maintenance of pluripotency, following 
aims are addressed. 
 
• Confirm the interaction between Pramel7 and UHRF1 and identify other potential bind-
ing partners. 
 
• Characterize domains of UHRF1 and Pramel7 necessary for the formation of a complex 
between the two proteins. 
  
• Study potential epigenetic effects induced by Pramel7 overexpression in HEK293T cells 
and pluripotent and differentiating mESCs. 
 
• Characterize the function of Pramel7 in the maintenance of pluripotency in vitro and 
draw conclusions for the mouse development in vivo. 
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B. Results 
1. Discovering interaction partners of Pramel7 
The novel protein Pramel7 is found expressed in the central part of the morula and the inner 
cell mass of the blastocyst exclusively, the pluripotent compartments of the early embryo 
(Cinelli et al., 2008). Moreover, for Pramel7-overexpression a supportive effect on the mainte-
nance of pluripotency is described in murine embryonic stem cells (mESCs) (Casanova et al., 
2011). However, the exact molecular function of Pramel7 remains unclear. 
1.1. Screening for potent interaction partners 
An initial search for conserved protein motifs in the open reading frame of Pramel7 using the 
LRR finder software revealed the existence of three leucine rich-repeat (LRR) structures (Fig. 6A, 
1-3). However, additional re-screening with the LRR search programme uncovered three other 
potentially important LRRs (Fig. 6A, 4-6). Re-screening was made after analysing the outcome 
of immunoprecipitation experiments described in chapter 1.5 (Results).  
 
Fig. 6: Pramel7 protein sequence with predicted LRRs and protein model. 
A: Pramel7 protein sequence with predicted LRRs. LRRs discovered in the initial screening are labelled in 
orange (1-3) (www.lrrfinder.com). LRRs identified by re-screening are coloured in blue (4-6) 
(www.lrrsearch.com). B: Predicted protein model designed with the Phyre2 software (Kelley and 
Sternberg, 2009). LRR=leucine rich repeat. 
 
LRRs are 20-30 amino acids long sequence motifs and consist of a N-terminally conserved se-
quence of eleven residues rich in leucines at defined positions (LxxLxLxxNxL, x is any amino 
acid). The asparagine and the leucine residues can be substituted by any hydrophobic amino 
acid. This conserved N-terminal region of the LRR is forming a ß-sheet and a loop-region lead-
ing to the C-terminal part that is more variable in structure and sequence. LRRs are present in 
many proteins and participate in protein-protein interactions in various cellular processes and 
locations (Kobe and Deisenhofer, 1994), (Kajava, 1998). Moreover, since no DNA-binding do-
main typical for transcription factors was identified, Pramel7 and other members of the family 
of PRAME-proteins might be involved in protein-protein interactions rather than regulate the 
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transcription of genes by direct binding to the DNA. In order to identify a specific interaction 
partner of Pramel7, a yeast two-hybrid assay was performed. A bait consisting of the full-length 
Pramel7-LexA fusion protein was used to screen a library containing cDNA generated from the 
whole transcriptome of wt E14 mESCs. After successful isolation of five clones, sequence analy-
sis of three of the clones revealed that all represented the coding sequence of a protein in-
volved in epigenetic regulation, UHRF1 (Fig. 7). The lacZ signal from UHRF1-clones was sub-
stantially stronger than the signal of the two residual clones suggesting that UHRF1 might be a 
potent interaction partner of Pramel7. Since this interaction had never been shown before, the 
binding of Pramel7 and UHRF1 had to be verified in a less artificial system than yeast two-
hybrid. 
 
Fig. 7: A yeast two-hybrid screen reveals UHRF1 as a possible binding partner of Pramel7. 
Yeast two-hybrid assay: Bait: Pramel7. Bait vector: Full-length & truncated pLexA-dir. Prey: cDNA library 
of E14 mESCs. Prey vector: pGAD-HA. Plasmid isolation: 5 clones. Successful plasmid rescue: 5 clones. 
3 clones (1-3) represent UHRF1. 
 
1.2. Generation of a polyclonal antibody specifically recognizing Pramel7 
Because of lack of commercial availability, we next decided to generate an antibody recogniz-
ing Pramel7 as a tool for immunodetection of the protein (in collaboration with Pineda Anti-
körper Service, Berlin, Germany). In a sequence alignment of Pramel7 and other members of 
the PRAME-gene family we screened for unique sequences suitable as epitopes for the anti-
body, revealing peptide sequences 4b and 5 as most convenient (Fig. 8A).  
Three rabbits were immunized with either peptide and the final antibody fraction of animal 2 
immunized with peptide 5 was successfully tested using Western Blotting and immunohisto-
chemistry on HEK293T cells transfected with a plasmid ectopically expressing Pramel7 (Fig. 
8B). However, the antibody was not able to recognize endogenously expressed Pramel7 in wt 
E14 mESCs. This is most likely due to endogenous expression levels under a detection thresh-
old. Nevertheless, a new tool in the analysis of Pramel7 has become available. 
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Fig. 8: Selected epitopes for antibody generation and testing of final antibody fraction. 
A: Pramel7 protein sequence with selected epitopes 4b and 5. B: After immunization of 3 animals with 
either peptide the final antibody fraction of animal 2 immunized with peptide 5 (Ab 5-2) was selected 
and successfully tested by Western blotting. (Ab=antibody). 
 
1.3. Pramel7 is interacting with UHRF1 in HEK293T cells and mESCs 
To prove the interaction of Pramel7 and UHRF1 not only with the artificial yeast two-hybrid 
approach but also in a living mammalian cell, we made use of HEK293T cells. First a FLAGHA-
tagged version of Pramel7 was cloned into an expression plasmid driven by a CMV promoter 
(pcDNA3.1_FLAGHA-P7). Expression of the plasmid was successfully tested using Western 
blotting of protein lysate from HEK293T cells transfected with the plasmid. While co-expressing 
mouse UHRF1 (pCMV_Sport6_UHRF1), subsequent co-immunoprecipitation (co-IP) against 
FLAG-Pramel7 followed by SDS-PAGE and Western blotting revealed a strong interaction of the 
two proteins (Fig. 9A). To confirm these results, FLAGHA was cloned in front of the N-terminus 
of UHRF1 and expressed under the pcDNA3.1 expression plasmid backbone. In turn, in 
agreement with the previous Western blot, upon co-transfection with a plasmid expressing un-
tagged Pramel7 followed by co-IP anti-FLAG, a strong co-precipitation of FLAG-UHRF1 and 
Pramel7 was obtained (data not shown). Moreover, in a third assay, Pramel7 was able to pre-
cipitate endogenous human UHRF1 from HEK293T cells. This suggests a high specificity and a 
cross-species conservation of the protein domain in UHRF1 responsible for this interaction (Fig. 
9C). After these observations in HEK293T cells, we were interested if the interaction could also 
be shown in mESCs. To achieve this, E14 mESCs cultivated in complete medium +LIF (CM+LIF) 
and in parallel 129 mESCs grown in N2B27 medium +2i +LIF were electroporated with a con-
struct expressing FLAGHA-Pramel7 (CAG promoter driven) and positively selected clones were 
expanded. After determining the expression levels of Pramel7 by RTQ-PCR and Western blot-
ting, clones with the highest Pramel7 overexpression levels were selected for the experiment. 
However, subsequent IP anti-FLAG-Pramel7 did not reveal a positive signal for UHRF1 in the 
output fractions from both cell types, E14 and 129. Therefore, we decided to change the 
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Pramel7-expression plasmid and replaced the CAG with an EF1 promoter (EF1_FLAGHA-P7). 
Wt E14 mESCs were again electroporated and positive clones selected and expanded. After 
characterization, wt E14 and EF1_HAFLAG-P7 mESCs were cultivated in self-renewing condi-
tions (CM+LIF) and collected. After IP anti-FLAG-Pramel7 low levels of UHRF1 could be de-
tected in the output fractions of Pramel7-overexpressing mESCs (Fig. 9B). Why the interaction 
was not detected in E14 CAG_FLAGHA-P7 and in 129 CAG_FLAGHA-P7 mESCs remained 
elusive.  
 
Fig. 9: Pramel7 interacts with UHRF1 in HEK293T cells and mESCs. 
A: FLAGHA-Pramel7 was co-expressed with murine UHRF1 in HEK293T cells and IP was performed 
anti-FLAG. B: FLAGHA-Pramel7 was stably overexpressed in wt E14 mESCs (EF1 promoter), IP was per-
formed anti-FLAG-Pramel7 and endogenous UHRF1 was detected in the output. C: FLAGHA-Pramel7 
was expressed in HEK293T cells, IP was performed anti-FLAG-Pramel7 and endogenous UHRF1 was 
detected in the output. P7=Pramel7, I=input, O=output. 
 
Taken together, for the first time, this novel interaction could be demonstrated in the mammali-
an system. The specific binding of the two proteins suggests a hypothetical role for Pramel7 in 
modifying the epigenetic regulation of the cell. 
1.4. Mass spectrometry reveals additional binding partners of Pramel7-UHRF1 
As the interaction of Pramel7 and UHRF1 could successfully be verified in HEK293T and 
mESCs, we were next interested if other proteins could be identified in the complex. After trans-
fection of pcDNA3.1_FLAGHA-P7 in HEK293T cells and subsequent IP anti-FLAG-Pramel7, the 
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protein fractions from the outputs were eluted. After precipitation of eluates with TCA, dried 
protein fractions were finally analysed by mass spectrometry. Interesting candidates are listed in 
Tab. 2. First, confirming the data obtained in 1.3, we were able to identify the endogenous hu-
man form of UHRF1 from HEK293T cells in the output of the IP. Furthermore, various types of 
histones were detected, such as H3.3, a histone variant of the canonical H3 and marker for 
transcriptional activation, and canonical histones H2A and H4. In addition, a protein named 
Transcription elongation factor B polypeptide 1 (TCEB1) could be identified. Its alternative 
name is ElonginC, which was reported to either be involved in the activation of transcription 
elongation (Garrett et al., 1994) or, by directly interacting with PRAME, to potentially act as a 
component of a Cullin-RING ligase complex (CRL), targeting substrate proteins for proteasomal 
degradation via attachment of Polyubiquitin peptides (Costessi et al., 2011). Finally, Polyubiq-
uitin itself was detected in the FLAG-Pramel7 precipitate, giving evidence that Pramel7 could 
have a similar role in recognizing a specific substrate that is subsequently targeted for pro-
teasomal degradation. The detection of histones may indicate a possible presence of Pramel7 at 
the chromatin. 
Tab. 2: Mass spectrometry data IP anti-FLAG-Pramel7 in HEK293T cells. 
Eluted IP-outputs were TCA-precipitated and fractions of FLAG-Pramel7 and pBS-control IPs were ana-
lysed by mass spectrometry. Pept.=number of peptide hits. Probability: over 95%. Mass spectrometry was 
performed at the Functional Genomics Center, Zurich (FGCZ). 
 
Protein name Protein ID FLAG-Pramel7 (pept.) 
pBS control 
(pept.) database 
         
E3 ubiquitin-protein ligase 
UHRF1 sp Q96T88 3 0 swiss human 
Histone H2A type 2 sp A1A4R1 2 0 swiss human 
Histone H3.3 sp A2XHJ3 1 0 swiss human 
Histone H4 sp P08436 3 0 swiss human 
BTB/POZ domain-containing 
protein KCTD5 sp Q9NXV2 4 0 swiss human 
Transcription elongation factor B 
(SIII) (ElonginC) gi 109495363 3 0 swiss human 
Heterogeneous nuclear ribonu-
cleoprotein U gi 125991756 4 0 swiss human 
Polyubiquitin gi 2627129 6 0 ncbi 
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Next, we intended to elucidate if the presence of Pramel7 might lead to differential binding of 
UHRF1 to its interactor proteins. Therefore, IP and co-IP anti-FLAG-UHRF1 was performed ei-
ther in presence (co-transfection with CAG_P7, untagged) or absence of Pramel7. The different 
outputs were analysed by mass spectrometry. As visible in Tab. 3, Pramel7 was pulled down in 
the corresponding sample. In both fractions (+/- Pramel7), independent of the presence of 
Pramel7, various histones and histone complexes could be found. Therefore, these proteins 
most likely represent binding partners of UHRF1. Moreover, Poly (ADP-ribose) polymerase 1 
PARP1 (ARTD1) was detected in both approaches, a multifunctional protein managing the 
structure and the function of high-order chromatin by on one hand binding to core histones and 
on the other hand poly-ADP-ribosylating other proteins that govern transcriptional processes 
(Pinnola et al., 2007). This leads to a supportive effect on heterochromatin formation and thus 
to prevention of gene transcription. XRCC5 (X-ray repair cross-complementing protein 5, Ku80) 
and XRCC6 (X-ray repair cross-complementing protein 6, Ku70) together are building dimers 
with major functions in DNA repair, in the regulation of transcription of specific genes, apopto-
sis, regulation of the cell cycle and telomere maintenance (Tuteja and Tuteja, 2000). SMARCA5 
(SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A mem-
ber 5) was seen to have an essential role in chromatin remodelling complexes (CHRAC, RSF, 
ACF/WCRF, WICH). The WICH complex for example was reported to regulate the transcription 
of various genes. In addition, roles in RNA polymerase I- and RNA polymerase III-mediated 
transcription and in the maintenance of chromatin structures during DNA replication were re-
ported (Dirscherl and Krebs, 2004). 
Tab. 3: Mass spectrometry data IP anti-FLAG-UHRF1 (+/- Pramel7) in HEK293T cells (1). 
Eluted IP-outputs were TCA-precipitated and fractions of FLAGHA-Pramel7 and pBS-control IPs were 
analysed by mass spectrometry. Pept.=number of peptide hits. Probability: over 95%. Numbers in (): 
probability <95%. Mass spectrometry was performed at the Functional Genomics Center, Zurich (FGCZ). 
 
Protein name Protein ID 
FLAG-
UHRF1/P7 
(pept.) 
FLAG-
UHRF1/pBS 
(pept.) 
pBS 
control 
(pept.) 
Database 
            
E3 ubiquitin-protein ligase UHRF1 Q96T88 5 12 0 swiss human 
PRAMEl7  Q810Y8 1 0 0 uniref 
Poly (ADP-ribose) polymerase 1 PARP1  P09874 9 11 0 swiss human 
Histone H1.3  P16402 5 9 0 swiss human 
Histone H2A type 1-C  Q93077 6 22 (1) swiss human 
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Tab.3: Mass spectrometry data IP anti-FLAG-UHRF1 (+/- Pramel7) in HEK293T cells (2). 
 
Protein name Protein ID 
FLAG-
UHRF1/P7 
(pept.) 
FLAG-
UHRF1/pBS 
(pept.) 
pBS     
control 
(pept.) 
Database 
            
Histone H2A.Z  P0C0S5 2 5 0 swiss human 
Histone 3.1  P68431 10 15 (1) swiss human 
Histone H4  P62805 7 17 0 swiss human 
X-ray repair cross-complementing 
protein 5 (XRCC5)  P13010 11 19 0 swiss human 
X-ray repair cross-complementing 
protein 6 (XRCC6)  P12956 9 19 0 swiss human 
Polyadenylate-binding protein 1 
PABP1  P11940 7 7 (1) swiss human 
DNA-dependent protein kinase 
catalytic subunit PRKDC  P78527 6 11 0 swiss human 
Probable ATP-dependent RNA 
helicase DDX5  P17844 3 2 0 swiss human 
ADP/ATP translocase 2   
SLC25A5/ADT2  P05141 2 3 0 swiss human 
Single-stranded DNA-binding pro-
tein, mitochondrial Q04837 3 2 0 swiss human 
Transcription factor A, mitochondrial 
(TFAM) Q00059 2 2 0 swiss human 
SWI/SNF-related matrix-associated 
actin-dependent regulator of chro-
matin subfamily A member 5 
SMARCA5/SMCA5  
O60264 2 1 0 swiss human 
FACT complex subunit 
SPT16/SUPT16H  Q9Y5B9 3 0 0 swiss human 
Nuclear migration protein nudC  Q9Y266 1 (1) 0 swiss human 
Chromobox protein homolog 3 
CBX3 (HP1γ) Q13185 3 0 0 swiss human 
Chromodomain-helicase-DNA-
binding protein 4 CHD4  Q14839 2 0 0 swiss human 
Transcription elongation factor B 
polypeptide 1 TCEB1 (ElonginC)  Q15369 2 0 0 swiss human 
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Tab.3: Mass spectrometry data IP anti-FLAG-UHRF1 (+/- Pramel7) in HEK293T cells (3). 
Protein name Protein ID 
FLAG-
UHRF1/P7 
(pept.) 
FLAG-
UHRF1/pBS 
(pept.) 
pBS     
control 
(pept.) 
Database 
            
Eukaryotic translation initiation factor 
3 subunit I EIF3I  Q13347 1 0 0 swiss human 
RNA-binding protein 39 RBM39  Q14498 1 0 0 swiss human 
DNA topoisomerase 2-alpha TOP2A  P11388 1 0 0 swiss human 
Elongation factor 2 EF2/EEF2  P13639 0 1 0 swiss human 
Puromycin N-acetyltransferase (CAG-
vector)  P13249 3 0 0 uniref 
Polyubiquitin-B P0CG47 2 3 (1) swiss human 
 
Following candidates were exclusively isolated in the protein fraction containing co-expressed 
Pramel7. Thus, their presence could hypothetically be dependent on the presence of Pramel7. 
SPT16 is one of two subunits assembling the FACT complex (SPT16 & SSRP1). FACT was 
shown to alleviate the transition of RNA polymerase II along the DNA by removing an H2A-
H2B dimer, facilitating transcription (Orphanides et al., 1998). In addition, the FACT complex 
was reported to interact with PARP1. PARP1 poly-ADP-ribosylates SPT16, leading to enhanced 
dissociation of FACT from the chromatin and therefore reduced transcriptional activity (Huang 
et al., 2006). CBX3 (heterochromatin protein 1 homolog γ, HP1γ) represents another interesting 
candidate. The family of HP1 proteins is generally linked to support the formation of hetero-
chromatin (Grewal and Moazed, 2003). However, other studies shed light on a different func-
tion where HP1γ is observed to predominantly localize to euchromatic regions (Fanti et al., 
2003). Moreover, HP1γ is found to associate with a set of transcribed genes. In mammalian 
cells, the protein is enriched at coding regions of transcribed genes (Vakoc et al., 2005). Inter-
estingly, even a direct link between HP1γ and FACT complex was described wherein HP1γ 
links FACT complex to RNA Polymerase II, resulting in transcription elongation in a subset of 
genes (Kwon et al., 2010). All these findings suggest that HP1γ might function not only in the 
formation of heterochromatin and thus silencing of genomic regions but also has a crucial role 
in euchromatic regions, supporting active gene transcription. When screening all factors identi-
fied in the IP anti-FLAG-UHRF1 with co-expressed Pramel7, TCEB1 (ElonginC) was the only 
protein also detected in the IP anti FLAG-Pramel7 (Tab. 2), providing further evidence that this 
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factor could specifically be dependent on the presence of Pramel7. Furthermore, we identified 
Polyubiquitin in the output fractions from both FLAG-UHRF1 IPs (+/- Pramel7). To in part verify 
the data of this proteomic mass spectrometry assay the outputs of an IP anti-FLAG-Pramel7 in 
HEK293T cells were loaded on an SDS gel and two of the identified candidates, H3 and 
PARP1, were successfully detected of by Western blotting (Fig. 10). 
 
Fig. 10: Verifying binding partners of Pramel7-UHRF1 identified in the mass spectrometry assay. 
FLAG-Pramel7 was expressed in HEK293T cells, IP was performed anti-FLAG-Pramel7 and endogenous 
PARP1 and H3 were detected in the output fractions. I=input, O=output, pBS=pBluescript. 
 
1.5. Mutated forms of Pramel7 show impaired binding to UHRF1 
To assess the impact of the region in Pramel7 containing the three identified LRRs on the inter-
action with UHRF1, three different FLAGHA-tagged expression constructs with major and mi-
nor deletions in the LRR area were generated. The smallest deletion has a length of 33 amino 
acids (AA) covering one LRR (Fig. 11B). The 61AA deletion lacks two LRRs (Fig. 11C). The larg-
est deletion affects three potential LRRs and is 82AA long (Fig. 11D). Co-IP anti FLAG-Pramel7 
and identification of UHRF1 levels in the output fractions revealed that all three mutations, re-
gardless if 33, 61 or all 82AA were deleted, showed a substantial decrease in bound UHRF1 
protein at similar levels, leading to the conclusion that the LRR crucial for the interaction most 
likely is located within the smallest 33AA protein fragment (Fig. 12, left). To verify this, a con-
trol construct lacking 63AA located N-terminally of the deletion area was generated (Fig. 11E). 
Interestingly, the control mutant could only partly restore, but not completely rescue the inter-
action (Fig. 12, right). An additional round of screening using another software (LRR search, 
www.lrrsearch.com) revealed three other LRRs located in the control region (Fig. 11, LRRs 4-6). 
This explains the only partial recovery of precipitated UHRF1 levels by the control mutant.  
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Fig. 11: Generation of mutated forms of Pramel7 containing deletions in the predicted LRR region. 
A: Full-length Pramel7 (FLAGHA-FL). B: 33AA deletion (FLAGHA-33) (green area deleted). C: 61AA dele-
tion (FLAGHA-61) (green and red areas deleted). D: 82AA deletion (FLAGHA-82) (green, red and orange 
areas deleted). E: 63AA control mutation (FLAGHA-63 C) (blue area deleted). Blue area: N-terminal con-
trol deletion. LRRs are marked by rectangles labelled with red numbers (blue numbers for additionally 
identified LRRs in the control region). Dotted rectangles indicate partially deleted LRRs. 
 
 
Fig. 12: UHRF1 binding ability of mutated forms of Pramel7 described in Fig. 11. 
Left: IP with LRR mutants. FLAGHA-tagged mutant forms of Pramel7 were co-expressed with UHRF1 in 
HEK293T cells and IP was performed anti-FLAG. Compared to full-length Pramel7 (FLAGHA-FL) all mu-
tants showed drastically lowered binding ability to UHRF1. Right: Control IP. The FLAGHA-tagged con-
trol mutation (FLAGHA-63C) of Pramel7 was co-expressed with UHRF1 in HEK293T cells and IP was 
performed anti-FLAG. The 33AA LRR mutant (FLAGHA-33) was used as a control. FLAGHA63-C partly 
restored the interaction between Pramel7 and UHRF1. Co-binding of histone 3 (H3) showed the same 
pattern as UHRF. I=input, O=output, pBS=pBluescript. 
 
When furthermore analysing co-precipitated levels of H3 (endogenous) this protein was follow-
ing the binding pattern of UHRF1 (Fig. 12, right). This suggests that, of LRRs detected in the first 
screening (LRRs 1-3), LRR 1 (LKHLCLRGVTL) is critical in mediating the interaction between 
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Pramel7 and UHRF1. However, it is likely that LRRs 4-6 from the second screening contribute 
to the interaction as well. 
1.6. Mutant forms of UHRF1 interact with Pramel7 at different strength 
As seen above, the region in Pramel7 rich in LRRs is involved in mediating the interaction with 
UHRF1. To gain insight into which domains of UHRF1 are contributing to the binding to 
Pramel7, six different FLAG-tagged human UHRF1 mutants were co-expressed with Pramel7 
(untagged) in HEK293T cells and co-IP was performed anti-FLAG. The constructs were kindly 
provided by Jiemin Wong from East China Normal University, Shanghai (Liu et al., 2013). A 
schematic illustration of full-length and mutated forms of UHRF1 and a successful expression 
test is depicted in Fig. 13. 
 
Fig. 13: FLAG-tagged forms of UHRF1 with different deletions.  
A: Schematic illustration of seven FLAG-tagged UHRF1 expression constructs. Numbers in front indicate 
the range of amino acids present related to the full-length protein. B: Expression test anti-FLAG. FL=full-
length. mRFP C (lane 8): HEK293T cells expressing red fluorescent protein were used as a transfection 
control and as a negative control for Western blotting. 
 
All six mutants are completely lacking the C-terminal part of the protein comprising SRA and 
RING domains and exhibit different appearances in UBL, Tandem-Tudor and PHD domains. 
After IP anti-FLAG, levels of Pramel7 in the output fractions were determined. As visible in Fig. 
14, by far most Pramel7 could be detected together with full-length UHRF1, followed by 
UHRF1_1-298 containing UBL- and intact Tandem-Tudor domains and UHRF1_182-408 con-
sisting of a partial Tandem-Tudor and a full PHD domain. These two forms of UHRF1 were 
displaying considerably reduced levels of Pramel7 compared to full-length UHRF1. Very weak 
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Pramel7 signals could be observed for UHRF1_1-408 (full UBL, Tandem-Tudor and PHD do-
mains), UHRF1_95-368 (full Tandem-Tudor and PHD domains, short tail at C-terminus) and 
UHRF1_95-408 (full Tandem-Tudor and PHD domains, long tail at C-terminus). The shortest 
form, UHRF1_95-298 (Tandem-Tudor domain only), was unable to give any signal for Pramel7.  
These results indicate that SRA and RING domains deleted in all the mutants significantly con-
tribute to the interaction of UHRF1 and Pramel7.  
 
Fig. 14: Interaction capacities of mutant forms of UHRF1 in presence of Pramel7 co-expression. 
FLAG-tagged UHRF1 mutations were co-expressed with Pramel7 in HKE293T cells and IP was performed 
anti-FLAG. Outputs were analysed for the presence of Pramel7, PARP1 and H3. Bands in rectangles: 
Signals of full-length UHRF1 in input and output fractions (lanes 1). I=input, O=output, FL=full-length, 
pBS=pBluescript.  
 
To elucidate if H3 and PARP1 show a differential binding pattern among UHRF1 mutants, we 
additionally analysed outputs of different IPs for these two candidates under ectopic expression 
of Pramel7. Interestingly, in comparison with Pramel7, opposite binding patterns could be ob-
served (Fig. 14). In mutations UHRF1_1-408, UHRF1_95-368 and UHRF1_95-408, all exhibit-
ing a comparably low interaction with Pramel7, a significantly higher affinity for PARP1 and H3 
could be shown. The two UHRF1 forms with a more efficient Pramel7 interaction, UHRF1_1-
298 and UHRF1_182-408, did show very low signals for PARP1 and H3. UHRF1_95-298, the 
shortest of UHRF1 fragments, did not exhibit any significant signals for any of the three binding 
partners Pramel7, H3 and PARP1.  
Remarkably, by looking more closely at the full-length form of UHRF1, almost no PARP1 and 
H3 could be precipitated, whereas a high amount of Pramel7 was present in the output (Fig. 14 
lane 1). Since it is known that UHRF1 is a potent interaction partner of PARP1 and H3 in wt 
conditions, the presence of Pramel7 might thus prevent the interaction of UHRF1 with PARP1 
Results  38 
and H3. Therefore, the experiment was repeated in complete absence of Pramel7 (Fig. 15). 
While binding between the deletion-mutants and H3/PARP1 remained similar as in the pres-
ence of Pramel7, in the case of full-length UHRF1 a clearly higher binding affinity for PARP1 
and a drastically higher interaction with H3 was observed when Pramel7 was absent. Interest-
ingly, determination of input and output fractions of full-length UHRF1 revealed that in the 
presence of Pramel7, full-length UHRF1 protein levels were drastically reduced already prior to 
being loaded for the IP (see bands in rectangles in Fig. 14 and Fig. 15, left). In contrast, in the 
absence of Pramel7, input amounts of full-length UHRF1 were not significantly lowered when 
compared to input levels of other UHRF1 versions.  
This remarkable finding might explain the differential interactions of full-length UHRF1 in pres-
ence or absence of Pramel7. The following chapters will focus on the explanation of this phe-
nomenon. 
 
Fig. 15: Interaction capacities of mutant forms of UHRF1 in absence of Pramel7 co-expression. 
FLAG-tagged UHRF1 mutations were co-expressed in absence of Pramel7 protein (except lanes 9) in 
HKE293T cells and IP was performed anti-FLAG. Outputs were analysed for the presence of Pramel7, 
PARP1 and H3. UHRF I=input, O=output, FL=full-length. Bands in rectangles: Full-length UHRF1 signals 
in input and output fractions with co-expression of Pramel7 (lanes 9). 
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2. Molecular effects caused by the interaction between Pramel7 and UHRF1 
2.1. Pramel7 as a potential recognition subunit of an E3-ligase complex 
After proving the interaction of the two proteins in HEK293T and mESCs, we next aimed to de-
cipher its biological consequence. Under consideration of the data obtained in 1.6 and know-
ing that PRAME is potentially able to participate as a substrate recognition subunit in an E3 CRL 
complex, we wondered if Pramel7 could act the same way and UHRF1 could be its specific 
substrate (see introduction chapter 2.1). Furthermore, when screening the amino acid sequence 
of Pramel7, potential protein motifs strengthening this hypothesis could be identified in the N-
terminal region, a BC-Box required for the interaction with ElonginC and a Cullin2-box mediat-
ing the binding to the Cullin scaffold protein (Fig. 16). However, in the Cullin2-box of Pramel7, 
the canonical proline (P) at position 31 and a canonical leucine (L)/isoleucine (I) at position 34 
are mutated. In addition, we showed that the LRR-region located in the C-terminal part of 
Pramel7 is responsible for the interaction with the potential substrate, UHRF1. According to 
data published for PRAME, ElonginC is further coupled to ElonginB. The Cullin scaffold protein 
links the complex to the E3 ubiquitin protein ligase Rbx1, catalysing the polyubiquitination of 
the target substrate and subsequent degradation in the 26S-proteasome (Costessi et al., 2011) 
(see also Fig. 37). 
 
Fig. 16: Conserved features in BC and Cullin2 boxes of Pramel7 and other proteins. 
Pramel7 shows canonical landmarks of the BC box. The canonical proline of the Cullin2 box is absent 
and the conserved leucine/isoleucine residue is replaced by phenylalanine. Yellow=identical amino 
acids, blue=very similar amino acids, green=similar amino acids. Canonical BC and Cullin2 box se-
quences are depicted below protein sequences. Alignment of candidate proteins (without Pramel7) was 
made by (Costessi et al., 2011) using the blosum62 mt2 alignment matrix with the AlignX program of the 
Vector NTI software package. Colour coding is based on the AlignX default similarity table. From 
Costessi et al., 2011, modified. 
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2.2. HEK293T and mESCs overexpressing Pramel7 display drastically reduced levels of 
UHRF1 
To assess if ectopic expression of Pramel7 is sufficient to lead to a degradation of UHRF1 and 
thus, to corroborate the above model, we first expressed Pramel7 in HEK293T cells for 48h and 
analysed UHRF1 levels in Pramel7-overexpressing, pBS-transfected control cells (to exclude 
transfection artefacts) and untransfected HEK293T cells. Strikingly, after 48h of Pramel7-
expression, UHRF1 levels were drastically and efficiently reduced, whereas in both control 
samples, UHRF1 levels remained comparably high. The murine protein Pramel7 was thus suffi-
cient to lead to this remarkable and efficient degradation of the human isoform of UHRF1, sug-
gesting a high degree of conservation also across species. To see if this is true for mESCs as 
well, UHRF1 levels of wt E14 mESCs and a mESC-line stably overexpressing CAG_FLAGHA-P7 
were determined. Consistent with the data from HEK293T cells, levels of murine UHRF1 were 
significantly lower also in Pramel7-overexpressing mESCs (Fig. 17A).  
 
Fig. 17: Protein levels and gene expression of UHRF1 in HEK293T and mESCs upon overexpression of 
Pramel7. 
A: Western Blot analysis displaying protein levels of Pramel7-overepxressing and control HEK293T (tran-
sient overexpression, untagged) and mESCs (stable overexpression, FLAGHA-tagged), respectively. B: 
Analysis of UHRF1 gene expression in Pramel7-overexpressing and control HEK293T cells. C: Analysis of 
UHRF1 and Pramel7 gene expression in FLAGHA-Pramel7 overexpressing (stable overexpression) and wt 
E14 mESCs. pBS=pBluescript, P7=Pramel7. Exp rel=Expression relative to. 
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We next wanted to verify if the decrease of UHRF1 protein levels is mediated through the inhi-
bition of UHRF1 gene expression, mRNA degradation or protein degradation. To achieve this, 
amounts of UHRF1-mRNA in Pramel7-overexpressing and wt HEK293T cells and mESCs were 
determined. RTQ-PCR analysis revealed that levels of UHRF1-mRNA were not altered in 
Pramel7-overexpressing HEK293T or mESCs indicating that the decline of UHRF1 protein level 
is mediated on the protein level (Fig. 17B/C) 
Finally, by confocal microscopic analysis after immunofluorescent labelling, the amounts and 
the cellular distribution of UHRF1 were assessed in wt E14 and Pramel7-overepxressing (CAG-
FLAGHA-Pramel7) mESCs. Consistent with the above observations, Pramel7-overexpressing 
mESCs exhibited a significantly weakened UHRF1 signal. Moreover, association of UHRF1 with 
DAPI-dense pericentric heterochromatin regions could easily be detected in wt E14 mESCs 
whereas in Pramel7-overexpressing these signals were drastically reduced or completely absent 
(Fig. 18). 
 
Fig. 18: Confocal microscopic analysis of UHRF1 levels in wt E14 and FLAGHA-Pramel7 overexpressing 
mESCs. 
a-c: Wt E14 mESCs. d-f: FLAGHA-Pramel7 overexpressing mESCs. a/d: Anti UHRF1 staining. b/e: DAPI 
signal. c/f: DAPI/UHRF1 overlay. Confocal microscopy was performed at the Center for Microscopy and 
Image Analysis of the University of Zurich (ZMB). Scale bar: 10µm. P7=Pramel7.  
 
Summing up, the expression of the protein Pramel7 is efficiently reducing the amount of 
UHRF1 in HEK293T cells and mESCs. Moreover, mouse Pramel7 is able to induce a degrada-
tion of both mouse and human UHRF1. 
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2.3. When ectopic expression of Pramel7 is lost, UHRF1 amounts are restored to wt 
levels 
To gain further evidence if the degradation of UHRF1 is indeed caused by the expression of 
Pramel7, we wondered if wt UHRF1 levels could be restored after loss of transiently expressed 
Pramel7. Therefore, a one week time course analysis in HEK293T cells was carried out and 
cells were collected at different time points ranging from 8h post transfection with CAG_P7, 
earliest, and 120h (5 days) post transfection, latest. 
In Fig. 19 it can be seen that Pramel7 protein became detectable 24h post transfection and ex-
pression peaked at 36h-48h. Remarkably, a simultaneous reduction of UHRF1 protein could be 
identified at these time points. After one passage and 72h of cultivation, Pramel7 expression 
was decreasing and expression was finally lost after 96h and second passaging of cells. Con-
comitant with the disappearance of Pramel7, UHRF1 levels were restored to control amounts, 
leading to the conclusion that the pure presence of Pramel7 indeed results in the drastic de-
crease of UHRF1.  
 
Fig. 19: Transient overexpression of Pramel7 in HEK293T cells for five days (120h). 
HEK293T cells were transfected with CAG_Pramel7 (left) and pBS (control, right). Cells were harvested at 
indicated time points and UHRF1 levels were determined by Western blotting. pBS=pBluescript. 
  
To verify these observations also in mESCs, we made use of our E14 cell line stably overex-
pressing FLAGHA-Pramel7. The overexpression construct was designed as seen in Fig. 20A, 
containing a FLAGHA-Pramel7-IRES-Puro cassette flanked by loxP sites followed by an EGFP 
(Casanova et al., 2011). Pramel7-overexpressing mESCs were electroporated with cre-
recombinase, FLAGHA-P7-IRES-Puro was floxed out and expression of EGFP was induced in 
recombined cells. We seeded the electroporated cells and selected the emerging clones based 
on intensity and homogeneity of the EGFP signal. EGFP-positive clones were finally picked and 
expanded. At this step, we immunofluorescently labelled the electroporated cells from the pri-
mary dishes with an antibody recognizing UHRF1. When comparing signal intensity and distri-
bution, a remarkable difference between EGFP-positive, recombined, and EGFP-negative, non-
recombined mESCs could be observed. While EGFP-positive colonies displayed an UHRF1 
signal similar to wt E14 cells (strong nuclear appearance), in EGFP-negative cells still carrying 
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the Pramel7-overexpression cassette firstly, UHRF1 signal intensity was much lower and sec-
ondly, we were unable to detect a clear nuclear expression pattern (Fig. 20B). 
 
Fig. 20: Cre-mediated excision of the Pramel7-expression cassette in mESCs. 
A: Schematic illustration of the CAG_FLAGHA-Pramel7 expression vector. Pramel7 (P7) carries the 
FLAGHA-tag on the N-terminus. Upon transfection of cre-recombinase the expression of Pramel7 is lost 
and expression of EGFP is activated. B: a: Phase contrast image showing mESC colonies after electro-
poration. b: The top colony did not undergo cre-recombination (EGFP-negative) whereas the bottom 
colony lost the expression of Pramel7 indicated by a strong EGFP signal. c: UHRF1 staining. The recom-
bined colony with lost Pramel7 expression (bottom) exhibits a strong nuclear wt-like expression pattern. 
d: DAPI signal. Scale bar: 100µm. C: Pramel7 and UHRF1 protein levels of expanded clones with re-
combined (GFP+, Pramel7-) or non-recombined Pramel7 (GFP-, Pramel7+).  
 
Next, five EGFP-positive and one EGFP-negative control clone from the electroporation fraction 
were expanded for three to four passages and further characterized by Western blotting. In-
deed, five recombinant, EGFP-positive clones showed restored wt-like UHRF1 levels, whereas 
a control clone retained undetectable UHRF1. Interestingly, the clone GFP+3 (Fig. 20C) still 
exhibited a weak signal for Pramel7, indicating a composition of a mixed population of recom-
bined EGFP-positive and EGFP-negative cells. Nevertheless, even this weak Pramel7 signal was 
sufficient to cause a partial decrease in UHRF1 levels. This indicates that the intensity of the 
degradation is dependent on the dosage of Pramel7 protein. Moreover, the degradation is re-
versible as soon as the expression of Pramel7 is below a critical threshold.  
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2.4. Is Pramel7 inducing the degradation of UHRF1 through the 26S-proteasome? 
The 26S-proteasome mediates the final step in the degradation of Polyubiquitin-tagged proteins. 
As seen above, the decrease of UHRF1 protein was not mediated on the mRNA level and is 
thus likely to be regulated on the protein level. To assess if the degradation process is mediated 
via the 26S-proteasome, Pramel7 was overexpressed in HEK293T cells and cells were cultured 
in the presence of the proteasome inhibitor MG132 for 4, 8 and 12h. It is noteworthy that the 
expression of Pramel7 was induced 24h prior to the addition of MG132. In accordance with the 
above data, 24h after transfection of Pramel7 the cells already displayed very low levels of 
UHRF1. 4, 8 and 12h after the addition of MG132, levels of endogenous UHRF1 were gradual-
ly increasing. In pBS-transfected control cells no significant change in UHRF1 levels could be 
observed throughout the whole experiment. These data indicate that degradation of UHRF1 
resulting from Pramel7 expression may occur via the 26S-proteasome (Fig. 21A). 
 
Fig. 21: Cultivation of HEK293T cells overexpressing Pramel7 in presence of MG132 and cyclo-
heximide. 
A: MG132 was added 24h after transfection of CAG_Pramel7 and pBS (control). Cells were incubated for 
4, 8 and 12h and levels of UHRF1 were determined by Western blotting. B: Functionality of MG132 was 
assessed by cultivating untransfected HEK293T cells in presence or absence of MG132 in medium con-
taining the inhibitor of translation cycloheximide for different time spans and UHRF1 levels were deter-
mined. pBS=pBluescript, MG=MG132, CHX=cycloheximide. 
  
To verify the functionality of MG132, we incubated HEK293T cells in the presence of firstly the 
inhibitor of translation cycloheximide and secondly of both cycloheximide and MG132 for 
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different periods. In steady-state culture conditions UHRF1 is reported to be gradually degraded 
by the proteasome via ubiquitination by the SCFß-TrCP E3-ligase (Chen et al., 2013). Therefore, 
lowered UHRF1 levels were expected in cells cultivated in cycloheximide only, whereas in 
cells supplemented with cycloheximide and MG132, UHRF1 levels should remain comparable. 
Indeed, UHRF1 levels were decreased already after 8h in presence of only cycloheximide. In 
contrast, upon addition of MG132, no significant change in UHRF1 levels could be observed 
(Fig. 21B). Another indicator for a correct function of MG132 is the gradual increase of overex-
pressed Pramel7 with time (Fig. 21A).  
2.5. Forms of Pramel7 mutated in the LRR-region cannot induce the degradation of 
UHRF1 
It was shown above that IP against FLAG-tagged forms of Pramel7 with deletions in the LRR-
region significantly reduced the potential of pulling down co-expressed UHRF1 (see Results 
1.5). In accordance with the reduced binding between the two proteins we were interested, if 
also the potential of inducing the degradation of UHRF1 is impaired or abrogated. To achieve 
this, full-length and mutant forms of Pramel7 (33AA, 62AA, 84AA, 62AA control, described in 
1.5) were expressed in HEK293T cells and effects on endogenous human UHRF1 levels were 
assessed. Indeed, only full-length Pramel7 was able to cause a decrease in UHRF1 (Fig. 22 lane 
1). In contrast, UHRF1 levels stayed comparably high in cells expressing the three LRR mutants 
(33AA, 62AA, 84AA). Interestingly, the expression of the 62AA control mutation affecting only 
one out of six potential LRRs induced a weak decrease of UHRF1 protein level (Fig. 22). Taken 
together, to mediate the degeneration of UHRF1, Pramel7 requires an intact LRR region. Dele-
tion of only 33AA is sufficient to completely inhibit the reduction of UHRF1 protein levels. 
 
Fig. 22: Degradation of UHRF1 by different variants of Pramel7 mutant in the LRR region. 
HEK293T cells were transfected with different constructs coding for the LRR mutants described in 1.5 and 
protein levels of UHRF1 were analyzed by Western blotting after 48h. FL=Full-length, pBS=pBluescript. 
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2.6. Pramel7 is unable to degrade different mutant forms of UHRF1 
We then wondered which mutant forms of UHRF1 (described in 1.6) could be primed for deg-
radation by full-length Pramel7. To assess this, Pramel7 was co-expressed with full-length 
UHRF1 and six UHRF1 mutants for 48h in HEK293T cells. Interestingly, only full-length 
UHRF1 protein was reduced, whereas all the mutant forms did not display any difference to the 
controls (Fig. 23). Thus, the C-terminal part of UHRF1 comprising RING and SRA domains de-
leted in all mutants plays a crucial role in enabling the degradation of the protein. It was de-
scribed in 1.6 (Results) that Pramel7 is able to best interact with full-length UHRF1 by far. The 
fact that the capacity of the mutants to bind Pramel7 was ranging from low to completely ab-
sent and that in addition, Pramel7 was seen to heavily reduce intracellular levels of only full-
length UHRF1 emphasizes the significance of a proper interaction between Pramel7 and 
UHRF1.  
 
Fig. 23: Pramel7-induced degradation of different variants of UHRF1. 
HEK293T cells were co-transfected with CAG_Pramel7 and different FLAG-tagged versions of UHRF1 
(described in 1.6). Cells were cultivated for 24h and protein levels assessed by Western blotting. 
P7=Pramel7. 
 
2.7. Reduction of UHRF1 results in decreased levels of DNA methylation 
During the S-phase of the cell cycle, UHRF1 guides DNMT1 to sites of hemimethylated DNA 
and ensures faithful propagation of the overall DNA methylome from mother to daughter cells. 
A very recent study goes one step further by demonstrating that UHRF1 is not only guiding 
DNMT1 but also increasing its activity (Bashtrykov et al., 2013). Two key publications in 
UHRF1 research state that a decrease or even full abolishment of UHRF1 levels in cycling 
mammalian cells leads to a gradual reduction of overall DNA methylation (Bostick et al., 
2007), (Sharif et al., 2007). We hence wondered if this effect could be caused by ectopic ex-
pression of Pramel7 as well. 
2.7.1. Digestion of genomic DNA from mESCs with methylation-sensitive restriction enzymes 
To get a first impression if DNA methylation in Pramel7-overexpressing mESCs or HEK293T 
cells is reduced, we extracted genomic DNA (gDNA) from either HEK293T cells transiently 
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overexpressing Pramel7 for 48h or from mESCs stably overexpressing FLAGHA-Pramel7 for at 
least ten passages. Methylation of gDNA was compared by digestion with the methylation sen-
sitive restriction endonuclease HpaII, an enzyme unable to digest methylated DNA. In 
HEK293T cells, no obvious difference in the amount of gDNA digested by HpaII could be ob-
served between cells transfected with Pramel7 and untransfected cells (data not shown). This 
was most likely due to a too short time span of Pramel7 expression (48h) since DNA methyla-
tion is thought to decrease in a replication-coupled manner and thus requires a certain number 
of cell divisions. In contrast, in mESCs, a substantially higher amount of gDNA was digested in 
Pramel7-overexpressing cells than in wt E14 cells (Fig. 24A, left).  
 
Fig. 24: Digestion of genomic DNA (gDNA) with methylation-sensitive restriction enzymes HpaII and 
McrBC. 
A: gDNA of wt E14 and FLAGHA-Pramel7 overexpressing mESCs cultivated in self-renewing conditions. 
B: gDNA of wt E14 and FLAGHA-Pramel7 overexpressing mESCs after 10d of differentiation. 
P7=Pramel7. Digestion experiments were performed by Eva Vollenweider, Santoro lab, Institute of Veter-
inary Biochemistry and Molecular Biology, University of Zurich. 
 
To corroborate this finding, gDNA of mESCs was digested with McrBC, a restriction enzyme 
requiring DNA in a (hemi-) methylated state for activity (Fig. 24A, right). Indeed, while E14 
cells showed a high degree of digestion, DNA of Pramel7-overexpressing mESCs was still pre-
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sent in larger fragments, indicating reduced digestion. In mESCs, it is widely recognized that the 
degree of methylation is increasing upon differentiation. Consequently, we were interested if 
the reduction in DNA methylation induced by Pramel7 is still detectable in mESCs differentiat-
ed for 10 days in feeder-free conditions and deprived from LIF. Indeed, comparable results 
could be observed also after differentiation, indicating that the presence of Pramel7 on one 
hand can be maintained and on the other hand is able to keep UHRF1 and thus DNA methyla-
tion on a low level throughout the process of differentiation (Fig. 24B). 
2.7.2. Confocal microscopy reveals reduced signals for 5mC in mESCs overexpressing Pramel7  
To further confirm the above findings, we immunofluorescently labelled Pramel7-
overexpressing and wt E14 mESCs with an antibody recognizing 5mC and analysed the signals 
by confocal microscopy. Whereas E14 cells displayed positive signals of nuclear heterochro-
matic foci rich in DNA methylation and thus 5mC, in Pramel7-overexpressing cells 5mC signals 
at DAPI-dense pericentric heterochromatin regions were reduced or absent. Taken together, 
over a certain number of passages low UHRF1 levels caused by the expression of Pramel7 lead 
to massively reduced DNA methylation in mESCs (Fig. 25). 
 
  
Fig. 25: Confocal microscopy analysis of 5mC levels in wt E14 and FLAGHA-Pramel7 overexpressing 
mESCs. 
a-c: Wt E14 mESCs. d-f: FLAGHA-Pramel7 overexpressing mESCs. a/d: Anti 5mC staining. b/e: DAPI 
signal. c/f: DAPI/5mC overlay. Confocal microscopy was performed at the Center for Microscopy and 
Image Analysis of the University of Zurich (ZMB). Scale bar: 10µm. P7=Pramel7.  
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2.7.3. Pramel7-overexpressing mESCs exhibit elevated expression levels of the trophectoder-
mal marker Elf5 
Embryonic stem cells with depleted DNMT1 (DNMT1-/-) exhibit a uniquely high potential for 
the trophectodermal lineage illustrated by the upregulation of the transcription factor Elf5. Elf5 
together with Cdx2 and Eomes take an important role in trophectodermal specification during 
the development of an early mouse embryo. Its aberrant upregulation is caused by inefficient 
methylation at promoters of trophectodermal genes (see Introduction chapter 1.5). To test if this 
side effect can also be observed in Pramel7-overexpressing mESCs, we analysed the expression 
levels of Elf5 in wt E14 and Pramel7-overexpressing mESCs (Fig. 26). Samples from various ex-
periments described in the figure legend of Fig. 26 were used. Indeed, amounts of Elf5 mRNA 
were significantly higher in all mESC samples overexpressing Pramel7 than in the correspond-
ing wt E14 samples. In samples representing mESCs cultured in self-renewing culture conditions 
(Fig. 26A) the upregulation effect of Elf5 caused by the overexpression of Pramel7 was 7.5-12.5-
fold. Upon differentiation of mESCs, the upregulation in Pramel7 overexpressing cells increased 
to 55-fold (d10 diff) and 255-fold (d14 diff), respectively (Fig. 26B). These data further confirm 
that via degradation of UHRF1 overexpression of Pramel7 in leads to impaired DNA methyla-
tion mESCs and therefore, resembling DNMT1-/- mESCs, aberrant expression of the trophecto-
dermal marker Elf5. 
 
 
Fig. 26: RTQ-PCR analysis for the trophectodermal marker Elf5 in self-renewing and differentiated 
Pramel7-overexpressing mESCs. 
Expression levels are compared to wt E14 cells in the corresponding condition/experiment. A: Samples 
from mESCs cultivated in self-renewing conditions (CM+LIF). Left: Wt E14 and Pramel7-overexpressing 
mESCs (FLAGHA-tagged) routinely used in this work. Middle: Wt E14 and two Pramel7-overexpressing 
clones (11&17) adapted to a new fetal bovine serum (NS) for 3 passages. Right: A wt E14 and a Pramel7-
overexpressing clone reconverted to pluripotency after differentiation (see experiment described in Re-
sults chapter 3.1.5). B: Samples from differentiated mESCs (CM-LIF, no feeders). Left: mRNA from d10 
differentiated mESCs (see Results chapter 2.7.1). Right: mRNA from d14 differentiated mESCs (see Results 
chapter 3.1.1). 
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2.8. Chromatin of Pramel7-overexpressing mESCs is enriched in activating histone 
marks 
Modifications of the N-terminal tail of histones can indicate an active or inactive chromatin 
state. By quantifying and comparing the expression of different histone marks in wt E14 and 
Pramel7-overexpressing mESCs we wanted to examine if the reduction in DNA methylation 
might have an effect on the prevalence of histone modifications. Using antibodies against dif-
ferent histone marks representing an either active or inactive chromatin state, whole cell lysates 
were analysed by Western blotting. Fig. 27 shows elevated levels of the activating histone 
marks H3K9ac, H3K27ac, H3K4me3 and H4ac in Pramel7-overexpressing cells when compar-
ing to E14 mESCs, whereas the repressive mark H3K27me3 was more abundant in wt cells. 
This is leading to the assumption that the reduction in DNA methylation caused by Pramel7-
induced degradation of UHRF1 results in a generally more open and thus more active transcrip-
tional state of the chromatin.  
 
 
Fig. 27: Levels of different histone modifications in wt E14 and Pramel7-overexpressing mESCs. 
Prevalence of histone modifications was analyzed from whole cell lysates from mESCs cultivated in self-
renewing conditions. P7=Pramel7. H-mod=histone modification. 
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2.9. Overexpression of Pramel7 is not altering cell cycle profiles of HEK293T and 
mESCs 
Previous works showed that in some mammalian cell lines a reduction of UHRF1 is influencing 
the distribution of cells in different phases of the cell cycle (Bonapace et al., 2002), (Jenkins et 
al., 2005). We therefore tested if this is also the case for both mESCs stably overexpressing 
Pramel7 and HEK293T cells ectopically expressing Pramel7 for 48h. After harvesting and fixa-
tion cells were subjected to PI-FACS analysis (Fig. 28). Neither in HEK293T nor in mESCs a 
significant difference between Pramel7-overexpressing and wt E14 cells could be observed, 
assuming that Pramel7 expression is not altering the distribution of cells in different phases of 
the cell cycle in these two particular mammalian cell types. 
 
 
 
Fig. 28: PI-FACS profiles of HEK293T and mESCs in presence or absence of Pramel7-overexpression. 
A: HEK293T cells. After transfection cells were cultivated for 48h and analyzed for PI intensity (left: 
Pramel7-tranfected; middle: pBS-transfected; right: untransfected). B: mESCs. Cells were cultivated in 
self-renewing conditions and analyzed for PI intensity (left: FLAGHA-Pramel7 overexpressing; right: wt 
E14). 
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2.10. Localization of Pramel7 in the cell 
To obtain further information about the localization of Pramel7 within the cell, several experi-
ments were executed. First, HEK293T cells were CaCl2-transfected with CAG_FLAGHA-
Pramel7, cultivated for 48h and immunofluorescently labelled for Pramel7 and HA, respective-
ly. As visible in Fig. 29A, Pramel7 exhibited different localization patterns in HEK293T cells. In 
one fraction of cells the protein was detected in the cytoplasm exclusively, whereas in other 
cells a nuclear enrichment was observed. However, many cells with nuclear enrichment were 
as well exhibiting a positive cytoplasmic signal. These observations could be made in immuno-
fluorescence experiment using both anti-HA (data not shown) and anti-Pramel7 antibodies. To 
exclude a detrimental side effect caused by transfecting too high amounts of plasmid DNA and 
thus excessive overproduction of the protein, transfected DNA was diluted from 1µg to 50ng. 
Even at these low dilutions a similar distribution pattern was observed (data not shown). 
 
Fig. 29: Localization of Pramel7 in the cell. 
A: HEK293T cells transfected with FLAGHA-Pramel7 and stained for Pramel7. Scale bar: 50µm. B: Wt 
129 mESCs transfected with CAG_FLAGHA-Pramel7 and stained for Pramel7. Scale bar: 30µm. C: 
HEK293T cells transfected with pEF_GFP-Pramel7. Scale bar: 50µm. D: Separation of chromatin and 
soluble fractions of wt E14 and FLAGHA-Pramel7 overexpressing mESCs cultivated in self-renewing con-
ditions. P7=Pramel7. 
 
Next, 129 mESCs cultivated on gelatin in defined serum-free conditions (2i+LIF) were transient-
ly transfected with CAG_FLAGHA-Pramel7, cultured for 48h and immunofluorescently labelled 
for Pramel7. As to expect, transfection efficiency was lower compared to HEK293T cells. Nev-
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ertheless, in all cells positive for FLAGHA-Pramel7 the signal was covering the whole cell and 
was not restricted to a particular subcellular region as cytoplasm or nucleus in both anti-HA 
(data not shown) and anti-Pramel7 assays (Fig. 29B).  
We then constructed a GFP-tagged version of Pramel7 (pEF_GFP-Pramel7), transfected it into 
HEK293T cells and analysed the GFP signal after 24-48h. Confirming the above data, GFP-
Pramel7 was restricted to the cytoplasm in one fraction of cells whereas in other cells an accu-
mulation in the nucleus coinciding with a cytoplasmic signal was detected (Fig. 29C). Taken 
together, these approaches show that in HEK293T cells Pramel7 is exhibiting a miscellaneous 
localization pattern. Pramel7 is either present in the cytoplasm exclusively or accumulates in 
the nucleus without completely losing its cytoplasmic localization. In 129 mESCs, no distinc-
tion between cytoplasmic and nuclear localization could be made when ectopically expressing 
Pramel7.  
We were also curious to see if and to what extent the protein is capable of interacting with the 
chromatin of mESCs. Therefore, we separated the chromatin from the soluble fraction (nucleo- 
and cytoplasm) of wt E14 and Pramel7-overexpressing mESCs and detected Pramel7 and 
UHRF1 by Western blot (Fig. 29D). Interestingly, in Pramel7-overexpressing cells a significantly 
higher amount of Pramel7 was detected in the chromatin fraction whereas levels in the soluble 
fraction were lower. As expected, by looking at the distribution of UHRF1, in wt E14 cells the 
major bulk of UHRF1 was associated with chromatin and only very few protein could be de-
tected in the soluble fraction. In contrast, confirming our previous findings, in the soluble frac-
tion of Pramel7-overexpressing cells, no UHRF1 could be observed and only a very faint band 
was detected in the chromatin fraction, representing degraded UHRF1 caused by the expres-
sion of Pramel7.  
2.11. Compared to Pramel7, PRAME exhibits a similar expression pattern in HEK293T 
cells 
As PRAME was described to be the founder gene of the PRAME-like family, we wanted to ex-
amine if the expression patterns of this gene are comparable to those of Pramel7. To verify this, 
a FLAGHA-tagged version of PRAME was cloned into a pcDNA3.1-expression plasmid. 
HEK293T cells were transfected with the construct, cells were cultivated for 24h and finally 
immunofluorescently labelled anti-HA (Fig. 30). Indeed, PRAME and Pramel7 proteins exhibit-
ed similar expression patterns. The signal was detected either exclusively in the cytoplasm or 
accumulating in the nucleus. Thus, these data are not excluding similar mechanistic roles for 
the two proteins and probably also for other members of the PRAME-like gene family. 
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Fig. 30: Expression of FLAGHA-PRAME in HEK293T cells. 
HEK293T cells were transfected with FLAGHA-PRAME, cells were cultivated for 24h and localization of 
PRAME analyzed by immunofluorescent labeling anti-HA. Scale bar: 50µm. 
 
2.12. PRAME and Pramel6 are not able to reduce UHRF1 levels after ectopic expres-
sion 
In context of the comparable subcellular localization of PRAME and Pramel7, it was assessed if 
expression of PRAME and Pramel6, a member of the PRAME-like family highly conserved to 
Pramel7, might also lead to a decrease in UHRF1 levels. Western blot analysis in Fig. 31A 
shows that in contrast to Pramel7, PRAME and Pramel6 were not able to induce a significant 
degradation of UHRF1 after 24h and 48h. Since no antibody recognizing Pramel6 is commer-
cially available, the expression of the plasmid was verified by RTQ-PCR, indicating a massive 
expression of the plasmid (Fig. 31B). Considering the conservation of the two proteins Pramel6 
and Pramel7 and the inability of Pramel6 to induce a degradation of UHRF1, it is to assume 
that the interaction between Pramel7 and UHRF1 is highly specific. This strengthens the hy-
pothesis that every member of the PRAME-like protein family might efficiently recognize and 
target a particular substrate for subsequent degradation with high specificity. 
 
 
Fig. 31: Capability of PRAME and Pramel6 to induce the degradation of UHRF1 
A: HAFLAG-PRAME and CAG-Pramel6 were expressed in HEK293T cells and cells were cultivated for 
48h. UHRF1 protein levels were determined by Western blotting. B: Verification of Pramel6 expression 
by determining dCT values (compared to actin). pBS=pBluescript. 
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3. A biological consequence of Pramel7 expression in mESCs 
Terminal differentiation of mESCs requires the establishment of DNA methylation and repres-
sive histone modifications at promoters of pluripotency-related genes such as Oct4, Nanog or 
Rex1 to ensure a faithful shutdown and to prevent their reactivation. 
Taking into account that Pramel7 maintains UHRF1 levels constantly low leading to loss of 
global methylation, we wondered if the presence of Pramel7 disturbs terminal differentiation of 
mESCs and facilitates the reactivation of a pluripotent state.  
3.1. mESCs overexpressing Pramel7 show impaired terminal differentiation 
3.1.1. After 14 days of differentiation, Pramel7-overexpressing mESCs exhibit a drastically 
elevated expression of pluripotency-related genes 
To assess if mESCs overexpressing Pramel7 are capable to undergo terminal differentiation or if 
the lack of global methylation prevents robust silencing of pluripotency-associated genes, we 
cultivated wt E14 and Pramel7-overexpressing mESCs in feeder-free conditions in complete 
medium deprived from LIF for 14 days. During this period, cells should not grow over conflu-
ence ensured by passaging them twice. When comparing the two differentiated mESC lines in 
terms of physical appearance, wt E14 mESCs developed into a homogeneous layer of cells 
whereas Pramel7-overexpressing mESCs were rather assembled into smaller groups and spots 
without any attached cells were visible (Fig. 32A/C). Differentiated cells were next subjected to 
analysis of protein levels by Western blotting to guarantee that Pramel7 overexpression was 
maintained during the whole process of differentiation. When looking at Fig. 32B, the expres-
sion of Pramel7 was still detectable after two weeks of differentiation, although at slightly re-
duced levels. UHRF1 amounts in Pramel7-overexpressing cells were comparably low in undif-
ferentiated and 14d-differentiated mESCs. As expected, UHRF1 levels in E14 control cells were 
drastically decreasing during differentiation, reflecting low proliferation of cells in the differen-
tiated state. Nevertheless, slightly more UHRF1 could be detected in control cells than in 
Pramel7-overexpressing cells. This indicates that UHRF1 levels in Pramel7-overexpressing 
mESCs were still affected by the expression of Pramel7 after two weeks of differentiation. 
Next, expression levels of the pluripotency-related genes Oct4, Nanog and Rex1 were deter-
mined from total mRNA of differentiated cells. Remarkably, when using mRNA levels of differ-
entiated E14 control cells as a baseline, expression levels of all three candidates were signifi-
cantly enhanced in differentiated mESCs overexpressing Pramel7. This suggests that in Pramel7-
overepxpressing mESCs, promoters of Oct4, Nanog and Rex1 could not be silenced as efficient-
ly as in control mESCs (Fig. 32 D). 
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Differentiated mESCs were also immunofluorescently labelled for the pluripotency marker 
Oct4. In accordance with the observations from RTQ-PCR analysis, the number of cells ex-
pressing detectable levels of Oct4 was drastically higher in Pramel7-overexpressing than in E14 
control cells (Fig. 32 C). These data strongly suggest that during differentiation of mESCs, re-
duced amounts of UHRF1 caused by the expression of Pramel7 lead to a less robust silencing of 
Oct4, Nanog and Rex1. 
 
 
Fig. 32: Wt E14 and Pramel7-overexpressing mESCs after 14d of differentiation. 
A: Phase contrast images of wt E14 and FLAGHA-Pramel7 overexpressing mESCs after 14d of differentia-
tion in CM-LIF -feeders. Scale bar: 100µm. B: UHRF1 and Pramel7 protein levels of wt E14 and 
FLAGHA-Pramel7 overexpressing mESCs in self-renewing conditions (CM+LIF, left) and after 14d of dif-
ferentiation (CM -LIF -feeders, right) C: Immunofluorescent Oct4-labeling of wt E14 and FLAGHA-
Pramel7 overexpressing mESCs differentiated for 14d in CM-LIF -feeders. Scale bar: 200µm. D: Gene 
expression analysis of different pluripotency markers in d14 differentiated mESCs overexpressing 
FLAGHA-Pramel7. Expression is compared to differentiated wt E14 mESCs. P7=Pramel7, Exp 
rel=expression relative to. 
 
3.1.2. Upon addition of LIF, differentiated mESCs overexpressing Pramel7 rapidly regain fea-
tures associated with pluripotency  
To elucidate to what extent differentiated mESCs are capable to be reconverted to a pluripotent 
state when re-exposed to culture conditions supporting pluripotency, we diluted 14d-
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differentiated wt E14 and Pramel7-overexpressing cells and seeded them at a density of 10 
cells/well in two 96-well plates (per cell type) containing feeder cells. After seven days of culti-
vation in self-renewing conditions (CM +LIF), wells were screened for colonies displaying a 
round, pluripotent morphology. In 96-well plates with Pramel7-overexpressing cells approxi-
mately 9/10 wells contained colonies, whereas in only around 1/10 of control wells mESC-like 
colonies could be observed. As a next step, 10 promising wells were passaged to 24-well plates 
for further expansion. Residual 182 wells were fixed and analysed for the expression of the plu-
ripotency marker alkaline phosphatase (AP) (Fig. 33 A/D). The number of wells containing AP-
positive colonies was quantified in Fig. 33 B/C. In 5/182 (2.7%) wells containing control cells 
one or more AP-positive colonies could be identified, whereas the number of wells with posi-
tive colonies in Pramel7-overexpressing cells was 147/182 (80.8%).  
 
 
Fig. 33: Re-cultivating d14 differentiated mESCs in self-renewing conditions. 
A: 96-well plates after re-cultivating d14 differentiated cells for 7d in self-renewing conditions followed 
by alkaline phosphatase (AP) staining. B/C: Numbers of wells containing AP-positive colonies after re-
cultivation for 7d in self-renewing conditions. A graphic illustration showing the average number of wells 
with AP-positive colonies (B) and a table (C) displaying total numbers and percentages. 5 promising 
wells/plate were previously passaged on 24-well plates for expansion. Av= average, P7= Pramel7. D: 
Example for AP-positive and AP-negative colonies. Scale bar: 100µm. 
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3.1.3. Expansion of reconverted E14-clones requires a longer cultivation period than of re-
converted mESCs overexpressing Pramel7 
Next, we were interested if the clones from the 96-well plates could successfully be expanded 
without loss of pluripotency-associated features. Moreover, we wondered if the duration of ex-
pansion might vary between Pramel7-overexpressing and wt E14 mESCs. After passaging 10 
selected clones from 96-well plates, cells were first cultivated on 24-well plates for one passage 
and further expanded on 3.5cm culture dishes four two passages. At this stage, cells were col-
lected for different experimental approaches. As schematically visible in Tab. 4, 9 out of 10 
Pramel7 clones could successfully be expanded over 3-4 passages within only 6 days. 5 of the-
se clones were harvested for further characterization by Western blotting, RTQ-PCR and immu-
nofluorescence. Remarkably, only one out of ten clones from 96-well plates was not successful-
ly expanded. In contrast, all wt E14 clones showed a delayed growing behaviour. Firstly, no 
colony-like phenotype was detectable during the first 3 days in 24-well and on day 4, only 2 
clones could be passaged the second time. Other 8 clones had to be transferred 1:1 to new 24-
wells. Finally, 10 or 11 days after initial passaging, 5 clones were harvested for further analysis. 
4 out of 10 clones were lost. Thus, E14 clones required almost double amount of time for the 
same steps of expansion. Taken together with data obtained in the last chapter, after addition of 
LIF, Pramel7-overexpressing cells reconvert to pluripotency at much higher frequency and con-
sequently, expansion of these clones was more efficient than in control cells. 
 
Tab. 4: Expansion time of d14 differentiated mESCs re-cultivated in self-renewing conditions (7d). 
Expansion duration is representing the number of days after which cells exhibited a pluripotency-like 
phenotype ready for further analysis or freezing. OE=overexpressing, NR=not rescued. 
 
  Clone Expansion duration   Clone Expansion duration 
FLAGHA-
Pramel7-OE 
mESCs 
1 d6  
Wt E14 
mESCs 
1 d10  
2 d6 2 d10  
3 d6 3 d11 
4 d6 4 d11 
5 d6 5 d11 
6 d5 (backup) 6 d11 (backup) 
7 d5 (backup) 7 NR 
8 d5 (backup) 8 NR 
9 d7 (backup) 9 NR 
10 NR 10 NR 
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3.1.4. Reconverted Pramel7-clones still exhibit downregulated UHRF1 and ectopic expression 
of Pramel7 
After 14 days of differentiation, Pramel7-overexpressing mESCs still expressed detectable 
amounts of ectopic Pramel7 protein and slightly reduced UHRF1 levels (Fig. 32). Therefore, it 
had to be verified if Pramel7 protein was detectable also in reconverted clones and as a conse-
quence, if amounts of UHRF1 protein were still reduced. Indeed, Western blot analysis re-
vealed that reconverted Pramel7-clones all expressed Pramel7 at similar levels. Also UHRF1 
amounts were comparable to control mESCs (original Pramel7-overexpressing mESC line in CM 
+LIF), indicating that during the whole process of differentiation and subsequent reconversion 
to pluripotency, ectopic expression of Pramel7 is sufficient to keep UHRF1 at low levels (Fig. 
34 A). Moreover, immunofluorescence of one selected reconverted clone of each cell type (wt 
E14 & FLAGHA_Pramel7-overexpressing) revealed positive signals for the pluripotency markers 
Oct4 and SSEA1, indicating a correct re-activation of these particular two genes (Fig. 34 B). 
 
 
Fig. 34: Analysis of reconverted cones. 
A: Western blot analysis showing protein levels of 4 reconverted clones overexpressing FLAGHA-
Pramel7. Controls are represented by mESCs cultivated in self-renewing conditions (CM+LIF). B: Im-
munohistochemical staining for Oct4 (a/c) and SSEA1 (b/d) of one reconverted clone overexpressing 
FLAGHA-Pramel7 (a/b) and one reconverted wt E14 clone (c/d). Scale bar: 200µm. ReC=reconverted 
clone, P7=Pramel7.  
 
3.1.5. Reconverted E14-clones fail to reactivate the expression of the pluripotency-related 
genes Rex1 and Pramel7 
To examine the pluripotent state of reconverted and expanded clones, expression levels of plu-
ripotency-associated genes Oct4, Nanog and Rex1 were analysed. RTQ-PCR data from Fig. 35 
shows that both Pramel7-overexpressing and wt E14 clones, although with delayed kinetics 
(Tab. 4), succeeded in reactivating the expression of Oct4 and Nanog. Reconverted Pramel7-
Results  60 
clones also displayed amounts of Rex1 mRNA comparable to initial levels of control mESCs. In 
remarkable contrast, all E14-clones analysed were unable to reactivate the expression of firstly 
Rex1 and secondly, endogenous Pramel7. These findings strongly suggest that in contrast to 
Pramel7-overexpressing clones, E14 clones cannot be fully reconverted to a pluripotent state 
after two weeks of differentiation. 
 
Fig. 35: Reconverted clones: expression of pluripotency markers. 
Expanded reconverted clones were harvested and expression levels of pluripotency markers were as-
sessed. Expression levels are compared to wt E14 cultivated in self-renewing conditions (CM +LIF). 
ReC=reconverted clone, P7=Pramel7, Exp rel=expression relative to. 
 
3.2. Pramel7-overexpressing mESCs are able to differentiate into cells positive for 
smooth muscle actin (SMA) 
We then wanted to clarify if mESCs overexpressing Pramel7 are able to adopt a differentiated 
phenotype. We exposed E14 and Pramel7-overexpressing cells to a feeder-free environment, 
cultivated them in smooth muscle differentiation medium for 9 days and analysed their expres-
sion for SMA, a marker for smooth muscle tissue, and for UHRF1. Fig. 36 reveals differentiated 
smooth muscle cells highly positive for SMA in both cell lines. As to expect, resulting from the 
differentiated state, no UHRF1 signal was obtained in either cell line. These data show that 
mESCs overexpressing Pramel7 are able to react to differentiation stimuli at least in vitro. Fur-
thermore, they are able to activate the expression of differentiation markers such as SMA. How-
ever, if Pramel7-overepxressing mESCs are indeed capable to terminally differentiate and how 
stable pluripotency-related genes are silenced, remains to be clarified. 
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Fig. 36: Differentiation of FLAGHA-Pramel7 overexpressing and wt E14 mESCs into smooth muscle 
cells for 9d. 
Differentiated (9d) smooth muscle cells from FLAGHA-Pramel7 overexpressing (a/b) and wt E14 mESCs 
(c/d) were immunohistochemically stained for smooth muscle actin (SMA) (a/c) and UHRF1 (b/d). Scale 
bar: 100µm. 
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C. Discussion  
This work for the first time identifies the functional role of a member of the PRAME-like gene 
family, Pramel7, that was originally found expressed in the pluripotent compartment of morula 
and blastocyst in the early mouse embryo (Cinelli et al., 2008). UHRF1 is a multi-domain pro-
tein mainly responsible for the recognition of hemimethylated DNA sites. Through guidance of 
DNMT1 to these sites UHRF1 mediates a faithful propagation of whole genome methylation 
during replication. After screening for possible binding partners we found that Pramel7, via its 
LRR-region, specifically interacts with the epigenetic regulator UHRF1 in HEK293T cells and 
mESCs. As a consequence, Pramel7 induces a rapid degradation of UHRF1 in a dose-
dependent manner. The reduction of UHRF1 levels induced by the expression of Pramel7 lead 
to severe global loss of genomic methylation in mESCs concomitant with a global enrichment 
of activating histone marks and enhanced expression of the trophectodermal marker Elf5. 
Moreover, after 14 days of differentiation mESCs overexpressing Pramel7 were efficiently re-
converted to the pluripotent state within 7 days. Finally, in this work we identified possible 
binding partners of the Pramel7-UHRF1 complex and set up a hypothetical model for a work-
ing mechanism of Pramel7 and possibly, other members of the PRAME-like gene family. 
1. UHRF1, a new interaction partner of Pramel7 
We identified UHRF1 as a binding partner for Pramel7 by a yeast two-hybrid assay (Fig. 7), a 
very suitable system to obtain initial hints for potential interaction partners. Nevertheless, this 
assay has certain limitations. First of all, the reliability is approximately 50% (Sprinzak et al., 
2003) since the rate of false-positive hits is very high. This may be due to the following reasons. 
Firstly, transcription of the reporter gene is induced spontaneously by factors bound to the DNA 
binding domain in absence of the interaction partner (Hamdi and Colas, 2012). Secondly, since 
the approach occurs in the nucleus, candidates interacting in natural conditions might be found 
non-interacting e.g. if one of the two proteins contained a different, non-nuclear localization 
signal (Overington et al., 2006). Finally, the yeast cell might not be able to set up correct post-
translational modifications as phosphorylation required for specific interactions in mammalian 
cells (Ngounou Wetie et al., 2014). 
To confirm that UHRF1 was indeed interacting with Pramel7, we verified this interaction in a 
mammalian system where we could show a strong binding of the proteins after co-IP experi-
ments in HEK293T cells (Fig. 9A). However, only a very weak signal of UHRF1 could be de-
tected in mESCs (Fig. 9B). One possible explanation is that mESCs, even upon stable electro-
poration of an expression vector containing suitable promoters as CAG or EF1, hardly reach 
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expression levels as high as the ones obtained in HEK293T cells (Thomas and Smart, 2005). 
Therefore, the ratio between recombinant FLAG-Pramel7 and total protein used as input for the 
IP is reasonably less in mESCs than in HEK293T cells. Furthermore, while in mESCs we pulled 
down the endogenous UHRF1, in HEK293T cells UHRF1 was co-expressed with FLAG-Pramel7 
resulting in more or less equal and high levels of bait and prey proteins. Furthermore, the con-
stant degradation of UHRF1 by Pramel7 leads to strongly reduced levels of pulled-down 
UHRF1 in the IP when using mESCs, complicating the detection of UHRF1.  
Interestingly, we were able to detect precipitated UHRF1 only when using mESCs expressing 
FLAG-Pramel7 driven by the EF1- but not by the CAG-promoter (Fig. 9). A study of Chen et al. 
compared the activities of different promoters driving a stably integrated luciferase reporter at 
the ROSA26 locus in mESCs. The authors found that the luciferase intensity in cells containing 
the construct driven by the CAG promoter was around 4 times higher than signals from cells 
containing the EF1 plasmid (Chen et al., 2011). Generally, HEK293T cells produce higher 
amounts of proteins from exogenously integrated constructs than mESCs. Moreover, in our case 
we need to consider the rapid decrease in UHRF1 levels upon Pramel7 overexpression (Fig. 
17). These aspects finally lead to a reduced efficiency of the IP. We interpret that through en-
hanced activity of CAG_FLAG-Pramel7 more UHRF1 is degraded already prior to the perfor-
mance of the IP than in mESCs expressing EF1_FLAG-Pramel7. This leads to the conclusion that 
for a successful demonstration of this interaction in mESCs, FLAG-Pramel7 should be expressed 
at levels sufficiently low to prevent excessive degradation of UHRF1 but high enough to enable 
a detectable precipitation of UHRF1. Thus, a successful demonstration of the interaction in 
mESCs requires a tight balance of Pramel7 and UHRF1 levels. 
Initial analysis of the Pramel7 protein sequence using the LRR finder software revealed three 
potential LRRs (Fig. 6). LRRs are patterns of repetitive sequences forming curved solenoid struc-
tures, which are particularly convenient for protein-protein interactions. These protein domains 
exhibit a huge structural and functional variability (Bella et al., 2008). Focusing on the region 
containing potential LRRs we wanted to narrow down the regions in Pramel7 mediating the 
interaction with UHRF1. For Pramel7, we cloned three different FLAG-tagged LRR deletion 
mutants of various lengths covering the predicted three LRRs and one control deletion located 
N-terminally of the LRRs (Fig. 11, Fig. 41/Fig. 42). Subsequent IP revealed all deletion mutants 
showed a drastically impaired potential of pulling down UHRF1. Interestingly, the control mu-
tant could partly restore but not completely rescue the interaction (Fig. 12). Indeed, additional 
screening using another LRR detection software (LRR search) revealed additional three poten-
tially important LRR located in the control region (Fig. 6). This indicates that the LRR with the 
sequence LKHLCLRGVTL is critical for the interaction. However, the three LRRs in the control 
area of Pramel7 identified in the second screening might also contribute to the interaction. The 
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shortest LRR deletion was 33AA in size. Hence, one could not rule out that the impaired ability 
in binding UHRF1 observed in all LRR mutants is originating from inappropriate protein fold-
ing. Nonetheless, in comparison with the LRR mutants, more UHRF1 was precipitated with the 
control deletion construct (62AA) (Fig. 12). This indicates that the observed effect is more likely 
to be a consequence of lacking LRRs than of aberrant protein folding. Thus, our data indicate 
that the LRR detected in the area of the control mutation together with the two LRRs affected in 
the smallest 33AA deletion are crucial for the interaction between Pramel7 with UHRF1.  
UHRF1 contains multiple protein domains. Tandem-Tudor and PHD domains are involved in 
the recognition of the H3 tail. Most well characterized, the SRA domain binds to hemimethyl-
ated DNA regions (Avvakumov et al., 2008), (Hashimoto et al., 2008) ensuring the faithful tran-
sition of methylation marks from mother to daughter cells by recruiting DNMT1 to these partic-
ular sites (Bostick et al., 2007), (Sharif et al., 2007). The RING domain exhibits reported E3-
ligase activity and the role of the C-terminal UBL domain is less clear (see Introduction chapter 
3). To identify the region in UHRF1 indispensable for the interaction with Pramel7 we made 
use of different FLAG-tagged mutants with deletions in UBL, Tandem-Tudor and PHD domains 
described in the study of Liu et al. (Liu et al., 2013). It remains to be mentioned that in all mu-
tants SRA and RING domains are absent (Fig. 13). As expected, Pramel7 was interacting most 
efficiently with full-length UHRF1 (Fig. 14). All other UHRF1 mutants were exhibiting weaker 
interactions indicating that the presence of the full-length UHRF1 protein is of great importance 
for a successful interaction. Consequently, this assigns a significant role to the C-terminal part 
of the protein comprising SRA and RING domains.  
Besides Tandem-Tudor and PHD domains together mediating the interaction of UHRF1 with 
the H3 tail (Cheng et al., 2013), (Liu et al., 2013) the linker region connecting the two domains 
was reported to have a crucial function in this process (Arita et al., 2012). Furthermore, Rottach 
et al. reported that in UHRF1 deletion experiments the behavior of different UHRF1 mutants in 
chromatin association and localization was drastically changing, depending on which domains 
were deleted or not (Rottach et al., 2010). The authors therefore stated that observations origi-
nating from experiments sequentially testing the function of single domains are hardly applica-
ble to the behavior of the full-length protein. Basically, all domains represent whole functional 
entities and, when present or deleted, might heavily influence the behavior and binding kinet-
ics of the other domains. Thus, the exact molecular reasons for the different binding patterns of 
UHRF1 deletion mutants with Pramel7 remain to be elucidated. 
The recognition of H3 by UHRF1 is very well documented (see Introduction chapter 3.4). Fur-
thermore, PARP1 was identified as an interaction partner of UHRF1 (Sharif et al., 2007). Con-
firming these data, we were able to precipitate both H3 and PARP1 in HEK293Tcells (Fig. 10). 
PARP1 is very abundant at chromatin sites and was described to interact with different kinds of 
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histones and DNMT1 (Reale et al., 2005), (Heo et al., 2007), (Messner et al., 2010). In our ex-
periments, using the UHRF1 deletion mutants, opposite binding patterns could be observed 
between H3/PARP1 and Pramel7. H3 and PARP1 among themselves both exhibited compara-
ble binding patterns and only interacted with versions of UHRF1 containing intact Tandem-
Tudor and PHD domains (UHRF1_1-408, UHRF1_95-368, UHRF1_95-408) (Fig. 14/Fig. 15). 
These forms of UHRF1 displayed a very low signal for Pramel7. Interestingly, the residual two 
deletion mutants with either incomplete Tandem-Tudor or PHD domain (UHRF1_1-298 and 
UHRF1_182-408) showed elevated levels of precipitated Pramel7 and very low H3/PARP1 (Fig. 
14).  
All UHRF1 deletion constructs were designed using the same expression plasmid (pSG5-FLAG) 
(Liu et al., 2013). Remarkably, very low amounts of full-length UHRF1 were detected in the 
input material of the respective IP when co-expressing Pramel7 (Fig. 14). As a consequence, 
nearly undetectable amounts of H3/PARP1 were observed in the respective precipitate. Repeti-
tion of the experiment in absence of Pramel7 revealed significantly higher amount of full-length 
UHRF1 in the starting material (Fig. 15). Concomitantly, a stronger UHRF1 enrichment co-
precipitating more H3/PARP1 was observed after the IP. Thus, this differential outcome is con-
ferred to the presence of Pramel7 and the accompanying degradation of full length UHRF1 as 
discussed below (Fig. 37). For other UHRF1 deletion mutants, no reduction was observed after 
co-expression of Pramel7. Moreover, binding patterns of H3/PARP1 were comparable among 
different mutants and thus independent on the presence of Pramel7. In addition, PARP1 seems 
to have a higher affinity to versions of UHRF1 containing Tandem-Tudor and PHD domains 
than to full-length UHRF1 (Fig. 15), indicating an effect impeding the interaction mediated by 
the C-terminal part of the full-length protein. 
2. Additional interaction partners 
We aimed at identifying additional potential binding partners of Pramel7-UHRF1 using mass 
spectrometry assays. In the first approach using FLAG-Pramel7 as bait we identified different 
types of histones, ElonginC (TCEB1) and Polyubiquitin in addition to UHRF1 in HEK293T cells. 
The complete list of factors was short, indicating that Pramel7 might interact with high speci-
ficity to particular proteins rather than being part of a big protein complex. 
Since no potential DNA binding domain could be identified in the amino acid sequence of 
Pramel7 we wondered about the localization of the protein in the cell. The presence of his-
tones, ElonginC and UHRF1 in the FLAG-Pramel7 precipitate suggested a nuclear localization. 
In fact, also for PRAME, a cell type-dependent cytoplasmic and/or nuclear localization was 
observed. Moreover, PRAME was reported to co-localize with ElonginC and to precipitate core 
histones. Therefore, PRAME is assumed to take over different roles in the cytoplasm and the 
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nucleus (Wadelin et al., 2013). This is also supported by our data from immunofluorescence 
experiments. Pramel7 and PRAME were localized at both cytoplasmic and nuclear sites (Fig. 
29/Fig. 30). Interestingly, after separation of the soluble fraction from the chromatin in Pramel7-
overexpressing mESCs, Western blot revealed a major bulk of Pramel7 associated to chromatin, 
suggesting a substantial role for Pramel7 in the nucleus directly at chromatin sites (Fig. 29). 
Since UHRF1 was shown to strongly interact with histones and other chromatin modifiers, we 
sought for members exclusively depending on the presence of Pramel7. To gain further infor-
mation we precipitated FLAG-UHRF1 in presence or absence of Pramel7. We then screened for 
factors present in only one of the two fractions since these hits were assumed to be dependent 
on the presence or absence of Pramel7, while proteins detected in both fractions were assigned 
to interact with UHRF1 independent of the presence of Pramel7. The only four proteins that 
could be detected in the presence of Pramel7 were ElonginC, HP1γ, CHD4 and SPT16. These 
factors are mainly involved in the establishment of chromatin and in transcription and elonga-
tion of a subset of genes (see Results chapter 1.4).  
Based on the identification of ElonginC and under consideration of Costessi et al.’s study (see 
Introduction chapter 2.1) (Costessi et al., 2011) we propose a mechanism of Pramel7-mediated 
UHRF1 degradation involving ElonginC (Fig. 37). This working model is explained in more de-
tail in the next chapter. Nevertheless, it cannot be excluded that factors as HP1γ, CHD4 and 
SPT16 also play a role connected to Pramel7-UHRF1. As an example, it was seen that overex-
pression of UHRF1 lead to misplacement of different HP1 proteins from pericentric hetero-
chromatin, including HP1γ (Papait et al., 2008). It remains to be elucidated if a decrease in 
UHRF1 levels induced by the expression of Pramel7 might also have an effect on the distribu-
tion of HP1 proteins and thus on the large scale organization of pericentric heterochromatin. 
Indeed, our data from mESCs overexpressing Pramel7 indicate a more active chromatin state 
shown by elevated levels of activating histone marks (Fig. 27). This is supported by the expres-
sion of the trophectodermal gene Elf5 usually silenced in this cell type (Fig. 26). Summarizing, 
we cannot rule out a functional connection between Pramel7 and chromatin remodeling en-
zymes other than UHRF1.  
3. Pramel7 as a substrate-recognition component of an E3-ligase complex 
Our working model defines Pramel7 as the substrate recognition component specific for 
UHRF1 in a Cullin-RING ligase (CRL) complex. Pramel7 is assumed to interact with UHRF1 via 
its N-terminal LRR-rich region and with ElonginC and Cullin via C-terminal BC- and Cullin-
boxes. Cullin is also associated with the E3-ligase Rbx1 (RING-box protein 1) that finally medi-
ates the attachment of Ubiquitin residues to the substrate (UHRF1). CRLs account for approx. 
half of all predicted human E3-ligases and can vary in the composition of substrate recognition 
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components such as F-box proteins, different types of Cullin scaffold proteins and E3-ligases 
(Duda et al., 2012). 
 
Fig. 37: Pramel7 as a substrate recognition component in a Cullin-RING ligase complex (CRL). 
Pramel7 is hypothesized to be the substrate recognition component specific for UHRF1. It interacts with 
UHRF1 (via the LRR-rich region), ElonginC (via BC-box) and one member (Culx) of the Cullin family (via 
Culx box). Cullin is again coupled to the E3-ligase Rbx1 (Ring-box protein 1), mediating the attachment 
of Ub-residues to the recognized substrate (UHRF1). Culx: Unknown member of the Cullin family. Ub: 
Ubiquitin. EloB/C: ElonginB/C. 
 
Fig. 15 shows that in the presence of Pramel7 levels of full-length UHRF1 in the input fraction 
of the IP were drastically lower than in its absence. In different follow-up experiments we de-
tected that Pramel7 expression in HEK293T and mESCs induced a dose-dependent, rapid and 
reversible downregulation of UHRF1 (Fig. 17 - Fig. 20). Chen et al. stated that UHRF1 is de-
graded in the steady state. A stronger degradation of UHRF1 was observed upon cellular stress 
such as DNA damage after UV irradiation (Chen et al., 2013). Nonetheless, we could exclude 
that the degradation of UHRF1 observed in our experiments is originating from the sole trans-
fection procedure of HEK293T cells coupled with massive production of Pramel7 and potential 
cell stress. In contrast to Pramel7, overexpression of PRAME, Pramel6 and also different dele-
tion mutants of Pramel7 did not lead to any alteration of UHRF1 levels (Fig. 31/Fig. 22). 
All of the three LRR deletion mutants of Pramel7 were all not able to induce a degradation of 
UHRF1 (Fig. 22). In contrast, the control mutation could induce a small decrease in UHRF1 
levels. This is in line with data from Fig. 12 where the Pramel7 control mutant was able to bind 
more UHRF1 than LRR deletion mutants, but could not rescue the interaction to wt levels. 
Here, we observed a similar effect in regard to UHRF1 degradation, indicating that the degrada-
tion of UHRF1 is dependent on the amount of UHRF1 bound to Pramel7.  
Pramel7 was not able to degrade any of the six UHRF1 deletion mutants (Fig. 23). Since the 
phosphodegron at S108 identified by Chen et al. is present in all the mutant UHRF1 proteins 
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(Chen et al., 2013), another feature catalyzing the degradation of the protein is likely to be lo-
cated in its C-terminal part containing SRA and RING domains, possibly an ubiquitin acceptor 
site. 
Our hypothesis is based on the findings originally made for the Von Hippel-Lindau (pVHL) tu-
mor suppressor protein. pVHL is a specific substrate recognition subunit of an E3 CRL complex 
(ElonginB/C, Cul2, Rbx1) targeting the protein HIF1 (Hypoxia inducible factor 1) for degrada-
tion. In many studies it was stated that lack or inappropriate expression of pVHL lead to in-
creased levels of HIF1 and consequently, to numerous benign and malign tumors (Kanno et al., 
1994), (Shuin et al., 1994), (Robinson and Ohh, 2014).  
In general, the process of ubiquitination involves a cascade of protein reactions. The E1 ubiqui-
tin-activating enzyme recruits and transfers a ubiquitin residue to the E2 conjugating enzyme. 
Finally, the E3 ubiquitin ligase interacts with E2 and coordinates the ligation of the ubiquitin to 
a lysine residue of the target substrate. The substrate recognition protein of the E3 complex, of 
which more than 1000 exist, provides specificity to the reaction. Besides this, it is not unusual 
that one E3 recognition subunit controls the degradation of different targets. However, the exact 
substrates for the major bulk of these subunits are still unknown (Zou and Mallampalli, 2014). 
In most cases, before interacting with an E3-ligase complex, substrates are modified via mecha-
nisms such as phosphorylation, dephosphorylation, methylation or acetylation (Xu et al., 2009), 
(Ravid and Hochstrasser, 2008), (Zou and Mallampalli, 2014). Cellular localization of E3-ligase 
complexes can be both cytoplasmic and nuclear. For instance, one isoform of the substrate 
recognition subunit ßTrCP of the SCF E3-ligase complex was found localized in the nucleus 
whereas another was associated with the cytoplasm (Seo et al., 2009). Taken together, Pramel7 
and other members of the PRAME-like family might act as substrate recognition components in 
the nucleus and/or the cytoplasm, depending on the presence of their target proteins. UHRF1 
displays nuclear localization and, as already mentioned above, in mESCs we could identify a 
substantial fraction of Pramel7 protein associated with chromatin (Fig. 29). Nonetheless, it is 
not ultimately evident if the presence of UHRF1, specifically, is targeting Pramel7 to chromatin 
sites.  
The SCFßTrCP E3-ligase, a specific CRL complex, was identified as a mediator degrading UHRF1 
under normal and in stress conditions (e.g. UV-response) via phosphorylation of UHRF1 S108 
by CK1∂ (Casein kinase 1∂) (Chen et al., 2013) (see Introduction chapter 3.3). Expression of 
Pramel7 leads to a similar effect. Now the question is to address if Pramel7 truly acts as a sub-
strate recognition subunit targeting UHRF1 in its own E3 CRL complex. It could also induce 
UHRF1 degradation indirectly such as by stimulation of ßTrCP expression or activity. However, 
based on our findings we favor the first possibility. We could identify ElonginC but not ßTrCP in 
our mass spectrometry and do not have any evidence of a connection between Pramel7 and 
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ßTrCP. According to our data and in contrast to ßTrCP, Pramel7 only has very few specific in-
teraction partners. Hence, Pramel7 is likely to represent a CRL-based substrate recognition sub-
unit in a degradation process of the specific target protein UHRF1.  
4. Overexpression of Pramel7 severely reduces global DNA methylation in 
mESCs 
As for the first time shown by Bostick et al. and Sharif et al. it is generally accepted that a de-
crease in UHRF1 gene expression leads to global DNA hypomethylation induced by disturbed 
guidance of the maintenance DNA methyltransferase DNMT1 to sites of hemimethylated DNA 
during the S-phase of the cell cycle (Bostick et al., 2007), (Sharif et al., 2007). Indeed, our re-
sults suggest the occurrence of a comparable effect after stable overexpression of Pramel7 in 
mESCs. In two approaches, we could demonstrate that in comparison to wt E14 mESCs the 
prevalence of 5mC is drastically reduced in Pramel7-overexpressing mESCs (Fig. 24/Fig. 25). 
Moreover, we observed an aberrant overexpression of the trophectodermal gene Elf5 in 
Pramel7-overexpressing mESCs usually seen in DNMT1/3a/3b-/- mESCs (Ng et al., 2008). Ab-
normal activation of Elf5 was detected in cells cultivated in steady state conditions (CM +LIF on 
feeders) but also in differentiated mESCs (CM -LIF, no feeders). Relative to wt E14 control cells, 
differences in Elf5 expression were drastically higher in differentiated than in pluripotent cells 
(Fig. 26). Taken together, these findings suggest that in mESCs through the sole overexpression 
of Pramel7 a similar state as observed in UHRF-/- and in DNMT1/3a/3b-/- mESCs can be estab-
lished. However, it is notable that UHRF1 levels in Pramel7-overexpressing cells were drastical-
ly reduced, but not fully absent (Fig. 17).  
According to Leitch et al., global DNA hypomethylation is associated with naïve pluripotency. 
When comparing mESC lines cultivated in parallel in serum and 2i conditions a dramatic de-
crease in global DNA methylation was observed in cells cultured in 2i, the culture condition 
closely mimicking the naïve pluripotent state (Ying et al., 2008). It is thought that in 2i mESCs 
are shielded from differentiation and kept in a naïve state by preventing de novo methylation 
(Leitch et al., 2013). Moreover, data from 2008 suggested that in mESCs the presence of H3K4 
methylation and the absence of the repressive H3K9 methylation are better predictors of un-
methylated CpGs than the sequence context alone (Meissner et al., 2008). Indeed, also in 
Pramel7-overexpressing mESCs we detected a correlation between low DNA methylation and 
histone modifications. Most activating histone marks were found enriched whereas repressive 
marks were reduced (Fig. 27). However, the coordination and the hierarchy of DNA and his-
tone modifications and the degree to which these two types of epigenetic modifications are 
dependent on each other remains debatable. Nevertheless, the ability of UHRF1 to read the H3 
tail, to interact with the DNA and to physically associate with chromatin remodeling enzymes 
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such as DNMT1, G9a or HDAC makes this molecule an interesting candidate to interpret the 
local epigenetic environment. UHRF1 might also create feedback loops leading to concerted 
reinforcement of DNA and histone modulation (Jin et al., 2011).  
During differentiation of mESCs, tissue-specific promoters have to be activated and genes pro-
moting pluripotency need to be silenced. It is assumed that silencing first occurs by binding of 
transcriptional repressors concomitant with deacetylation of activating histone marks at the 
promoter region. This is followed by the establishment of repressive histone modifications such 
as H3K9me3 in association with deposition of HP1 (Feldman et al., 2006). Then, after subse-
quent de novo DNA methylation by DNMT3a/b, these marks are stably maintained by DNMT1. 
This maintaining process is orchestrated by UHRF1 (Bostick et al., 2007), (Sharif et al., 2007). 
Resulting from global hypomethylation, we observed that Pramel7-overexpressing mESCs have 
difficulties in undergoing terminal differentiation. After culturing these cells in differentiating 
conditions for 14d, expression of the pluripotency-associated genes Oct4, Nanog and Rex1 was 
higher than in wt E14 control cells. Then, the major fraction of Pramel7-overexpressing cells 
was able to rapidly regain pluripotent features demonstrated by the successful reactivation of 
pluripotency-associated genes. In contrast, almost all wt clones remained differentiated and the 
few re-converted wt clones were not able to reactivate the expression of Rex1 and endogenous 
Pramel7 (Fig. 32 - Fig. 35).  
These findings are corroborated by another study of our group stating that mESCs overexpress-
ing Pramel7 are disturbed in differentiation. When exposed to an in vivo environment, Pramel7-
overexpressing mESCs firstly were not able to generate teratoma after injection into immunode-
ficient mice and secondly, after morula aggregation using Pramel7-overexpressing mESCs, de-
veloping embryos analyzed at E5.5 showed malformations. Furthermore, when stimulated for 
differentiation in vitro with RA (retinoic acid), Pramel7-overexpressing mESCs were extensively 
undergoing cell death (Casanova et al., 2011). For the pluripotency associated gene Oct4 
Feldman et al. observed a similar phenomenon. They successfully demonstrated that G9a-/- 
mESCs were not able to efficiently shut down the promoter of Oct4. Moreover, these cells 
could easily be reconverted to the pluripotent state after RA-induced differentiation (Feldman et 
al., 2006). In conclusion, for an efficient and stable differentiation of mESCs, different compo-
nents regulating epigenetic silencing on the chromatin and the DNA level are required. Recon-
sidering its bi-modal capacity, UHRF1 represents one of these candidates. Taken together, we 
hypothesize that overexpression of Pramel7 results in an active genomic state in mESCs. When 
Pramel7-overexpressing mESCs are forced to differentiate, promoters of pluripotency genes may 
be silenced transiently through repressor binding and eventual establishment of repressive his-
tone marks. However, these cells are not able to undergo efficient terminal promoter silencing 
ultimately characterized by robust DNA methylation (Gaspar-Maia et al., 2011). As a conse-
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quence, as soon as pluripotency promoting stimuli (LIF) are re-sensed the core pluripotency 
network might again be induced and mESCs re-adapt pluripotent features. Therefore, we pro-
pose that as long as the mESCs express Pramel7 at a sufficient level, these cells are not able to 
undergo terminal differentiation. 
Since Pramel7 was initially found expressed in the pluripotent compartments of a preimplanta-
tion embryo (Cinelli et al., 2008) we would like to speculate about possible roles in vivo. Dur-
ing embryonic development of the mouse different waves of global DNA demethylation were 
described. After fertilization, the paternal genome is actively demethylated whereas methyla-
tion marks of the maternal genome are thought to undergo passive erasure, peaking at the ICM 
stage (Smith et al., 2012). How this demethylation process is orchestrated in detail is largely 
unknown. Relating to our data, we provide a model in which intracellular UHRF1 levels can be 
kept at a minimum through consecutive expression of Pramel7, supporting a replication-
coupled, passive demethylation process.  
It is not negligible that a similar mechanism could also be involved in the epigenetic repro-
gramming of PGCs (primordial germ cells) from E9.5-E11.5 in the mouse embryonic develop-
ment. Kagiwada et al. recently showed that the erasure of DNA methylation marks during PCG 
reprogramming is very likely to as well take place in a replication coupled, passive manner. 
Also UHRF1 levels (gene expression & protein levels) during this period of embryonic devel-
opment (E10.5/E11.5) were very low (Kagiwada et al., 2013). Interestingly, another study found 
UHRF1 to be expressed at the mRNA level in E10.5 PGCs but no UHRF1 protein was detected 
(Ciccarone et al., 2012). Thus, it remains to be defined to what extent Pramel7 or other proteins 
of the PRAME-like family are expressed in these stages of development or if they are at all im-
plicated in the regulation of this particular epigenetic event.  
PRAME is defined as a cancer-testis antigen. The expression of these genes can be detected in 
male and female gonads and in germ cells. Since the expression of PRAME-like members seems 
to be specifically restricted to a specific developmental period it seems that these genes may be 
involved modularly in different stages of gametogenesis and embryogenesis (Mistry et al., 
2013). Very preliminary data from our lab displayed expression of Pramel7 in maturating 
mouse spermatids (data not shown). Since developmental gene promoters of sperm cells were 
described to be generally hypomethylated (Carrell, 2012) Pramel7 might be involved in main-
taining this effect. However, very little is known about DNA methylation in spermatogenesis 
and more research has to be undertaken in this field. 
5. Future perspectives and concluding remarks 
The molecular role of PRAME-like genes is largely elusive. In this work, we, for the first time 
provide evidence of a functional role for one of its members. We demonstrate that the protein 
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Pramel7 is firstly interacting with and secondly rapidly mediating the degradation of UHRF1. 
Thirdly, as a consequence of the reduction of UHRF1 levels, global DNA methylation is drasti-
cally reduced in mESCs overexpressing Pramel7. This leads to a more active epigenetic state 
and aberrant terminal differentiation. 
However, many questions still need to be answered in the future. In additional mechanistic 
approaches, features mediating the interaction of the two proteins could be determined in the 
amino acid context. Regarding Pramel7, the region containing three crucial LRRs identified in 
Fig. 11 and Fig. 12 has to be narrowed down by generating single amino acid mutations. In 
UHRF1, the C-terminal region containing SRA and RING domains should be sequentially de-
leted to identify possible motifs indispensable for the binding. 
Since in mass spectrometry experiments only ElonginC and Polyubiquitin but no other compo-
nents of a potential CRL complex were identified, it remains to be clarified if Pramel7 indeed is 
a recognition component specific for targeting UHRF1. This can be achieved by IP and subse-
quent detection of possible CRL candidates (different Cullin members, Rbx1/2). Furthermore, it 
has to be verified if knockdown of the above factors inhibits the degradation of UHRF1 after 
induction of Pramel7 expression. To obtain further understanding if the sole presence of 
UHRF1 attracts Pramel7 to chromatin sites, the amount of Pramel7 in chromatin and soluble 
fractions of UHRF1-/- mESCs should be determined. Moreover, to assess the impact of Pramel7 
expression on DNA methylation, degrees of 5mC in UHRF1-/- and Pramel7-overexpressing 
mESCs could be quantified and compared.  
Caused by reduced DNA methylation, we provided evidence that Pramel7-overepxressing 
mESCs display major difficulties in the establishment of a stable terminally differentiated state. 
Nonetheless, Pramel7-overexpressing cells were able to adapt a differentiated fate as shown by 
differentiation into smooth muscle cells positive for SMA (Fig. 36). This implicates that these 
cells have the ability to activate developmental genes crucial for their specification. However, if 
pluripotency-associated genes as Oct4 or Rex1 are stably and efficiently silenced in these cells 
remains to be clarified.  
In vivo, knockdown of Pramel7 in preimplantation mouse embryos with subsequent determina-
tion of UHRF1 and 5mC levels would provide more evidence if Pramel7 is involved in the reg-
ulation of a replication-coupled, passive DNA methylation mechanism during the early devel-
opment of the mouse embryo.  
Despite all the open questions, we for the first time were able to describe a functional role for a 
member of the PRAME-like gene family, Pramel7. It will be interesting to see if other family 
members of and possibly PRAME itself hold similar roles. Therefore, according to our working 
model, every PRAME-like protein possesses the ability to induce the degradation of a specific 
interaction partner. As seen for UHRF1, this could heavily affect the developmental fate of a 
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particular cell type. In conclusion, with these findings, a new window aiming on the character-
ization of this manifold family of proteins has been opened. 
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D. Materials 
1. Cell culture media and supplements 
 
Fibro medium: Dulbecco’s Modified Eagle Medium (DMEM) (Sigma) 
 10% Fetal Calf Serum (PAA) 
 1mM Sodium Pyruvate (Sigma) 
 
Complete medium: Glasgow Minimal Essential Medium (GMEM) (Sigma) 
 10% Fetal Calf Serum (PAA) 
 1mM Sodium Pyruvate (Sigma) 
 1x Non-Essential Amino Acids (Life Technologies) 
 1x Penicillin-Streptomycin-L-Glutamine (Life Technologies) 
 0.1mM 2-Mercaptoethanol (Life Technologies) 
 
N2B27 medium: 1:1 Neurobasal Medium:DMEM/F-12 
 (both Life Technologies) 
 1x Penicillin-Streptomycin-L-Glutamine (Life Technologies) 
 1x N2-Supplement (Life Technologies) 
 1x B27 Supplement (Life Technologies) 
 0.05mM 2-Mercaptoethanol (Life Technologies) 
 
N2B27 supplements (2i): 1µM PD0325901 (Stemgent) 
 3µM CHIR99021 (Stemgent) 
 
Smooth muscle differentiation: DMEM (Sigma) 
 10% Fetal Calf Serum (PAA) 
 
Cell culture supplements:  1000U/ml Leukemia Inhibitory Factor (LIF) (Millipore) 
 1µM MG132 proteasome inhibitor (Calbiochem) 
 10µg/ml cycloheximide (Sigma)  
 
Antibiotics: Puromycin (Sigma) 
 G418 (Neomycin) (PAA) 
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Others:  0.1% Gelatin from porcine skin (Sigma) 
 Trypsin EDTA (10x stock) (Sigma) 
 PBS (w/o Ca and Mg) (different distributors) 
 Fugene HD transfection reagent (Roche) 
 Xtremegene HP transfection reagent (Roche) 
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2. Plasmids 
2.1. Pramel7 expression constructs 
 
Fig. 38. Construction of constructs expressing versions of Pramel7 (1). 
A FLAGHA-tagged version was cloned under a CMV promoter (left, pcDNA3.1) and a pCAG promoter 
(right). pcDNA3.1 backbone vector was provided by Raffaella Santoro, University of Zurich. 
 
 
 
Fig. 39: Construction of constructs expressing versions of Pramel7 (2). 
Untagged Pramel7 is expressed under a pCAG promoter (left) and FLAGHA-tagged Pramel7 under a pEF1 
promoter (right). Dr. Elisa Casanova constructed pCAG_P7 (left) and the empty pEF1_IRES_neo backbone 
generated by Thomas Zwaka was obtained at Addgene (www.addgene.com). 
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Fig. 40: Construction of constructs expressing versions of Pramel7 (3). 
A GFP-Pramel7 fusion protein is expressed under a pEF promoter (left). The empty pEF_GFP backbone 
(right) cloned by Dr. S. Sugano, University of Tokyo, was obtained at Addgene (www.addgene.com). 
 
 
 
 
 
Fig. 41: Generation of Pramel7 versions mutant in the LRR region. 
The pcDNA3.1_FLAGHA-P7 expression vector was mutated in the LRR region using a PCR-based ap-
proach. 3 expression plasmids mutant in the LRR region of Pramel7 were generated with deletions of 
33AA, 41AA and 82AA, respectively (from left to right). The N-terminal control region was not affected. 
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Fig. 42: Generation of a Pramel7 version with mutated N-terminal control region.  
The control region is located N-terminally of the region containing predicted LRRs. Length of the dele-
tion: 63AA. 
 
2.2. UHRF1 expression constructs 
 
 
Fig. 43: Construction of constructs expressing versions of UHRF1. 
FLAGHA was cloned in front of UHRF1’s N-terminus and expressed under a pcDNA3.1 backbone (CMV 
promoter) (right). UHRF1 CDS was cloned out of the pCMV_SPORT6 expression vector (left) obtained 
from Harvard Medical School’s plasmID database (plasmid.med.harvard.edu). 
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2.3. Other expression constructs 
 
 
Fig. 44: Expression constructs for human PRAME and mouse Pramel6. 
The CDS of PRAME was cloned out of a pCMV_SPORT6 expression vector obtained from Harvard Medi-
cal School’s plasmID database (plasmid.med.harvard.edu) and inserted into a pCDNA3_FLAGHA expres-
sion plasmid (left) from Addgene (www.addgene.com). The pCAG_Pramel6 expression construct was 
cloned by Dr. Elisa Casanova (University Hospital, Zurich). 
 
 
Fig. 45: pBluescript control plasmid. 
Control transfections were carried out using a pBluescript II KS plasmid obtained from Silvia Marino 
(Barts and the London School of Medicine and Dentistry) and was originally constructed by Stratagene 
(Agilent). 
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3. Cell lines 
 
Feeder cells:  Mitotically inactivated (Mitomycin C, Sigma) E14.5 mouse 
 embryonic fibroblasts, cultivated in Fibro medium 
 
E14 mESCs: 129-background ESC line, cultivated in complete medium 
 +LIF 
 
E14 CAG_FLAGHA-Pramel7 mESCs: E14 mESCs overexpressing FLAGHA-tagged Pramel7 under
 CAG promoter, cultivated in complete medium +LIF 
 
E14 EF1_FLAGHA-Pramel7 mESCs: E14 mESCs overexpressing FLAGHA-tagged Pramel7 under 
EF1 EF1 promoter, cultivated in complete medium +LIF 
 
129 mESCs: 129 background, cultivated in N2B27 +2i +LIF 
 
129 CAG_FLAGHA-Pramel7 mESCs: 129 mESCs overexpressing FLAGHA-tagged Pramel7 under
 CAG promoter in N2B27 +2i +LIF 
 
HEK293T cells: Human embryonic kidney cells (obtained from Raffaella
 Santoro, University of Zurich), cultivated in Fibro medium 
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4. Buffers and solutions 
 
Alkaline Phosphatase (AP) buffer: 0.1M Tris-HCl  
 0.1M NaCl 
 20mM MgCl2 
 pH 9.5 
 
AP staining solution: AP Buffer containing: 
 0.5µl/ml NBT (Nitro blue tetrazolium chloride) (Roche) 
 3.5µl/ml BCIP (5-bromo-4-chloro-indolyl phosphate 
 (Roche) 
  
BES solution: 50mM BES (Sigma) 
 280mM NaCl (Sigma) 
 1.5mM Na2HPO4 (Sigma) 
 Adjust pH to exactly 7.0 
 
RIPA buffer: 50mM Tris-HCl pH 7.4 (Sigma) 
 1% (v/v) NP-40 (Sigma) 
 0.25% (v/v) Na-Deoxycholate (Sigma) 
 150mM NaCl (Sigma) 
 Add 1 tablet of complete mini proteinase inhibitor (ROCHE) 
 /10ml 
 
Nuclear Extraction (NE) buffer: 50mM Tris-HCl pH 7.5 (Sigma) 
 150mM KCl (Sigma) 
 5mM MgCl2 (Sigma) 
 0.2mM EDTA (Sigma) 
 20% (v/v) Glycerol (Sigma) 
 Add prior use: 
  
 0.5mM DTT (Sigma) 
 0.1% (v/v) NP-40 (Sigma) 
 Add 1 tablet of complete mini proteinase inhibitor (ROCHE) 
 /10ml 
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Silver staining solution A: 50% MeOH 
(100ml) 10% acetic acid, fill to 100ml with ddH20 
 
Silver staining solution B: 5% MeOH 
(100ml) Fill to 100ml with ddH20 
 
Silver staining solution C: 0.2g Na2S2O3 
(1l) Fill to 100ml with ddH20 
 
Silver staining solution D: 200mg AgNO3 
(100ml) Fill to 100ml with ddH20 
 
Silver staining solution E: 3g Na2CO3 
(100ml) 50µl HCOH (37%) 
 2ml of silver staining solution C 
 Fill to 100ml with ddH20 
 
Silver staining solution F: 10ml 0.5M EDTA 
(100ml) Fill to 100ml with ddH20 
 
Chromatin extraction buffer: 10mM NaCl 
 30mM Hepes 
 3mM MgCl2 
 0.5% TritonX-100 
 
Proteinase-K buffer: 100mM NaCl 
 10mM Tris-HCl pH 8.0 
 0.5% SDS 
 
gDNA elution buffer: 10nM Tris pH 8.0 
 1mM EDTA pH 8.0 
 
LB medium: 10g NaCl (Sigma) 
 10g Bacteriological peptone (Sigma) 
 5g Yeast Extract (Sigma) 
 Fill to 1l with ddH20 and autoclave 
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E. Methods 
1. Cloning 
Restriction digestions were performed according to manufacturers instructions (NEB, Promega). 
Quick Blunting Kit (NEB) was used for carrying out blunting reactions. DNA fragments were puri-
fied using QIAQuick PCR Purification and QIAQuick Gel Extraction Kits (Qiagen). Fragments were 
ligated with NEB T4 DNA ligase and constructs were transformed into chemically competent MAX 
Efficiency DH5α E.Coli (Life Technologies). Plasmid DNA from picked candidate clones was puri-
fied using QIAPrep Spin Miniprep Kit (Qiagen). After confirmation of correctly integrated clones by 
Sanger sequencing (Microsynth AG, Balgach, Switzerland) positive clones were multiplied in LB 
medium and DNA was isolated using QIAFilter Plasmid Maxi Kit (Qiagen). Agarose gel electropho-
resis was performed using 5x TBE buffer (5PRIME) and agarose (Sigma) and gels were run at 120-
150V. 
2. Western blotting 
Protein amounts were normalized using the Pierce BCA Protein Assay Kit (Thermo Scientific) and 
protein absorbance was measured using Nanodrop technology. Lysates were further processed 
with the NuPAGE SDS PAGE Gel system (Life technologies). SDS-gels were run at 160-190V and 
proteins were either wet-blotted overnight (40V, 4°C) or for 1.5h (120V) at room temperature (ice 
block-cooled) on a PVDF Immobilon-P transfer membrane (Millipore). Membranes were fixed us-
ing Western Blocking Reagent (Roche) for at least 1h and incubated with primary antibodies over 
night at 4°C or at room temperature for 1h (in blocking solution). Membranes were washed 3 times 
with 1x TBST (TBS supplemented with 1% Tween-20 (Sigma), 10’ each step) and secondary anti-
bodies were added for 30’-1h at room temperature (in blocking solution). After four washing steps 
(3x TBST, 1x TBS, 10’ each) signals were enhanced using Chemiglow Peroxide Buffer and Lumi-
nol/Enhancer Solution (Protein Simple) and detection was carried out with Amersham Hyperfilm 
ECL high performance chemiluminescence film (GE healthcare). 
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Tab. 5: List of antibodies used for immunodetection by Western blotting 
 
Antibody Species Supplier Catalog No. 
α-tubulin mouse Sigma T8203 
α-FLAG rabbit Sigma F7425 
α-HA mouse Santa Cruz sc-7392 
α-PARP1 rabbit Cell Signaling 9532 
α-Pramel7 rabbit selfmade 
 α-UHRF1 rabbit Santa Cruz sc-98817 
α-H3 rabbit Abcam 
 α-H3K4me3 rabbit Cell Signaling 9751 
α-H3K9ac rabbit Cell Signaling 9649 
α-H3K9me3 rabbit Millipore 07-442 
α-H3K27me3 rabbit Cell Signaling 9756 
α-H4ac rabbit Millipore 06-866 
α-H4K5ac rabbit Millipore 07-327 
α-mouse HRP goat Santa Cruz sc-2031 
α-rabbit HRP goat Santa Cruz sc-2030 
    
 
3. RNA extraction, reverse transcription and quantitative real-time PCR (RTQ-
PCR) 
First cell pellets were resuspended in RLT buffer provided with the RNEasy Mini Kit (Qiagen) con-
taining 0.1% 2-mercaptoethanol (100%, Sigma) and RNA was extracted following manufacturer’s 
instructions. RNA concentrations were measured with the Nanodrop technology and 500ng or 1µg 
of RNA were reverse transcribed using Oligo(dT)12–18 Primer (Life Technologies), 10mM dNTP 
Mix (Life Technologies), RNAsin Plus RNAse Inhibitor (Promega) and SuperscriptIII Reverse Tran-
scriptase (Life Technologies). cDNA was analysed with the Rotor-Gene SYBR Green PCR Kit (FAST) 
(Qiagen). Primers for RTQ-PCR were obtained at Microsynth AG, Balgach, Switzerland. 
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Tab. 6: List of primers used for quantitative real-time PCR (RTQ-PCR) 
 
Gene name Sequence 
β-actin_fw 5'-CAT CCA GGC TGT GCT GTC CCT GTA TGC-3' 
β-actin_bw 5'-CAT CCA GGC TGT GCT GTC CCT GTA TGC-3' 
hElonginC_fw 5'-ACC TAT GGT GGC TGT GAA GG-3' 
hElonginC_bw 5'-AGG TGC AAT TGG GAA TTC AG-3' 
FGF5_fw 5'-TCC TCA CCA GTC GCA GCT TC-3' 
FGF5_bw 5'-TTC AGG GCC ACG TAC CAC TC-3' 
Gata4_fw 5'-GCC TGT ATG TAA TGC CTG CG-3' 
Gata4_bw 5'-CCG AGC AGG AAT TTG AAG AGG-3' 
Gata6_fw 5'-GCA ATG CAT GCG GTC TCT AC-3' 
Gata6_bw 5'-CTC TTG GTA GCA CCA GCT CA-3' 
Nanog_fw 5'-ACA AGG GTC TGC TAC TGA GAT GC-3' 
Nanog_bw 5'-GGA GAC TTC TTG CAT CTG CTG G-3' 
Nestin_fw 5'-AGG CTG AGA ACT CTC GCT TGC-3' 
Nestin_bw 5'-GGT GCT GGT CCT CTG GTA TCC-3' 
Oct-3/4_fw 5’-GGC GTT CGC TTT GGA AAG GTG TTC -3’ 
Oct-3/4_bw 5’-CTC GAA CCA CAT CCT TCT CT -3’ 
Pax6_fw 5'-TAA CGG AGA AGA CTC GGA TGA AGC-3' 
Pax6_bw 5'-CGG GCA AAC ACA TCT GGA TAA TGG-3' 
Pem/Rhox5_fw 5'-CTT CCG TGG ACA AGA GGA AG-3' 
Pem/Rhox5_bw 5'-TGT CAT AGC CGG CAT ATG TG-3' 
hPRAME_fw 5'-TAT CGC CCA GTT CAC CTC TC-3' 
hPRAME_bw 5'-TCG GGA CTT ACA TCG GTC AG-3' 
Pramel7_fw 5'-GTC AGA CTT GGA GTC ATT TG-3' 
Pramel7_bw 5'-CGG AGA TGT CAT TGT CAT AG-3' 
Rex1/Zfp42_fw 5'-AGA AAG CAG GAT CGC CTC AC-3' 
Rex1/Zfp42_bw 5'-AGG GAA CTC GCT TCC AGA AC-3' 
T-Brachyury_fw 5'-ATG CCA AAG AAA GAA ACG AC-3' 
T-Brachyury_bw 5'-AGA GGC TGT AGA ACA TGA TT-3' 
hUHRF1_fw 5'-GCA CCA AGG AAT GTA CCA TC-3' 
hUHRF1_bw 5'-GTC CAC ATC ATC CTC ATA GC-3' 
mUHRF1_fw 5'-ACA GTG AAT CAG ACA AGT CGT-3' 
mUHRF1_bw 5'-ATT CTT GGC GGG TTT GAC AAT GTC-3' 
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4. Immunofluorescent detection (wide field/confocal) and alkaline phosphatase 
staining 
Cells were fixed by the addition of Roti-Histofix 4% formalin solution for 10-20’. For confocal 
analysis formalin was additionally supplemented with 1:555 100% TritonX-100 (Sigma) (18µl in 
10ml). After fixation, cells were washed 3 times in PBS (10’ each step). Primary antibodies were 
diluted in PBST (PBS containing 0.1% Tween-20) and 4% horse serum and cells were incubated 
over night at 4°C or at room temperature for 2-4h. After washing 3 times with PBST (10’ each step) 
secondary antibodies were added (in PBS only) and cells were incubated for 1-4h at room tempera-
ture protected from light. Following two washing steps (PBS, 10’ each) nuclei were stained with 
DAPI (1:2000, in PBS) (Roche) or Hoechst (1:2000, in PBS) (obtained from Lukas Sommer lab, 
UZH, in PBS) for 1’ and washed again twice with PBS before wide field microscopic analysis. For 
confocal microscopy cells were cultivated directly on gelatinized conventional microscopy glass 
cover slips (Menzel) placed in 3.5cm dishes (Corning), mounted using mounting medium supple-
mented with DAPI (obtained from Massimo Lopes lab, UZH) and sealed with conventional trans-
parent nail polish. Wide field images were taken on a Zeiss Axiovert 40 CFL and processed using 
AxioVision 4.6 software (Zeiss) and Adobe Photoshop CS6. Confocal pictures were shot in the Cen-
ter for Microscopy and Image Analysis (ZMB) of the UZH and processed with IMARIS 7.6 software.  
For alkaline phosphatase staining cells were first fixed in Roti-Histofix 4% formalin solution for 10-
20’ and washed 3 times 10’ in PBS. After 2 washing steps in AP buffer cells were subjected to AP 
staining solution. Staining intensity was checked after 20’ the first time and then every 10’. When 
staining was enough strong the reaction was stopped using 1x Tris-EDTA (20mM Tris-HCl, 5mM 
EDTA) and cells were washed twice in PBS.  
 
Tab. 7: List of antibodies used for immunofluorescent staining 
 
Antibody Species Supplier Catalog No. 
α-Oct-3/4 rabbit Santa Cruz sc-9081 
α-Smooth muscle actin mouse Sigma A2547 
α-SSEA1 mouse Developmental studies Hybridoma bank 
  
University of Iowa 
 α-Pramel7 rabbit Selfmade 
 α-UHRF1 rabbit Santa Cruz sc-98817 
α-5mC mouse Diagenode C15200081 
α-ß-Tubulin isotype III mouse Sigma T8660 
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5. Yeast-two hybrid assay 
The assay was performed in collaboration with DualsystemsBiotech in Schlieren ZH, Switzerland. 
Pramel7 was used as bait and a cDNA library of E14 ESCs was the pool of prey proteins. First the 
bait was cloned into a lexA-expression vector and tested for self-activation and successful expres-
sion. Then the cDNA library was transformed and co-expressed with the bait plasmid. Positive 
clones were selected and library plasmids were isolated. Finally positive clones were sequenced 
and BLAST analysis was performed.  
 
The exact procedure can be obtained here:  
http://www.dualsystems.com/fileadmin/user_upload/z_download/manuals/P01004_DUALhybrid.pdf 
6. Derivation and testing of an antibody recognizing Pramel7 
Generation of the antibody was performed in collaboration with PINEDA Antikörper Service, Ber-
lin, Germany. To determine unique epitopes protein sequences of PRAME-family members were 
aligned and analysed and two suitable, unique Pramel7-epitopes were chosen for immunization. 3 
rabbits were immunized with either peptide. Pre-immune sera were tested using immunohisto-
chemical staining and final fraction of purified antibodies was verified by immunoblotting. 
7. Co-immunoprecipitation, TCA precipitation and silver staining (mammalian 
cells) 
Cell pellets were collected and washed 1x with PBS. At this step pellets could be stored at -80°C. 
After thawing on ice pellets were resuspended in 200-400µl of NE buffer and sonicated twice (30’’ 
each step). Following DNAse treatment (1µl DNAse/200µl lysate) (Fermentas) lysates were incubat-
ed for 30’ on ice. Meanwhile ANTI-FLAG M2 Affinity Gel beads (Sigma) were washed 3 times in 
PBS (centrifugation at 500g, 5’, 4°C), resuspended in NE buffer and distributed in required amounts 
of non-safe lock 1.5ml Eppendorf tubes (20-30µl packed beads/sample). After DNAse digestion, 
cell lysates were again sonicated once (30’’) and centrifuged at 6000rpm for 10’ (4°C). Protein 
concentration was determined by Bradford assay, 1-2mg of protein/sample was added to the beads 
and tubes were filled up to 1ml with NE buffer. Following incubation over night on a rotator beads 
were washed 3 times with 800µl-1ml of NE buffer (5’ on rotator, centrifugation 500g for 5’, 4C°). 
After final washing and centrifugation residual NE buffer was gently removed from the beads. 
7.1. Analysis by Western blotting 
 Beads were resuspended in appropriate amount of reducing agent and sample buffer from the Nu-
PAGE protein analysis system (Life Technologies), heated to 80°C for 10’ and finally analysed by 
Western blotting. 
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7.2. TCA precipitation for proteomic analysis 
After washing, beads were eluted twice by adding 100µl M2 FLAG-peptide (stock 5mg/ml, working 
solution 200µg/ml) (Sigma) and rotation for 30’ (200µl eluate). 20µl of each eluate was kept for 
silver staining analysis. 45µl 100% trichloro-acetic acid (TCA) was added to each eluate, tubes 
were gently shaken by finger tipping and kept on ice for at least 30’ (also possible over night) and 
then centrifuged for 5’ on full speed (4°C). Supernatant was removed without affecting protein pel-
let and pellet was washed 4-6 times with pure acetone (-20°C) every time followed by a full-speed 
centrifugation step for 5’ (4°C). After last washing pellet was shortly dried at 95°C and then stored 
at 4°C. Proteomic analysis was carried out by the Protein Analysis group of the Functional Ge-
nomics Centre (FGCZ) of the ETH/UZH. 
7.3. Silver staining 
Inputs and eluates were loaded on an SDS gel and gel was run on 140V for 2h. After fixation for 
30’ in solution A (gently shaking) the gel was washed in solution B for 15’. Then the gel was 
washed 3 times in ddH2O for 5’ and sensitized for 2’ in solution C by repeatedly adding and spill-
ing solution C using up all 500ml during 2’, always shaking by hand. Following 3 washing steps 
with ddH2O for 30’’ the gel was stained for 25’ in solution D and then washed 3 times for 1’ in 
ddH2O. The staining was developed in solution E for 5-10’, always checking staining intensity, and 
the reaction was stopped by incubation in solution F for 10’ minimum. Finally the gel was washed 
in ddH2O and stored at 4°C. 
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8. Cell culture experiments 
8.1. CaCl2-transfection of plasmid DNA in HEK293T 
Plasmid DNA was mixed with 2.5M CaCl2 and H2O was added to reach the reaction volume (Tab. 
8). While vortexing BES solution was added drop wise within 10’’ on a vortex, tube was removed 
from vortex for 10’’ and re-vortexed for another 10’’. Then the solution was equally distributed on 
the adherent cells. To reach the indicated amounts of DNA, the transfection mix was equalized 
with pBluescript DNA. As a transfection control plasmids expressing EGFP or mRFP were used. The 
next morning culture medium was changed. 
 
Tab. 8: Amounts and volumes used for CaCl2 transfection 
 
Plate size Cell number DNA (µg) 2.5M CaCl2 (µl) Total reaction volume (µl) 2x BES (µl) 
15cm 2.5x106 40 100 1000 1000 
10cm 106 20 50 500 500 
6cm 0.5x106 10 20 200 200 
6well 1.7x106 2.5 7 72 72 
12well 105 1.2-2.4 4 40 40 
24well 0.5x105 0.5 2 20 20 
 
8.2. Transfection of plasmid DNA in HEK293T cells using transfection reagent 
After DNA, DMEM and Xtremegene HP transfection reagent had reached room temperature de-
sired amount of DNA was added to a corresponding amount of DMEM and everything was mixed 
well. Required amount of transfection reagent (for exact amounts see supplier’s manual) was added 
drop wise to the DNA/DMEM mix, gently mixed by finger tipping and incubated for 15’ at room 
temperature. After incubation, the solution was equally distributed on the adherent cells and gently 
mixed with the culture medium when placing the dishes back into the incubator. After 48h the 
medium was changed. 
8.3. Separation of mESCs from feeders, electroporation of plasmid DNA, selection and 
expansion of ESCs 
For stable integration of plasmid DNA mESCs were first separated from feeder cells by 4’ trypsinisa-
tion (1x trypsin), 4’ centrifugation (1000rpm) and incubation on a non-gelatinized culture dish. 
Feeder cells were attached after 20’ and the supernatant containing the mESC-fraction was collect-
ed and centrifuged (4’, 1000rpm). After washing the pellet 1x with PBS and re-centrifugation (4’, 
1000rpm) plasmid DNA was added to the pellet and pellets were incubated for 4’. Pellet with DNA 
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was resuspended in 800µl of PBS and loaded on a 0.4cm gap Gene Pulser/Micro Pulser electro-
poration cuvette for mammalian cells (Bio Rad). Cells were electroporated at 500µF capacitance 
and 240V using a Bio Rad Gene Pulser II. Electroporated cells were resuspended in an appropriate 
amount of culture medium and distributed on culture dishes. Antibiotic selection was started 24-
48h after electroporation and selection was carried out for 4 days (puromycin) or 8-10 days (neo-
mycin). After selection medium was changed to standard conditions and resistant colonies were 
grown to a pickable size. For picking a 96-well plate (BD Falcon) with 60µl PBS/well/colony was 
prepared. Colonies were picked (before picking cells were washed 1x with PBS and then picked in 
PBS or pure DMEM) into 60µl of PBS and 60µl 2x trypsin was added. Trypsinisation was stopped 
after 4-6’ by the addition of 120µl culture medium containing serum, cells were resuspended well 
and added to a previously prepared 24-well plate (Thermo Scientific) containing feeders. Resulting 
clones were expanded, analysed and frozen. 
8.4. Time course experiment UHRF1 degradation 
300’000 to 500’000 HEK293T cells were seeded onto 3.5cm culture dishes (Corning). The next day 
the medium was changed. After 1h of recovery cells were transfected with CAG-Pramel7 plasmid 
DNA or pBluescript, respectively, using Xtremegene HP (see 8.2). At desired time points (8h, 12h, 
24h, 36h, 48h, 72h, 96h) after transfection cells were scraped directly in the culture medium and 
centrifuged for 4’ (1000rpm). The pellet was washed 1x with PBS, re-centrifuged and finally resus-
pended in 100-300µl of RIPA buffer, depending on the number of cells. Protein concentrations 
were determined and expression levels of Pramel7 and UHRF1 were determined by Western blot-
ting (see 7.1). 
8.5. Inhibition of UHRF1-degradation by MG132 
UHRF1 degradation experiment was carried out as described above. 24h after transfection of 
Pramel7/pBluescript the proteasome inhibitor MG132 was added to the culture medium (1µM final 
concentration). Cells were incubated with MG132 for desired time periods (4h, 8h, 12h, 24h, 30h) 
and cells were harvested, protein amounts normalized and expression was determined by Western 
blotting (see 7.1). 
8.6. MG132 functionality test 
To test the functionality of MG132 untransfected HEK293T cells were incubated with 50µg/µl cy-
cloheximide for indicated time (4h, 8h, 12h, 24h) in presence or absence of MG132, harvested and 
analysed as described above (see 7.1). 
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8.7. Differentiation and reversion of wildtype E14 and CAG_FLAGHA-Pramel7-
overexpressing mESCs 
Wt E14 and Pramel7-overexpressing mESCs were separated from feeders (see 8.3) and differentiat-
ed on gelatinized 6cm culture dishes (Corning) in complete medium without LIF. Cells were split 
after 6 days and 10 days. After 14 days cells were trypsinised and distributed at a dilution of 
10cells/well on two 96-well plates containing feeders (for each cell type). Replicates of 14 days-
differentiated cells were harvested and analysed for the expression of pluripotency factors by RTQ-
PCR and protein levels of Pramel7 and UHRF1 were verified by Western blotting. In addition 
methylation of genomic DNA was assessed (see 9). Cells in 96-well plates were cultivated in com-
plete medium containing LIF for 1 week and analysed for colony formation. 10 clones per cell type 
were selected on morphological criteria and split on 24-well plates. Residual wells of 96-well 
plates were fixed in 4% formalin and analysed for the expression of alkaline phosphatase and posi-
tive colony formation was assessed counting wells containing AP-positive colonies. Different 
clones were expanded for 3 to 4 passages and expression of pluripotency markers was tested using 
RTQ-PCR and immunofluorescent staining. 
8.8. Smooth muscle differentiation 
Wt E14 and Pramel7-overexpressing mESCs were separated from feeders and plated on gelatinized 
6well plates (Thermo Scientific). 50’000 Cells were cultivated in smooth muscle differentiation 
medium for 9 days, fixed with 4% formalin and analysed by staining against smooth muscle actin 
(SMA). 
9. Isolation of genomic DNA and methylation-sensitive restriction digestion 
9.1. Isolation of genomic DNA 
After trypsinisation and centrifugation (4’, 1000rpm) and 1x washing (PBS) cell pellets were careful-
ly resuspended in 100-400µl of proteinase-K buffer and 4µl proteinase-K (10mg/ml) was added. 
The mixture was incubated over night at 50°C on a shaker. The next day, following the addition of 
2µl RNAse A (Fermentas) and incubation for 30’ at 37°C, 25:24:1 Phenol:Chloroform:Isoamyl Al-
cohol (Sigma) was added and lysates were shaken (avoid vortexing) and centrifuged for 10’ at 
7500rpm. Meanwhile new tubes with 0.5 volumes of 7.5M NH4Ac were prepared. After centrifuga-
tion upper and interphases were transferred into NH4Ac-containing tubes, two volumes of 100% 
EtOH were added and samples were centrifuged at 4200rpm for 2’. Supernatants were carefully 
discarded without touching the pellet and pellets were dried on 40°C for 1h maximum. Pellets 
were resuspended in gDNA elution buffer, incubated for 15’ and shaken at 65°C to dissolve and 
then, if needed, further dissolved in required amount of gDNA elution buffer. 
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9.2. Restriction digestion for methylation assay 
4µg of gDNA were digested over night with 3µl HpaII or McrBC in 20µl total reaction volume con-
taining 0.5ng of pBluescript plasmid DNA for testing the efficiency of the HpaII digest. The next 
day the reaction was heat-inactivated for 15’ and 2µg (10µl) of DNA were loaded on a 1% agarose 
gel. The gel was run for 1h at 180V and degrees of digestion were analysed. 
2µl of the mixture were diluted 1:5 with H2O and digestion efficiencies were additionally 
quantified by amplification of pBluescript sequences containing HpaII (+2049 to +2606, HpaII 
site +2580). Data was normalized to the total amount of pBluescript DNA calculated by ampli-
fication of sequences lacking HpaII (+2049 to +2573). 
10. PI-staining of DNA for flow cytometry 
Cells were trypsinised and centrifuged for 4’ at 1000rpm. Pellets were washed once with 4°C PBS 
and re-centrifuged. PBS was then discarded and pellet was resuspended by finger tipping the tube. 
While gently vortexing, 1ml of ice cold 70% EtOH was added to the cells drop per drop. Cells 
were incubated on ice for at least 30’ (can also be stored at 4°C for 2-3 weeks at this step). Follow-
ing 5’ of centrifugation (400g) cells were washed with 1ml of PBS and spun down again (400g, 5’). 
Supernatant was discarded and 500µl of RNAse A (100µg/ml) and 5µl of PI (2.5mg/ml) were added. 
Finally cells were incubated for 30’ at least and then analyzed by flow cytometry. 
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